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CATIONIC LIPOSOME-DNA COMPLEX-BASED IMMUNOTHERAPEUTIC AND 
IMMUNIZATION STRATEGIES FOR CONTROL OF LA CROSSE VIRUS AND 
LEISHMANIA MAJOR INFECTIONS 
The morbidity and mortality affiliated with vector-borne diseases are staggering, 
and the associated economic and social hardships are overwhelming, especially in 
populations without the political or financial means for effective control or treatment.  
Many of these diseases continue to re-emerge in former endemic areas and/or emerge in 
new parts of the world, and conventional means of control are often inadequate due to the 
appearance of pesticide-resistant vectors, drug resistant-pathogens, and the collapse of 
vector control programs, among other factors.  At present, safe and efficacious vaccines 
and therapeutics for prevention and treatment of many of these diseases are lacking.   
La Crosse virus (LACV), family Bunyaviridae, is a mosquito-borne pathogen and 
is the leading cause of pediatric arboviral encephalitis in the United States.  LACV is not 
only an important human pathogen, but it is also a model for development of vaccines 
and antiviral therapies for other pathogens in the family Bunyaviridae.  Many 
bunyaviruses are designated as National Institute of Allergy and Infectious Diseases 
(NIAID) priority pathogens and there is cause for concern that they could be exploited as 
bioweapons.  Aerosol infection animal models are essential to test the efficacy of 
candidate vaccines and antiviral therapies for these important pathogens.  There are no 
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human vaccines or antiviral treatments for LACV or other members of the family.  
Accordingly, in Chapter 2, aerosol and intranasal inhalational challenge models of LACV 
infection in mice were developed and tested.  Following aerosol or intranasal challenge 
with LACV, 100% of normally-resistant adult mice developed clinical signs of LAC 
encephalitis and died.  LACV was detected in high titers in the nasal turbinates, brains 
and lungs of aerosol- or intranasally-challenged mice, as well as in the sera and livers of 
mice challenged intranasally.  Brains of LACV-challenged mice exhibited histologic 
lesions of meningoencephalitis, and LACV RNA was detected and amplified from brains 
of challenged mice.  To our knowledge, this is the first report of aerosol-transmission of 
LACV leading to the development of lethal encephalitis in adult mice.  The experimental 
challenge models described herein should be useful tools in the eventual development of 
sorely-needed vaccines and antivirals for the prevention or treatment of bunyavirus 
aerosol infections. 
Immunotherapy using cationic liposome-DNA complexes (CLDC) has been 
shown to promote antiviral, antitumor, and antibacterial immune responses in various 
experimental animal models.  This protection relies on non-pathogen-specific activation 
of soluble and cellular innate immune effectors.  In Chapter 3, we evaluated the ability of 
CLDC to protect adult mice from the development of encephalitis in a LACV aerosol 
challenge model.  Both pre-challenge (prophylactic) and post-challenge (therapeutic) 
administration of CLDC significantly increased survival in LACV-challenged animals in 
this model system. Intraperitoneal administration of CLDC elicited reductions in viral 
titer in both peripheral tissues and the central nervous system (CNS) and decreased the 
severity of CNS lesions in treated mice compared to sham-treated control mice.  
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Protection was associated with increased expression of IFN-α5 and IFN-β1 in the spleen, 
as well as IFN-γ in the brain.  Systemic depletion of natural killer (NK) cells prior to 
treatment was found to abrogate the full protective ability of CLDC administration, 
suggesting an integral role for this cell type in CLDC-induced protection.  These data 
indicate that CLDC is an effective antiviral immunotherapy that provides both 
prophylactic and therapeutic protection against an otherwise lethal aerosol challenge with 
a viral pathogen.    
Leishmania major, one causative agent of Old World cutaneous leishmaniasis, is 
a vector-borne protozoan parasite transmitted by the bite of infected female phlebotomine 
sand flies.  At present, there is no vaccine approved for use in humans for the prevention 
of L. major infection.  Chapter 4 describes significant protection against infection with L. 
major induced by CLDC-based immunization against the immunomodulatory salivary 
peptide maxadilan (MAX) from the sand fly Lutzomyia longipalpis.  Following 
intraperitoneal or subcutaneous immunization with MAX, both lesion sizes and parasite 
burdens of infected footpads of immunized mice were significantly reduced in 
comparison to those of non-immunized mice.  The protection elicited using a CLDC 
adjuvant exceeded that elicited using a human-approved aluminum hydroxide adjuvant 
(Alhydrogel®); additionally, notable inflammation and tissue damage present at the site of 
immunization when Alhydrogel® was employed as adjuvant was completely absent in 
mice immunized with CLDC as adjuvant.  Intracellular cytokine staining of CD4+ 
lymphocytes identified important differences in IFN-γ and IL-4 production in the context 
of infection due to immunization or lack thereof.  The protection described herein 
highlights the importance of salivary immunomodulation in the initiation of vector-borne 
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pathogen infections, and provides compelling evidence in support of the inclusion of 
salivary molecules as antigens in the formulation of subunit vaccines intended to protect 
against transmission of arthropod-borne pathogens.        
In these studies, we utilized CLDCs as both immunotherapeutics and vaccine 
adjuvants to induce innate and Th1-type immune responses protective against infection 
with LACV and L. major, both of which are arthropod-borne intracellular pathogens that 
require the induction of pro-inflammatory Th1-biased immune responses for clearance.  
This body of work presents evidence that CLDC administration induces protective 
immune responses against aerosolized LACV challenge and parenteral challenge with L. 
major, suggesting that CLDCs are versatile and effective vehicles for the elicitation of 
immune protection against pathogens susceptible to pro-inflammatory and Th1-biased 
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 As the field of immunology has grown rapidly in breadth and complexity over the 
past 200+ years, so too has our knowledge of the innate immune system.  The wealth of 
recent knowledge has revealed the significance and intricacy of innate immunity in terms 
of guiding and regulating ensuing adaptive immune responses.  Over 2 decades ago, 
Charles Janeway first hypothesized that in addition to serving as a first line of defense 
against pathogen invasion, innate immune responses might also function to initiate and 
direct the development of the ensuing adaptive immune responses (1989).  In the decades 
since, the identification and characterization of various pattern recognition receptors 
(PRRs) of the innate immune system (including the Toll-like receptors (TLRs), NOD-like 
receptors (NLRs) and intracellular receptors for nucleic acids), has enriched our 
understanding of how immune responses are both initiated and shaped via initial 
interactions with pathogens and other microorganisms.  Armed with an increased 
comprehension and appreciation of the early immunological events that determine the 
quality and character of subsequent responses, investigators have increasingly focused 
their research efforts on utilization of the innate immune system for prevention and 
treatment of disease.  The discovery of the naturally-occurring ligands for various PRRs 
and the production of alternative synthetic agonists have empowered researchers with the 




suppression, induction, or enhancement of distinct immune responses for control and 
treatment of infection or disease. 
Toll-like Receptors and Innate Immunity 
The innate immune system detects the presence of pathogens using a collection of 
PRRs that recognize and bind to various pathogen-associated molecular patterns 
(PAMPs), or conserved structural features shared by many different groups of 
microorganisms, providing immune differentiation between noninfectious structures of 
the host and infectious foreign materials.  PRRs are expressed in a variety of cellular 
locations, including within intracellular compartments and upon the cellular surface, or 
can alternatively be secreted into the fluids of the bloodstream or host tissues (Medzhitov 
and Janeway, 1997).  Recognition of foreign, non-self structural motifs by PRRs serves to 
not only initially detect both the presence and nature of the pathogen, but also to induce 
an immediate inflammatory immune response against that pathogen, as well as to initiate 
the development of an adaptive immune response suitable for control of the particular 
pathogen (Janeway and Medzhitov, 2002; Akira et al., 2006; Sansonetti, 2006).   
Among these PRRs is a family of membrane-bound receptors termed the Toll-like 
receptors (TLRs), which are expressed primarily (though not exclusively) on innate 
immune cells such as macrophages, neutrophils, and dendritic cells (DCs).  A total of 13 
different TLRs have been identified in mammals (Takeda et al., 2003; Tabeta et al., 2004; 
Zhang et al., 2004), and each serves to recognize and bind to a particular natural ligand or 
set of ligands (many of which have been identified), resulting in the expression of a wide 
variety of genes involved in host defense including major histocompatibility complex 




inflammatory chemokines and cytokines.  For example, TLR3 recognizes the double-
stranded RNA present in the genome of some viruses (Alexopoulou et al., 2001), TLR4 
binds to the lipopolysaccharides of Gram-negative bacteria (Medzhitov et al., 1997; 
Poltorak et al., 1998; Qureshi et al., 1999; Hoshino et al., 1999), and TLR5 recognizes 
bacterial flagellins (Hayashi et al., 2001).  Of particular interest to this body of work is 
TLR9, which is selectively expressed within the endosomal compartment of human and 
murine plasmacytoid DCs (pDCs) and B cells, as well as murine monocytes and myeloid 
DCs (Iwasaki and Medzhitov, 2004), where it surveys endocytosed material and engages 
unmethylated CpG oligodeoxynucleotide sequences overexpressed in bacterial DNA (in 
comparison to mammalian DNA, which is mostly methylated) and in various viral 
genomes (Krieg, 2000; Hemmi et al., 2000).  Interaction between TLR9 and ligand leads 
to the recruitment of the adapter protein MyD88 (myeloid differentiation primary-
response protein 88) to the receptor complex (Medzhitov et al., 1998; Schnare et al., 
2000), leading ultimately to the activation of signaling cascades that induce the 
production of various pro-inflammatory cytokines  (including IFN-α, IFN-β, IFN-γ, TNF-
α, and IL-12), chemokines, and co-stimulatory molecules via signaling through NF-κB-
mediated (Meylan et al., 2006; Akira and Takeda, 2004) and interferon regulatory factor 
7 (IRF-7)-dependent pathways (Sato et al., 2000; Barnes et al., 2002).  The cytokine 
profile induced following activation of TLR9 (primarily the production of IFNs and 
resultant activation of IFN-dependent antiviral mechanisms) is particularly effective for 
treatment or prevention of viral infections (Stetson and Medzhitov, 2006a; Kawai and 
Akira, 2006), and these topics will be discussed in further detail later.  A direct role for 




observations that production of type I IFNs by pDCs following challenge with either 
herpes simplex virus- (HSV) 1 or HSV-2 is abrogated using TLR9-/- mice (Lund et al., 
2003; Krug et al., 2004).  In fact, prophylaxis with TLR9 agonists has been shown to 
elicit a temporal window of protection against viral challenge that can last for a number 
of weeks (Klinman, 2004; Amlie-Lefond et al., 2005), suggesting that TLR9-based 
immunotherapeutics might be useful in inducing protection against viral pathogens 
released in acts of bioterrorism or biological warfare. 
The cytokine and chemokine milieu induced following ligation of TLRs 
ultimately determines the development and nature of the subsequent acquired immune 
response via the attraction of additional effector cells to the site of infection, resulting in a 
specific pattern of cytokine secretion and activation of primarily antigen-specific T-
helper 1 (Th1) or T-helper 2 (Th2) cells.  In fact, the induction of any acquired immune 
response (especially Th1-cell responses) is dependent upon the initial activation of the 
innate immune system via PRRs such as the TLRs (Akira et al., 2001; Medzhitov, 2001), 
highlighting the importance of PRRs in induction of both the innate and subsequent 
adaptive immune responses.  The integration of innate immune responses and 
downstream adaptive responses is a task performed by antigen presenting cells (APC), 
principally DCs.  Ligation of TLRs on DCs leads to maturation of immature DCs into 
professional APCs, stimulating the expression of co-stimulatory molecules necessary for 
activation of T cells and inducing the production of cytokines that serve to regulate T-cell 
differentiation and thus the quality of subsequent adaptive immune responses.  Research 
utilizing TLR9 agonists as vaccine adjuvants has repeatedly demonstrated their ability to 




1997; Roman et al., 1997) and cytotoxic T-lymphocyte (CTL) development (Sparwasser 
et al., 2000; Lipford et al., 1997).  Due to the Th1-bias of the cytokine response following 
TLR9 activation, ensuing adaptive immune responses are primarily cell-mediated and are 
thus appropriate for control of intracellular pathogens such as viruses and certain 
protozoan parasites (e.g., Leishmania major) (Zimmerman et al., 1998).  Additionally, it 
has been demonstrated that the immunostimulatory capability and adjuvant activity of 
TLR9 agonists can be dramatically enhanced by combining them with lipid carriers 
(Krieg and Davis, 2001).   
Cationic Liposome-DNA Complexes 
 Cationic liposomes have been shown to significantly enhance the innate immune 
stimulatory properties of certain adsorbed molecules, particularly those with intracellular 
receptors, such as the non-methylated CpG motif agonists of TLR9 (Gursel et al., 2001; 
Krieg, 2002; Zaks et al., 2006), the TLR3 agonist polyI:C (Zaks et al., 2006), and ssRNA 
and dsRNA agonists of TLR7/8 (Wong et al., 1999; Hamm et al., 2007).  In fact, CpG-
induced production of cytokines (such as type I and II IFNs) can be increased between 
10- to 100-fold when the CpG agonists are complexed with cationic liposomes (Dow et 
al., 1999b; Sellins et al., 2005), forming cationic liposome-DNA complexes (CLDC).  
This potentiation of the innate immune response is multifactorial, dependent upon the 
abilities of cationic liposomes to protect adsorbed nucleic acids from extracellular 
degradation while simultaneously facilitating endocytic uptake and localizing the 
complexes to the early endosomal compartment of targeted cells, the primary site of 
expression for nucleic acid PRRs (Akira and Takeda, 2004; Akira, 2006; Zaks et al., 




CLDC have also been shown to be regulated in part by TLR-independent pathways and 
receptors, such as the cytosolic DNA sensor DAI (DNA-dependent activator of IFN-
regulatory factors) (Ishii and Akira, 2006; Stetson and Medzhitov, 2006b), activation of 
which leads to increased production of both pro-inflammatory cytokines and type I IFNs 
via activation of NF-κB-mediated and IRF-3- and IRF-7-dependent pathways, 
respectively (Takaoka et al., 2007; Takaoka and Taniguchi, 2008).  A proposed model of 
CLDC processing leading to stimulation of innate immune responses is provided in 
Figure 1.1. 
 
Figure 1.1.  Possible routes of CLDC processing within a human host resulting in 
stimulation of the innate immune response.  Figure is borrowed from Logue et al., 2010.  
Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western 
equine encephalitis virus (WEEV) challenge.  Antiviral Res.  87(2):195-203.   
 
The first detailed descriptions of intravenous treatment with liposome-DNA 




designed to assess their efficacy in immunotherapeutic treatment of tumors (Dow et al., 
1999a).  The authors determined that the observed CLDC-induced antitumor effects were 
a result of stimulation of the innate immune system, specifically the activation of natural 
killer (NK) cells and resultant production of IFN-γ (Dow et al., 1999b).  Subsequent 
research has shown that CLDCs are actively endocytosed by APCs such as pDCs and 
ferry molecules to endosomally-expressed TLRs such as TLR3, TLR7/8, and TLR9.  
Ligation of TLR9 along with cytosolic DAI leads to prompt non-specific activation of the 
immune system, principally in the spleen and draining lymph nodes. This response is 
typified by the release of pro-inflammatory cytokines, including TNF, IL-1β, IL-6, IL-12, 
IFN-γ, IFN-α and IFN-β (Ishii et al., 2004; Klinman et al., 2004).  The ability of CLDCs 
to selectively activate potent innate immune responses characterized by robust production 
of pro-inflammatory cytokines and IFNs strongly underscores their potential clinical use 
as non-specific immunotherapeutics.  CLDCs or liposomal CpG oligodeoxynucleotide 
(ODN) complexes have not only been shown to exert notable anticancer activity in 
various animal tumor models (Dow et al., 1999a; Dow et al., 1999b; Whitmore et al., 
1999; Whitmore et al., 2001; Lanuti et al., 2000), but have also been successfully used for 
immunotherapeutic treatment of acute viral (Gowen et al., 2006; Gowen et al., 2008; 
Logue et al., 2010) and bacterial infections (Goodyear et al., 2009; Troyer et al., 2009). 
In addition to its remarkable ability to activate the innate immune response and 
elicit production of Th1-biased cytokine responses, administration of CLDCs also 
stimulates the upregulation of co-stimulatory molecules on DCs and macrophages, 
functional maturation of APCs, and NK cell activation and infiltration (Dow et al., 




for direct loading of most peptide and protein antigens, making CLDCs also quite-
effective as vaccine adjuvants.  When formulated together with antigens, CLDCs not only 
retain their ability to potently stimulate innate immune responses and activate immune 
cells, but serve as a platform to directly target bound antigens to DCs and other APCs.  
Vaccines utilizing CLDCs as adjuvants have been demonstrated to induce balanced 
cellular and humoral immunity, eliciting strong responses from both CD4+ and CD8+ T-
cells, as well as inducing antibody responses either comparable to or exceeding those 
induced by Freund’s complete adjuvant or aluminum hydroxide adjuvants (Chen, et al., 
2008; Zaks, et al., 2006; Dow, 2008).  The cross-priming and induction of CD8+ T cell 
responses has been attributed to the unique ability of the liposomal formulation to 
transport antigens into the cytosol and engage the MHC class I pathway (Walker, et al., 
1992; Chikh and Schutze-Redelmeier, 2002; Zaks, et al., 2006).  Additionally, some of 
the adjuvant effects of CLDCs have been attributed to cationic liposomes themselves 
(Latif and Bachhawat, 1984), as they have been shown to not only activate DCs directly 
(Cui, et al., 2005), but also to induce cellular necrosis (Khazanov, et al., 2006), which can 
lead to the activation of innate immune responses due to the liberation of endogenous 
immune activators, such as uric acid (Shi, et al., 2000).  Due to the described potency of 
CLDCs as immunotherapeutics and adjuvants and their abilities to induce strong T cell 
responses and Th1-biased cytokine production, we elected to utilize CLDCs as both 
immunotherapeutics for treatment of aerosolized La Crosse virus infections and as an 
adjuvant in a vaccine formulation intended to protect against challenge with Leishmania 





Interferons and Interferon-induced Antiviral Effectors 
 Interferon (IFN) was first described in 1957 as an inhibitor of influenza virus 
replication (Isaacs and Lindenmann, 1957).  Since then, three separate classes of IFNs 
have been identified, and the production of IFNs is now recognized as providing an initial 
line of defense against viral infections by both inducing the production of antiviral 
proteins and initiating an appropriate, cell-mediated adaptive immune response (Samuel, 
2001).  Type I IFNs (including IFN-β and various subtypes of IFN-α, among others) bind 
to the ubiquitously-expressed IFN-α receptor and are absolutely required for the 
development of potent immune responses against viral infection (Pietras et al., 2006).  
Type II IFN (IFN-γ), which binds to the IFNGR receptor complex, is produced by 
effector CD4+ Th1 cells, CD8+ T cells, and NK cells.  Although a principal function of 
IFN-γ is the activation of macrophages, it additionally serves to mediate a wide spectrum 
of immune responses to a variety of pathogens (including intracellular pathogens such as 
viruses) via its abilities to induce the polarized development of Th1 cells, as well as to 
enhance both antigen processing and MHC expression (Sijts et al., 2002; Steimle et al., 
1994).  Type III IFNs, also known as IFN-λ or IL-28/29, have recently been discovered 
and are also recognized as regulators of the antiviral immune response.  Presently, they 
are not completely understood, and are not discussed in detail here (for a review of the 
Type III interferon family, see Donnelly and Kotenko, 2010).   
Most nucleated cell types are capable of producing IFN-α/β in response to viral 
infection via binding of viral structures (such as dsRNA, CpG DNA, or envelope 
glycoproteins) to PRRs expressed intracellularly or in endosomal compartments (Kawai 




infected cells and nearby uninfected cells leads to activation of signaling cascades that 
ultimately induce the production of a variety of antiviral effector molecules, leading to 
the development of an antiviral state of resistance in which intracellular viral replication 
is inhibited (Pietras et al., 2006).  Production of IFN-α/β also activates NK cells, which 
then act to selectively kill virus-infected cells.  Additionally, IFN-α/β production serves 
to induce the production of MHC class I molecules in most cell types, which both 
increases the resistance of uninfected cells to killing by NK cells and increases the 
susceptibility of infected cells to killing by CD8+ cytotoxic T cells (Pietras et al., 2006).    
Many of the antiviral effects of IFN production are due to activation of IFN-
induced proteins, such as protein kinase R (PKR), the 2’,5’-oligoadenylate synthetase 
(OAS) and RNase L, the RNA-specific adenosine deaminase (ADAR1), and the 
myxovirus-resistance (Mx) proteins.  Protein kinase PKR is a constitutively-present, IFN-
inducible RNA-dependent protein kinase that inhibits the translation of mRNA into 
protein, effectively interfering with synthesis of viral polypeptides (Clemens and Elia, 
1997; Samuel, 1993).  OAS is a constitutively-present, IFN-inducible PRR for viral 
dsRNA (Rebouillat and Hovanessian, 1999) which functions in concert with RNase L to 
lead to the degradation of both viral and cellular RNA (Floyd-Smith et al., 1981; 
Wreschner et al., 1981).  ADAR1 is induced by IFN and covalently edits RNA substrates 
via deamination of adenosine to inosine, which both modifies the protein-coding capacity 
of the RNA transcript and destabilizes the dsRNA helix (Patterson et al., 1995).  The Mx 
proteins are GTPases that serve to identify and bind to viral ribonucleoproteins, 
interfering with either the transport of viral nucleocapsids to the nucleus or with viral 




respectively (Staeheli et al., 1993; Haller et al., 1998; Haller and Kochs, 2002).  By 
interfering with various cellular functions required for the production of viral genomes 
and other required structural elements, IFN-induced antiviral effectors provide an 
important line of defense against viral infections, effectively arresting early spread of the 
infection and allowing time for the development of a cell-mediated adaptive immune 
response.  The central significance of the IFNs and their effects in immune defense 
against viral infection is underscored by the fact that the genomes of many viruses encode 
for mechanisms that interfere with or evade the antiviral responses induced by IFNs.  For 
example, the NS1 protein of influenza virus sequesters dsRNA activators of PKR (Lu et 
al., 1995), the E3L protein of vaccinia virus binds to dsRNA activators of OAS (Rivas et 
al., 1998), and many viruses encode for soluble IFN receptor homologues (Alcami et al., 
2000; Colamonici et al., 1995; Smith et al., 1998).  Such observations highlight the 
central importance of IFN production in controlling initial viral replication and spread to 
neighboring cells, and provide sufficient rationale for the use of IFN-inducing 
immunotherapies such as CLDCs as approaches toward the prevention and treatment of 
infection with viral pathogens.   
La Crosse Virus 
La Crosse virus (LACV), family Bunyaviridae, genus Orthobunyavirus, 
California serogroup, is a mosquito-borne pathogen endemic to various regions of the 
Midwestern United States (Calisher, 1994; Rust et al., 1999).  LACV is predominantly-
transmitted by the bite of its principal vector, Aedes triseriatus, and is amplified and 
maintained in a transmission cycle involving  Eastern chipmunks (Tamias striatus 




amplifying verterbrate hosts.  Transmission from mosquitoes to vertebrate hosts occurs 
when an infected female mosquito takes a blood meal, transferring LACV to the 
vertebrate via the mosquito’s saliva.  While the natural rodent hosts do not become ill 
following infection, subsequent LACV replication leads to the development of a viremia 
sufficient to infect naïve mosquitoes seeking an ensuing blood meal (Borucki et al., 
2002).  Infection of the vector has little deleterious effect on the health of the mosquito, 
and LACV can also be maintained in the mosquito population via transovarial or vertical 
transmission (Watts et al., 1973), in which the virus replicates in the ovaries and embryos 
of the mosquito and overwinters in her eggs, which hatch in the spring to release LACV-
infected offspring (Beaty et al., 2000).    
LACV has a tripartite, negative-sense RNA genome consisting of large (L), 
medium (M), and small (S) RNA segments (Obijeski et al., 1976).  The L segment 
encodes the RNA-dependent RNA polymerase, the M segment encodes a polyprotein that 
is post-translationally processed to form the Gn and Gc glycoproteins and a nonstructural 
protein NSM, and the S segment encodes the nucleocapsid (N) protein and an additional 
nonstructural protein NSS in overlapping reading frames (Elliott, 1990; Schmaljohn, 
1996; Bishop, 1996).  The pleomorphic virion is comprised of helical structures 
containing the L, M, and S RNA segments encapsidated with the nucleocapsid protein, 
polymerase molecules required for transcription of the negative-sense viral genome, and 
a host-derived lipid envelope intercalated with the Gn and Gc glycoproteins (Bishop, 
1996). 
Infection of naïve mosquitoes occurs following the ingestion of an infected blood 




pending successful midgut escape, LACV then disseminates to the hemocoel, where it 
subsequently transits to and replicates in various tissues including the fat body, neural 
ganglia, heart, ovaries, and eventually the salivary glands at 7-16 days following virus 
ingestion (Beaty and Calisher, 1991; Schmaljohn, 1996).  LACV replicates to high titers 
in the salivary glands and can subsequently be transmitted to vertebrate hosts via the 
mosquito’s saliva.  While the natural transmission cycle principally involves chipmunks 
and squirrels as amplifying vertebrate hosts, humans can act as tangential vertebrate 
hosts, and LACV infection of humans can potentially lead to serious disease, especially 
in children.  In fact, > 90% of symptomatic LACV infections occur in patients younger 
than 15 years old (Rust et al., 1999; McJunkin et al., 2001). 
LACV was initially isolated post-mortem in 1964 from the brain of a 4 year-old 
female patient from Minnesota diagnosed with meningoencephalitis who subsequently 
died in La Crosse, Wisconsin in 1960 (Thompson et al., 1965).  LACV has since become 
an important public health problem in the United States, where it has remained the most 
common cause of pediatric arboviral encephalitis (Calisher, 1994), with an incidence in 
endemic areas exceeding that of bacterial meningitis (20-30 cases per 100,000 children 
under 15 years of age) (McJunkin et al., 2001).  Annually, there are approximately 
300,000 LACV infections, 70-130 cases of which have diagnoses of severe neurological 
involvement; the estimated case-fatality rate is approximately 0.3% (Rust et al., 1999; 
McJunkin et al., 2001; Jones et al., 1999).  The actual number of cases of La Crosse 
(LAC) encephalitis is thought to be vastly underrecognized and underdiagnosed 
(Calisher, 1994), due in part to the close resemblance between clinical symptoms of 




LACV is now considered in the differential diagnosis of herpes simplex virus PCR-
negative cases in patients with potential exposure to LACV (Sokol et al., 2001; Wurtz 
and Paleologos, 2000).  In humans, severe LACV infection of the central nervous system 
(CNS) commonly presents as meningoencephalitis with inflammation largely confined to 
the cerebral cortex, often resulting in seizures and eventual coma (McJunkin et al., 1997; 
Kalfayan, 1983).  Milder infections are presumably far-more common and lead to flu-like 
symptoms, such as vomiting, fever, stiff neck, and headache (McJunkin et al., 2001).  
Following recovery, many patients experience significant neurologic sequelae, including 
continued seizures, learning disabilities, and attention deficit hyperactivity disorder 
(McJunkin et al., 2001; Balfour et al., 1973).  The financial burden related to these 
sequelae has been projected to range from $48,775 – $3,090,398 over the lifetime of each 
patient (Utz et al., 2003).  Unfortunately, at present there is neither a licensed vaccine nor 
a standard antiviral therapy for prevention of LACV infection or treatment of LAC 
encephalitis (Hollidge et al., 2010).   
In the past, most cases of LAC encephalitis have occurred in states of the upper 
Midwest; more recently, however, cases have been identified in North Carolina, West 
Virginia, Tennessee, and Missouri (Jones et al., 1999; CDC, 2010; Haddow and Odoi, 
2009;  Haddow et al., 2011 ).  The recent isolation of LACV from field-collected larvae 
and male Aedes albopictus (an aggressive, day-feeding species introduced into the North 
American continent within the last two decades) and the connection of this vector to 
human cases in Tennessee collectively are a cause for concern to public health (Gerhardt 
et al., 2001; Erwin et al., 2002) as Ae. albopictus has been shown to be a competent 




on the rise in the South, where recent cases have been reported in Louisiana, Alabama, 
Georgia, and Florida (Lambert et al., 2010). 
The pathogenesis of LACV infection in mammalian hosts or experimental 
animals has not been completely determined, and our understanding of how peripheral 
infection spreads to the CNS to cause clinical manifestations of disease is limited to a 
small number of reports (Gauld et al., 1975; Amundson and Yuill, 1981; Amundson et 
al., 1985; Ksiazek and Yuill, 1977; Bennett et al., 2008).  Peripheral injection of LACV 
does not typically result in the development of encephalitis in adult mice, even when 
administered at quite high subcutaneous doses (Johnson, 1983; Janssen et al., 1984).  
Prior studies from our own laboratory have shown that less than 10% of adult mice 
develop neurological disease when given as much as 1 x 105 infectious units of virus 
subcutaneously or intramuscularly (unpublished observations).  As mice age, they 
become decreasingly susceptible to the development of LAC encephalitis, an observation 
similar to that made in human populations, in which infection causes neurological disease 
primarily in younger patients (Johnson, 1983; McJunkin et al., 2001).  In models of 
subcutaneous inoculation of suckling mice, LACV replicates initially in striated skeletal 
muscle tissue near the site of infection, eventually leading to infection of the vascular 
endothelium and development of a viremia.  The virus is then thought to bypass the 
blood-brain barrier and enter the CNS through infection of the vascular tissue supplying 
the brain (Johnson, 1983; Janssen et al., 1984; Griot et al., 1993a; Griot et al., 1993b); 
once in the brain, LACV infects and replicates in neurons, ultimately inducing neuronal 
apoptosis (Pekosz et al., 1996).  Previous studies using the murine model of LACV 




capability to develop a high viremia, which in turn is correlated with previous viral 
replication in striated muscle tissue (Janssen et al., 1984). A more recent study involving 
intraperitoneal or intranasal inoculation of weanling mice concluded that after first 
replicating in various tissues near the site of inoculation, LACV can then infect the nasal 
turbinates via the bloodstream, eventually making its way into the CNS via infection and 
ascent of the olfactory nerves (Bennett et al., 2008).  Disease presentation and organ 
pathologic changes in the mouse model are similar to that seen in human infections, 
making the murine model of LACV infection a useful tool with which to mimic the 
course of disease in humans, allowing for study of the transit of LACV from the 
periphery to the CNS and subsequent mechanisms of neuropathogenesis (Hollidge et al., 
2010).  An additional point of relevancy to this body of work is the observation that 
infection with LACV is dramatically modulated by the activity of mosquito saliva, which 
interferes with the induction of protective IFN responses, among other antiviral immune 
responses.  The importance of this immunomodulation will be highlighted in the 
subsequent sections of this dissertation concerning potentiation of Leishmania infection 
by sand fly saliva.  The salivary-antigen immunization approaches explored in Chapter 4 
might be extrapolated to natural transmission models of not only LACV, but also the 
many other pathogens of the Bunyaviridae transmitted by the bites of infected arthropod 
vectors.   
Previous studies have identified both IFN-α and IFN-β as important mediators of 
protection against murine LACV infection (Blakqori et al., 2007).  The importance of the 
IFN response in protection against infection with LACV is further highlighted by in vivo 




protein NSs is to usurp the antiviral type I interferon response in mammalian hosts 
(Blakqori et al., 2007).  Additionally, production of IFN-γ is known to exert direct 
antiviral responses through the induction of various antiviral effectors, including PKR, 
OAS and RNase L, and the dsRNA-specific adenosine deaminase (dsRAD) (Boehm et 
al., 1997).  In fact, IFN-γ is critical for antiviral responses in the CNS, in which non-
cytolytic clearance of intracellular viruses is required for preservation of neuronal 
function (Chesler and Reiss, 2002).  Also, research involving the IFN-induced MxA 
protein has demonstrated that it binds to and effectively sequesters LACV nucleocapsid 
proteins in the cytoplasm, interfering with successful amplification of the viral genome, 
production of infectious virions, and thus the spread of the infection to neighboring cells 
(Kochs et al., 2002).  These combined observations further highlight the importance of 
the IFN response in protecting against LACV infections.        
In addition to being an important human pathogen, LACV is also a well-studied 
model system that can be utilized for the development of antiviral therapies and vaccines 
for other pathogens in the family Bunyaviridae, many of which are designated by the 
National Institute of Allergy and Infectious Diseases as priority pathogens.  Many 
members have been characterized as likely agents of bioterrorism due in part to their 
ability to induce serious illness in humans and the potential to be transmitted by aerosol 
(Sidwell and Smee, 2003).  Additionally, the potential of a second wave of infection 
involving conventional transmission by indigenous vector species is cause for concern.  
Indeed, this sequela of a bioterrorist attack could have greater impact on public health 
than the initial aerosol event.  Rift Valley fever virus (RVFV), also a member of the 




potential to emerge in new areas with devastating consequences to both human and 
animal populations.  Considering the impact of the Bunyaviridae on human and 
veterinary health (Calisher, 1994), the expeditious development of novel, safe, and 
efficacious vaccines and therapeutics is clearly warranted.  Aerosol infection animal 
models are essential to test the efficacy of candidate vaccines and antiviral therapies for 
these important pathogens.  Accordingly, in work described herein, inhalational models 
of LACV infection were developed and tested (see Chapter 2); in addition, CLDC was 
investigated as a potential anti-LACV immunotherapeutic (see Chapter 3).   
Leishmaniasis 
 The leishmaniases are a group of zoonotic vector-borne diseases caused by 
infection with obligate intracellular protozoa of the genus Leishmania, transmitted by the 
bite of infected female sand flies of the genera Phlebotomus and Lutzomyia.  
Leishmaniasis is presently a concern for more than 350 million humans living in more 
than 88 endemic countries on 6 continents throughout the world, with an estimated 
worldwide prevalence of more than 12 million cases and an annual increase of 1.5-2 
million new cases (World Health Organization, Leishmaniasis home page: 
http://www.who.int/leishmaniasis/en/; Desjeux, 2004).  Leishmaniasis is commonly 
referred to as a group of several clinical diseases, as infection with various species of 
Leishmania can lead to a wide spectrum of clinical presentations, including cutaneous, 
mucocutaneous, and visceral leishmaniasis, depending in part on the site of parasitic 
replication within macrophages of the dermis, naso-oropharyngeal mucosa, or 
mononuclear phagocyte system, respectively (Herwaldt, 1999).  There are more than 30 




(Cupolillo et al., 2000), and disease manifestation is additionally dependent upon the 
particular species involved in infection.  Following infection with the various species of 
Leishmania that lead to cutaneous leishmaniasis (such as L. major, L. tropica, L. 
aethiopica, L. mexicana, and L. amazonensis,), amastigotes replicate in macrophages 
resident in the dermis, resulting in a wide range of clinical manifestations from 
subclinical, self-healing infections to chronic disease typified by the formation of 
ulcerating lesions and scarring.  In some cases, particularly those involving L. 
braziliensis, cutaneous infections can metastasize and disseminate to macrophages 
resident in the naso-oropharyngeal mucosa, resulting in mucocutaneous leishmaniasis, a 
disfiguring form of the disease characterized by degradation of mucosal membranes 
(Herwaldt, 1999).  Infection with other species of Leishmania (such as L. 
chagasi/infantum and L. donovani) can lead to visceral leishmaniasis, also known as kala-
azar, in which parasites spread from cutaneous sites to the bone marrow, liver and spleen, 
commonly leading to parasitemia and mortality (Pearson and de Queiroz Sousa, 1996; 
Herwaldt, 1999).            
Leishmaniasis has been classified as both a zoonosis (linked to wild and/or 
domestic animal reservoir hosts) and an anthroponosis (linked to human reservoir hosts), 
with parasites cycling between intracellular forms in immune cells of the vertebrate hosts 
and extracellular forms in the digestive tract of vector sand flies.  Transmission of 
Leishmania parasites to mammalian hosts occurs when an infected female sand fly 
seeking a bloodmeal regurgitates the elongate and flagellated metacyclic promastigote 
form of the parasite into the skin of the host, along with various biologically-active 




subsequently enter and replicate within phagocytic cells (primarily macrophages) present 
in the skin at the bite site.  Once inside the macrophage, Leishmania develop into the 
round, non-flagellated amastigote form of the parasite and replicate within 
phagolysosomes, ultimately leading to lysis of the macrophage and subsequent spread to 
nearby macrophages (Handman and Bullen, 2002).  Subsequent infection of sand flies 
occurs following ingestion of blood containing infected macrophages.  The infected 
bloodmeal is transported to the posterior midgut, a starting point from which Leishmania 
parasites subsequently migrate anteriorly toward the stomodeal valve while 
differentiating through a number of stages of development (Bates, 2007).  At the juncture 
of the foregut and midgut, the haptomonad promastigote forms of the parasite attach 
themselves to the stomodeal valve, forming a parasite plug which impairs the 
bloodfeeding abilities of the fly, eventually causing regurgitation of metacyclic 
promastigotes (the flagellated, free-swimming form of the parasite infective to 
vertebrates) into a subsequent bite wound, where they infect resident macrophages, 
completing the natural transmission cycle (Schlein et al., 1992; Rogers et al., 2002b).   
Immunology of Leishmaniasis 
Our present understanding of the immune response following infection with 
Leishmania parasites relies heavily on observations stemming from experimental mouse 
models of infection, and although the results cannot be directly applied to infection of 
dogs or humans, this research has led to many important conclusions concerning the cell-
mediated immune response required for control of infection.  Effective immunity to 
infection with Leishmania parasites is dependent upon the interconnected actions of 




(Reiner and Locksley, 1995).  While CD4+ CD25+ regulatory T cells play crucial roles 
in mediating parasite persistence and the maintenance of immunity to reinfection 
(Belkaid et al., 2002a) and CD8+ T cells are known to play an important protective role 
via the production of IFN-γ (Müller et al., 1993; Belkaid et al., 2002b), CD4+ T cells 
have been identified as the primary mediators of resistance or susceptibility to infection.  
In fact, the murine model of cutaneous leishmaniasis persists as one of the best models 
for understanding the immune mechanisms mediating the balance between Th1 and Th2 
CD4+ cell populations.   
As Leishmania parasites are obligate intracellular pathogens, control and 
clearance of infection are dependent upon the development of a CD4+ mediated Th1 
cellular immune response characterized by the production of cytokines (e.g., IL-12, IFN-
γ and TNF-α) that lead to the activation of infected macrophages, eliciting the production 
of nitric oxide (NO) by inducible nitric-oxide synthase (iNOS), which results in killing of 
intracellular parasites (Reiner and Locksley, 1995).  The development of this protective 
Th1 response is dependent upon the early production of IL-12 and TNF-α by 
macrophages and/or DCs, which leads to the activation of NK cells and early production 
of IFN-γ, which further supports the outgrowth of Th1 cells and subsequent control of 
infection (Scharton-Kersten and Scott, 1995).  In contrast, the development of a CD4+ 
mediated Th2 cellular immune response characterized by the secretion of Th2-biased 
cytokines (e.g., IL-4 and IL-13) leads to alternative activation of macrophages and 
polarizes the immune response towards an antibody-mediated response ineffective 
against intracellular organisms such as Leishmania parasites.  The development of this 




by macrophages and/or DCs, which promotes the outgrowth of Th2 cells and the 
production of IL-4, which can subsequently negate the actions of Th1 type cytokines.  In 
the presence of a Th2-biased immune response, production of IFN-γ is inhibited and thus 
infected macrophages do not become activated to produce NO and instead produce 
arginase-1, leading to uncontrolled replication of intracellular parasites and ultimately to 
the development of progressive disease (Reiner and Locksley, 1995; Matthews et al., 
2000).  The amino acid substrate L-arginine is shared by both the Th1 and Th2 inducible 
enzyme systems; iNOS catabolizes L-arginine into protective NO, while arginase-1 
hydrolyzes L-arginine to urea and L-ornithine, a molecule required for the production of 
polyamines vital for growth of Leishmania within macrophages (Modolell et al., 1995).  
As a result, macrophages can either destroy or host intracellular Leishmania amastigotes, 
depending on the relative balance of iNOS and arginase-1, which is contingent upon 
initial priming of either Th1 or Th2 cells.  Thus, early induction of an innate immune 
response that leads to the outgrowth of Th1 cells is an important facet of the development 
of immune responses appropriate for control of Leishmania infections (Liese, et al., 
2008).  Figure 1.2 provides a visual representation of healing vs. non-healing 
immunological responses to infection with L. major.   
Although the definitive host cells for Leishmania parasites are macrophages, DCs 
are the primary cell type involved in antigen presentation and instructing the development 
of ensuing adaptive T cell responses, and thus early events involving DCs (such as IL-12- 
and type I IFN-induced activation of NK cells to produce protective IFN-γ) are of 
paramount significance in determining the immunological events that subsequently occur 





Figure 1.2.  Leishmania major: healing and non-healing immunological responses. 
Following L. major infection of macrophages or DCs, IL-12 production by infected cells induces 
activation of NK cells, CD4+ Th1 differentiation and IFN-γ production. IFN-γ stimulates iNOS 
expression and NO production in the macrophage, mediating parasite killing and a healing 
response. Failure to produce IL-12 (or production of IL-4/IL-13) results in uncontrolled parasite 
replication within the infected cells facilitated by IL-10 production. IL-10 production by CD4+ 
CD25+ T regulatory cells both facilitates non-healing disease and maintains latent infection and 
long-term immunity. Figure is borrowed from Alexander and Bryson, 2005.  T helper (h) 1/Th2 
and Leishmania: paradox rather than paradigm.  Immunol. Lett.  99(1):17-23. 
 
of myeloid DCs by genomic parasite DNA following parasitic degradation has been 
shown to play a part in protective innate and adaptive immune responses to L. major 
(Liese et al., 2007; Liese et al., 2008; Schleicher et al., 2007).  The importance of this 
initial immune response, particularly TLR-mediated signaling pathways, is further 




deficiency are highly susceptible to L. major infection and respond with an ineffective 
Th2-biased response (Muraille et al., 2003).   
Leishmania parasites themselves employ a number of mechanisms that aid them 
in eluding potentially-protective actions of the host immune system.  These include 
evasion of complement-mediated lysis prior to entering host cells (Brittingham et al., 
1995), “silent” entry of macrophages that avoids the oxidative burst normally associated 
with phagocytosis (Mosser and Edelson, 1987), and additional cell-specific mechanisms 
including those aimed at macrophages (such as interfering with NO-mediated killing 
functions and phagosomal maturation and acidification), DCs (such as inhibition of 
chemotaxis and DC-maturation), and the recruitment of CD4+CD25+FoxP3+ regulatory 
T cells that themselves inhibit the development of protective immune responses 
(Brandonisio et al., 2004; Belkaid et al., 2002a; Peters and Sacks, 2006; Nylen et al., 
2007).  In addition, L. major parasites initially phagocytosed by polymorphonuclear 
neutrophil granulocytes are capable of utilizing this cell type as a vector for undetected 
entry into macrophages, effectively avoiding detection by or activation of host 
macrophages (van Zandbergen et al., 2004; Laskay et al., 2008).  Such strategies for 
immune evasion further illustrate the importance of early induction of appropriate 
immune responses in control of Leishmania infections, and stress the need for 
interventions that fulfill this requirement.     
Most mouse strains (e.g., C3H, C57BL/6, and CBA) challenged with L. major 
effectively control the infection and develop self-healing cutaneous lesions similar to 
those seen during human infection; in these resistant mouse strains, clearance of infection 




treatment with anti-IFN-γ monoclonal antibodies prior to challenge with L. major was 
shown to block the outgrowth of Th1 cells (Scott, 1991), rendering otherwise-resistant 
C3H/HeN and C57BL/6 mouse strains susceptible to infection and progressive disease 
development (Belosevic et al., 1989; Sadick et al., 1990).  Other strains of mice (e.g., 
BALB/c) are exceedingly susceptible to infection with L. major, developing progressive 
cutaneous disease that eventually leads to systemic infection and death; this strain of 
mouse responds to infection with L. major by developing a non-protective Th2-biased 
immune response, typified by IL-4, IL-13, and IL-10 production and the absence of 
macrophage activation and clearance of intracellular parasites (Matthews et al., 2000).  
The central role of IL-4 in progression of cutaneous disease is underscored by the 
observation that an increase in Th1-like immune responses and clearance of L. major 
infection can be induced in BALB/c mice via treatment with anti-IL-4 monoclonal 
antibodies (Sadick et al., 1990; Nabors and Farrell, 1994).  However, although a great 
deal of research has implicated IL-4 as a definitive marker of susceptibility to L. major 
infection, the actions of regulatory cytokines such as IL-10 and TGF-β have also been 
shown to elicit important effects that contribute to susceptible vs. resistant immunological 
phenotypes (Scharton-Kersten and Scott, 1995).  Such observations have made it 
apparent that effective immunity against infection with L. major is highly-dependent 
upon the early induction of an innate immune response that leads to the outgrowth of Th1 
cells appropriate for control of intracellular infections.  Unfortunately, research has 
shown that the development of this protective immune response is perturbed not only by 
the parasite itself, but also by the actions of immunomodulatory salivary components co-




Salivary modulation of Leishmania infection 
Leishmania major, one causative agent of Old World cutaneous leishmaniasis, is 
transmitted by the bite of infected female sand flies of the species Phlebotomus papatasi, 
and is 1 of 10 species of Leishmania deemed to be of public health significance (Bates, 
2007).  As L. major is vector-transmitted, the inoculum contains not only infective 
metacyclic promastigotes, but also sand fly saliva containing various salivary 
components.  The salivary molecules of blood-feeding arthropods serve multiple roles, 
including acting as anesthetics, inducing vasodilation, and inhibiting both coagulation of 
blood and the development of host inflammation and a subsequent immune response 
(Kamhawi, 2000; Schoeler and Wikel, 2001; Rogers et al., 2002a; Titus et al., 2006).  By 
dilating the blood vessels of the vertebrate host, the sand fly increases blood flow to the 
bite site, maximizing its chances of a successful blood meal.  Additionally, via 
suppression of the host inflammatory response, the sand fly interferes with the ability of 
the host to become sensitized to its saliva, again increasing the chances of successful 
bloodfeeding and solidifying that particular vertebrate as a source of a potential future 
blood meal.  Due to this immunomodulation, any pathogen transmitted via sand fly bite 
will be confronted by a skin environment that has been substantially altered by the effects 
of the co-injected saliva; depending on the quality of the immune environment induced at 
the bite site, there is a possibility that pathogens might benefit from the changes induced 
by the saliva.  It is now widely-accepted that arthropod saliva can serve to enhance the 
infectivity of pathogens transmitted to the vertebrate host during the bloodmeal (Titus 
and Ribeiro, 1988; Mbow et al., 1998; Belkaid et al., 1998; Jones et al., 1989; Labuda et 




part, account for the impressive ability of many arthropods to so effectively transmit such 
a wide variety of pathogens (including the causative agents of many diseases of 
worldwide health importance, such as leishmaniasis, onchocerciasis, lymphatic filariasis, 
Chagas disease, malaria, African trypanosomiasis, and dengue fever). 
The initial observations concerning the role played by sand fly saliva in 
transmission of Leishmania parasites were a result of research involving co-injection of 
mice with L. major promastigotes and salivary gland lysates (SGL) from the New World 
sand fly Lutzomyia longipalpis.  Inclusion of sand fly SGL in the inoculum led to an 
unexpected degree of exacerbation of infection: cutaneous lesions grew 5-10 times larger 
than lesions of mice injected without SGL, and the parasite loads within the lesions 
contained as many as 5,000-fold more parasites (Titus and Ribeiro, 1988).  The dramatic 
exacerbation of infection caused by co-injection of sand fly SGL has subsequently been 
attributed to a multitude of effects on the vertebrate host immune system.  Sand fly saliva 
has been experimentally shown to inhibit the activation of T cells (Theodos and Titus, 
1993; Titus, 1998) and macrophages (Theodos and Titus, 1993), to simultaneously block 
the production of Th1-biasing cytokines (Mbow et al., 1998) and augment the production 
of Th2-biasing cytokines (Norsworthy et al., 2004; Mbow et al., 1998; Belkaid et al., 
1998), and to decrease the production of molecules that serve to kill intracellular 
parasites, such as macrophage-produced H2O2 and NO (Hall and Titus, 1995; Waitumbi 
and Warburg, 1998; Gillespie et al., 2000; Norsworthy et al., 2004).  As effective control 
and clearance of L. major infection is dependent upon the outgrowth of Th1 cells and 
subsequent activation of macrophages to kill intracellular parasites, it is quite apparent 




development of an immune environment in which L. major can thrive and successfully 
develop an initial focus of infection.  Therefore, as an important initial step in efforts to 
block or neutralize the exacerbative effects of sand fly saliva on L. major infection, 
successful identification of the salivary component(s) responsible for such 
immunomodulation became a priority for a number of research groups. 
The saliva of Lu. longipalpis contains a wide variety of biologically-active 
molecules, including anti-platelet factors, anti-clotting factors, and vasodilators, many of 
which are also capable of immunomodulation (Kamhawi, 2000).  The salivary 
component of chief interest to our laboratory and these studies is a vasodilatory peptide 
termed maxadilan (MAX) (Lerner et al., 1991; Lerner and Shoemaker, 1992).  MAX 
earned its name due to its impressive vasodilatory effects: at the time of its 
characterization, MAX was the most powerful peptide vasodilator known (maximum 
dilation), capable of eliciting more than 500 times the vasodilatory activity of Calcitonin 
Gene-Related Peptide (CGRP), the strongest vasodilatory peptide known at the time 
(Lerner and Shoemaker, 1992).  MAX was subsequently cloned, and functional studies 
showed that the recombinant 63-amino acid peptide product was capable of eliciting 
responses qualitatively and quantitatively similar to those of the native peptide found in 
sand fly saliva (Lerner and Shoemaker, 1992).  Studies revealed that MAX binds to and 
activates the mammalian type I receptor for the pituitary adenylate cyclase-activating 
neuropeptide (PACAP), which is expressed on both vascular and neural tissues and 
mediates the potent vasodilatory effects of both PACAP and MAX (Moro et al., 1996; 
Moro and Lerner, 1997; Eggenberger et al., 1999).  Of particular relevance to this study 




DCs, and T cells (Arimura and Said, 1996; Torii et al., 1998).  Thus, in addition to its 
remarkable ability to affect the vertebrate vasculature, MAX has also been shown to elicit 
profound immunosuppressive and anti-inflammatory effects (Bozza et al., 1998; Brodie 
et al., 2007; Guilpin et al., 2002), including modulation of DC phenotype and function 
(Wheat et al., 2008), inhibition of T cell activation (Qureshi et al., 1996), and modulation 
of a wide variety of macrophage functions (Brodie et al., 2007).  MAX-specific effects 
with the potential to exacerbate and affect control of L. major infection include 
modulation of DC functions (such as delayed migration to lymph nodes, altered surface 
expression of co-stimulatory molecules, and  modifications in cytokine secretion), 
decreased production of protective Th1-biasing cytokines and effector molecules that 
serve to kill intracellular parasites (such as macrophage-produced H2O2 and NO), as well 
as increased production of exacerbative Th2-biasing cytokines (Gillespie et al., 2000; 
Soares et al., 1998).  In the context of L. major infection, the combination of MAX’s 
multiple and varied immunomodulatory effects clearly leads to the inhibition of 
protective immune responses, ultimately leading to exacerbation of infection and 
resultant disease.  In fact, some studies have suggested that successful natural 
transmission of L. major is literally dependent upon these immunomodulatory effects of 
salivary molecules: mice challenged with a biologically-relevant dose (10-100) of L. 
major in the absence of sand fly saliva do not become productively infected, while an 
identical dose of parasites co-injected with sand fly saliva leads to infection and disease 
(Titus and Ribeiro, 1988).  These observations indicated that immunization against MAX 
might elicit protection against challenge with L. major + Lu. longipalpis saliva, a 




and that we intended to further develop and characterize with the experiments described 
in Chapter 4.    
It has been repeatedly shown that the immunomodulatory effects of Lu. 
longipalpis SGLs can notably exacerbate infection with various Leishmania species of 
both New and Old World origin (Titus and Ribeiro, 1988; Samuelson et al., 1991; 
Warburg et al., 1994), and that MAX alone can substitute for the effects induced by SGLs 
(Morris et al., 2001).  In addition, there is a convincing catalog of evidence suggesting 
that an anti-saliva approach towards immunization is a realistic option for prevention of 
leishmaniasis.  Immunization with salivary proteins (such as MAX from the New World 
sand fly Lu. longipalpis or SP-15 from the Old World sand fly P. papatasi), whole saliva, 
or via pre-exposure to uninfected sand fly bites have all elicited significant protective 
immunity against infection with L. major and the subsequent development of cutaneous 
disease, typified by the production of anti-saliva antibodies and/or a cellular immune 
response characterized by high levels of IFN-γ production (Morris et al., 2001; 
Valenzuela et al., 2001; Kamhawi, 2000; Belkaid et al., 1998; Oliveira et al., 2008).  It is 
hypothesized that the IFN-γ response might have the dual effects of (1) causing enhanced 
early destruction of parasites and (2) accelerating the development of a protective, Th1-
biased anti-L. major response.  The results from these vector-saliva-based approaches to 
immunizing against infection with L. major are impressive and convincing, and warrant 
further investigation and characterization of the protective immune responses induced.      
Vaccines for prevention of leishmaniasis 
Following infection with L. major, most humans elicit an immune response 




reinfection (Neva and Brown, 1994), making cutaneous leishmaniasis one of the few 
parasitic human diseases for which a protective vaccine might be developed with a 
reasonable and realistic expectation of success.  However, there still exists no innocuous 
and useful human vaccine for prevention of cutaneous leishmaniasis.  Proposed 
requirements for an effective anti-Leishmania vaccine include the induction of strong IL-
12 and IFN-γ responses, elicitation of CD4+ Th1 responses and activation of CD8+ T 
cells, and the inclusion of a very potent adjuvant (Scott et al., 2004; Kedzierski et al., 
2006).   
A concise summary of the history of attempts to immunize against Leishmania 
infection is as follows:  “leishmanization”, or inoculation with live, viable Leishmania 
parasites, remains as the only genuinely-successful immunization strategy to be used in 
humans, but the safety concerns involved make it an unacceptable option for widespread 
prevention of infection (Modabber, 1995).  Vaccines utilizing killed Leishmania parasites 
have reduced the concerns of safety, but have proven to be much less efficacious, due in 
part to destruction of parasitic antigen epitopes and PAMPs that might otherwise elicit 
protective immune responses (Noazin, et al., 2009).  As a result, there have been repeated 
attempts to produce a vaccine formulation that is as safe as killed vaccines, but as 
efficacious as leishmanization; however, the general lack of effective adjuvants with the 
ability to induce a Th1-biased immune response is a major impediment to progress.  The 
most common adjuvants used in human immunization (the aluminum salt adjuvants) are 
potent inducers of antibody responses, but are not effective at eliciting antigen-specific 




Nevertheless, attempts to immunize against Leishmania parasites have yielded 
one particularly promising candidate, Leish-111f, which is a single recombinant 
polyprotein consisting of three fused molecules from L. major and L. braziliensis co-
administered with either IL-12 or a human-approved detoxified lipid A derivative from 
the lipopolysaccharide of Salmonella minnesota admixed with squalene (MPL-SE).  
After eliciting promising protection against both L. major and L. amazonensis in mouse 
challenge studies (characterized by both humoral and CD4+ T cell responses), Leish-111f 
became the first leishmaniasis vaccine to enter human clinical trials, and has already 
successfully completed Phase I and II trials in healthy human subjects (Coler et al., 
2007).  The efficacy of the Leish-111f vaccine has been, in part, attributed to the use of 
the MPL-SE adjuvant, which acts through TLR4 activation and is the first T-cell adjuvant 
approved for use in humans (Persing et al., 2002).  However, aside from this one 
particular success story, the development of effective anti-Leishmania vaccines for use in 
humans is still a considerable challenge.  Additionally, with more than 20 different 
pathogenic species of Leishmania being transmitted by more than 30 different species of 
sand flies, the task of developing multiple stand-alone vaccines that target individual 
Leishmania species will be difficult.  There is therefore a considerable need for 
innovative approaches to successful immunization against Leishmania.   
The availability of a strong adjuvant capable of eliciting responses from CD4+ 
Th1 and CD8+ T cells and the production of IL-12 and IFN-γ will considerably aid in 
these tasks.  As described previously, CLDCs possess all these qualities, and thus are a 
very promising option.  CLDC is also a logical choice of adjuvant because it activates 




responses to L. major (Liese et al., 2007; Schleicher et al., 2007).  Also, the development 
of a Th1-biased immune response following infection with L. major has been partially-
attributed to the early production of IFN-γ by NK cells, and it has been suggested that 
vaccine formulations that target NK cells (such as CLDC) might effectively promote Th1 
cell development (Scharton-Kersten and Scott, 1995).  Furthermore, CpG ODN treatment 
was shown to support the development of Th1 effector cells and elicit protective 
immunity against infection with L. major in susceptible BALB/c mice (Zimmerman et 
al., 1998), indicating again that CLDC might be a suitable adjuvant for polarizing the 
immune response toward protection.   An additional rationale for utilizing CLDC as an 
adjuvant in these experiments is based on the hypothesis that the anti-saliva Th1 immune 
response induced by immunization with a CLDC adjuvant might suppress the initial Th2-
biased immune response induced by co-injection of MAX (Roman, et al., 1997), allowing 
instead for the early development of immune responses appropriate for control of 
intracellular pathogens such as L. major.   
Dissertation Project 
At present, safe and efficacious vaccines and therapeutics for prevention and 
treatment of many arthropod-borne diseases are lacking.  The overall goal of this 
dissertation was to investigate CLDCs as potential immunotherapeutics and vaccine 
adjuvants for treatment or prevention of infection with arthropod-borne pathogens, 
whether occurring by natural or purposeful means.  We utilized CLDCs due to their 
abilities to selectively induce both a pro-inflammatory innate immune response typified 
by IFN-production and a resultant Th1-type adaptive immune response, which are 




CLDCs were demonstrated to be novel and effective vehicles for inducing protective 
immunity in these two very-disparate pathogen models that both require a host immune 
response appropriate for intracellular pathogen clearance.   
We show that (1) La Crosse virus (LACV) is transmissible via inhalation, and 
leads to the development of lethal LAC encephalitis in normally-resistant adult mice, (2) 
CLDC immunotherapy elicits prophylactic and therapeutic protection against aerosolized 
LACV challenge, and (3) immunization against the sand fly salivary peptide MAX using 
CLDC as adjuvant induces significant protection against challenge with Leishmania 
major + MAX.  These findings significantly enhance our understanding of the 
transmission and pathogenesis of these important pathogens, and provide supportive 
evidence of the efficacy of CLDCs as both immunotherapeutics and vaccine adjuvants for 
the treatment or prevention of intracellular pathogen infection requiring induction of a 







AEROSOL AND INTRANASAL CHALLENGE MODELS OF MURINE  
LA CROSSE VIRUS INFECTION 
Introduction 
 The Bunyaviridae comprise the largest family of arthropod-borne viruses, and 
bunyaviruses continue to emerge throughout the world, posing significant public health 
risk (e.g., encephalitis, meningitis, hemorrhagic fever and respiratory distress syndromes) 
to humans and animals (Calisher, 1994).  Many viruses in the family Bunyaviridae are 
designated as National Institute of Allergy and Infectious Diseases (NIAID) priority 
pathogens, including: Rift Valley fever virus (RVFV), Congo-Crimean hemorrhagic 
fever virus (CCHFV), La Crosse virus (LACV), Sin Nombre virus (SNV) and other 
hantaviruses, etc.  Members of the family Bunyaviridae have been described as likely 
agents of bioterrorism because of their ability to induce serious illness in human subjects, 
the ease with which large volumes of infectious material can be produced, the potential 
for transmission via aerosol, and the current lack of prophylactic or therapeutic 
approaches to treatment (Sidwell and Smee, 2003).  Considering the extraordinary 
evolutionary and epidemic potential of these viruses, their ability to emerge in new 
places, and their significance in human and veterinary health (Calisher, 1994), it is 
remarkable that licensed human vaccines or therapeutics for any of the bunyaviruses are 




LACV, family Bunyaviridae, genus Orthobunyavirus, is designated as an NIAID 
priority B pathogen.  The virus emerged as a significant human pathogen in the 1960s; 
the virus was isolated from the brain of a 4 year-old patient from Minnesota who was 
diagnosed with meningoencephalitis and subsequently died in La Crosse, Wisconsin 
(Thompson et al., 1965; Calisher, 1994; Rust et al., 1999).  Since its emergence, LACV 
has remained a significant cause of encephalitis and an important public health problem 
in the United States (Rust et al., 1999; McJunkin et al., 2001).   LACV is maintained in 
nature in a cycle involving Aedes triseriatus mosquitoes and chipmunks (Tamias striatus 
grinseus) and tree squirrels (e.g., Sciurus carolinensis).   
Humans are tangential hosts, and pre-pubertal children are at greatest risk for 
severe infections.  LACV infection of the central nervous system (CNS) in humans 
typically presents as meningoencephalitis with inflammation largely confined to the 
cerebral cortex, frequently resulting in seizures and coma and misdiagnosis as herpes 
encephalitis (McJunkin et al., 1997; Kalfayan, 1983; Sokol et al., 2001; Wurtz and 
Paleologos, 2000).  Milder infections typically occur in older individuals and result in 
flu-like symptoms, such as headache, fever, and vomiting (McJunkin et al., 2001).  
Although the mortality rate in children is low, recovery can be associated with significant 
neurologic sequelae, including learning disabilities, attention deficit hyperactivity 
disorder and seizures (McJunkin et al., 2001; Balfour et al., 1973).  Life-long costs 
attributed to these sequelae have been projected to range from $48,775 – $3,090,398 per 
patient (Utz et al., 2003).   There is neither a licensed vaccine nor a standard antiviral 
therapy for prevention of infection or treatment of La Crosse (LAC) encephalitis 




Mouse models of LACV infection following parenteral challenge have been 
developed and exploited to understand the pathogenesis of the virus in vertebrate hosts.  
Injecting suckling mice subcutaneously (sc) with as little as one plaque-forming unit 
(PFU) of LACV results in viremia, neuroinvasion, and fatal encephalitis.  However, by 3 
weeks of age, mice are almost uniformly-resistant to sc injection, even with >5 logs of 
virus, and neuroinvasion does not occur (Janssen et al., 1984).  In contrast, the virus is 
neurovirulent in both age cohorts; injecting one PFU of LACV intracranially into 
suckling or adult mice uniformly results in encephalitis and death.  Following sc 
inoculation, LACV replicates initially in striated muscle tissue, leading to a viremia and 
infection of the brain, possibly via passage of virus through vascular endothelial cells 
(Johnson, 1983; Janssen et al., 1984; Griot et al., 1993a; Griot et al., 1993b).  In weanling 
mice, intraperitoneal inoculation of LACV results in viremia and infection of multiple 
tissues, with the nasal turbinates yielding the greatest viral titers.  Intranasal inoculation 
of LACV in weanling mice also results in nasal turbinate infection, and virus can directly 
enter the CNS via the olfactory nerves in the nasal epithelium (Bennett et al., 2008).    
LACV is not only an important human pathogen, but it can also serve as a model 
for aerosol transmission of bunyaviruses.  Development of new, safe, and efficacious 
vaccines and therapeutics for bunyavirus infections, whether occurring by natural or 
purposeful airborne events, needs to be expedited.  Although LACV is naturally 
transmitted by the bite of an infected arthropod vector, in the studies described herein we 
developed inhalational challenge models using aerosol and intranasal inoculation in order 
to address this roadblock.  We hypothesized that inhalational challenge with LACV 




the infectivity, tissue tropism, and pathogenesis of LACV when delivered in aerosol or 
intranasal mouse challenge models.  
Materials and Methods 
 
Mice. 
5-6 week old (25g) female C3H, BALB/c, and ICR outbred mice were obtained 
from Harlan Laboratories (Indianapolis, IN) and National Cancer Institute (Frederick, 
MD).  All animals were housed for a minimum of 7 days prior to manipulation or 
challenge in order to allow for acclimation to the research facility.  All protocols and 
procedures involving animals were approved by Colorado State University’s Animal 
Care and Use Committee. 
Virus. 
La Crosse virus (wildtype(wt) human/1960), originally isolated from a human 
case in 1960 from La Crosse, WI, was used in all aerosol-challenge experiments.  The 
virus had been passed three times in suckling mouse brain followed by three passages in 
BHK-21 cells.  Stock virus (LAC wt) was then prepared by amplification in a fourth 
passage in BHK-21 cells in Leibovitz’s L-15 (Invitrogen, Carlsbad, CA) supplemented 
with 10% FCS (Colorado Serum Co., Denver, CO) and L-glutamine (Invitrogen), titrated 
in Vero cells in 96-well plates, and titers were determined and expressed as log10 tissue 
culture 50% infectious doses (TCID50) per mL or per gram of tissue (Kärber, 1931).  La 
Crosse virus (strain Lac Ori) was used in all intranasal-challenge experiments.  Lac Ori 
virus stocks were maintained and amplified in BHK-21 cells as described above.   
 
Aerosol challenge with LACV. 
For aerosol challenge, mice were exposed to LACV in a Middlebrook Airborne 




instructions in a BSL3 laboratory.   The mice were exposed to a suspension (5mL) of 
LACV (2.3 x 108 TCID50/mL).  All aerosol challenge experiments included a nebulizing 
time of 20 minutes (60 ft3/hr), followed by a 20 minute cloud decay and a 10 minute 
decontaminating UV exposure.  Experiments typically involved the exposure of 30 to 40 
mice per aerosolization.  Mice were then examined twice daily for a minimum of 28 days 
post-exposure for the development of signs of encephalitis (including sick rodent posture, 
repetitive behaviors, and hind limb paralysis).  All animals were humanely-sacrificed 
upon development of symptoms of clinical illness. 
Intranasal challenge with LACV. 
For intranasal challenge, mice were anesthetized with ketamine (100 mg/kg; Fort 
Dodge Animal health, Overland Park, KS) and xylazine (10 mg/kg; Ben Venue 
Laboratories, Bedford, OH).  LACV was thawed just before use, diluted in whole media 
and delivered in a 50 µL total volume (25µL/nostril) to anesthetized mice in groups of 4-
10 within a dose range of 5 x 101 - 5 x 106 TCID50.  Mice were then examined twice daily 
for a minimum of 28 days post-exposure for the development of signs of encephalitis, 
and animals were humanely-sacrificed upon development of clinical illness as described 
above. 
Histological staining and examination of brain tissue. 
Brains were harvested from 4-5 mice per challenge group at various time points 
following challenge (both prior to and concurrent with the development of clinical signs 
of encephalitis) in order to examine the histologic changes in the 2 experimental groups.  
The brain of each mouse was removed immediately after euthanasia, fixed in 10% neutral 
buffered formalin, and then coronally sectioned.  Tissue sections were processed 




eosin.  Tissue pathologic changes were determined by a professional veterinary 
pathologist.    
Determination of viral titer in tissues. 
Following aerosol LACV challenge, the following tissues and organs were 
extracted from 3 mice per timepoint at 2, 4, 6, 8 and 10 days post-challenge: serum, 
brain, nasal turbinates, lung, spleen, liver and kidney.  Following intranasal LACV 
challenge (5 x 104 TCID50 per mouse), identical tissues were collected from 5 mice per 
timepoint at 1, 2, 3, 5, 7 and 8 days post-challenge.   
Harvested tissues were placed in pre-weighed tubes containing 1 mL L-15 media plus 
10% FCS and stored at -70oC until homogenized via glass dounce grinder.  To determine 
viral titers, homogenates were briefly centrifuged (2 minutes at 14,000 rpm), diluted 
serially 1:10 in triplicate and added to Vero cells in a 96-well microplate format.  
Endpoints were determined, and titers were calculated (Kärber, 1931).  
Results 
Aerosol infectivity of LACV in ICR mice. 
Ten 6-week old female ICR mice were exposed to 2.3 x 108 TCID50 of LACV in a 
whole body Glas-Col aerosol exposure chamber for 20 minutes.  All mice subsequently 
developed clinical signs of CNS infection within 14 days post-challenge (Fig. 2.1).  Mice 
displayed a range of symptoms from sick rodent posture (lethargy or unwillingness to 
move, lack of grooming) to uncontrollable repetitive behavior (e.g., constant circling), to 
hind limb paralysis.  All mice were sacrificed immediately upon observation of any CNS 
symptoms.  The earliest time point that any mouse became sick was day 7 post-challenge 





Figure 1.1.  Aerosol challenge with LACV leads to 100% mortality.  ICR, BALB/c, and C3H 
mice (n = 10 animals) were challenged with a suspension (5.0 mL) of LACV (2.32 x 108 TCID50 
/mL) via aerosol exposure and survival times were determined as described in Materials and 
Methods.  Data shown are representative of two independent experiments.   
 
Aerosol infectivity of LACV in BALB/c and C3H mice. 
To ascertain whether similar kinetics of infection and/or levels of mortality would 
be observed in inbred mouse strains with differing genetic and immunologic 
backgrounds, ten female BALB/c mice and ten female C3H mice were challenged 
identically to the outbred mice.  A single mouse from each group was euthanized on day 
2 post-exposure, and the lungs were examined for lesions characteristic of infection (e.g., 
consolidation).  No pathologic changes were observed in the lungs of either mouse, 
suggesting that early viral replication in the lungs was not prominent in mice challenged 
in this fashion.  The remaining mice were then observed for at least 28 days for the 
development of signs of encephalitis.  Regardless of genetic background, all aerosol-






















challenged mice developed symptoms within 15 days following challenge, just as the 
ICR outbred mice had. The kinetics of symptom development were also comparable 
between the two inbred strains, as well as similar to that seen in the ICR challenge 
experiments (Fig. 2.1). The earliest time point for development of symptoms was day 8 
post-challenge for both C3H and BALB/c strains, while the latest development of 
symptoms was observed on day 13 for C3H and day 15 for BALB/c mice.  We chose to 
continue all further experiments with C3H mice because of their genetic similarity. 
Histologic lesions in mice following LACV aerosol challenge. 
In order to observe the pathogenesis of LACV in mice following aerosol 
challenge, brains were harvested at selected post-challenge time points for histological 
examination.  Only one mouse displayed clinical signs of CNS infection at the time of 
sacrifice (day 10).  In aerosol LACV-challenged animals, brain tissues contained 
histologic lesions of meningoencephalitis starting as early as day 3 post-challenge (Fig. 
2.2).   
 
Figure 2.2.  Histologic lesions in the CNS of aerosol-challenged animals.  C3H mice (n = 5 
animals) were challenged via aerosol with a suspension (5.0 mL) of LACV (2.32 x 108 
TCID50/mL) and brains were harvested at the first signs of disease.  Panel A illustrates severe 
lymphocytic necrotizing meningoencephalitis with areas of gliosis.  Panel B, at a higher 
magnification, shows parenchymal necrosis and inflammation.  Images are representative of 





18 post-challenge.  H&E stain, 4x objective magnification.  (B): Aerosol-challenged mouse brain, 
day 11 post-challenge.  H&E stain, 20x objective magnification. 
 
Lesions were extensive and severe in the brains of all mice by day 10 post-
challenge, regardless of symptom presentation or lack thereof.  Lesions presented in a 
patchy, multifocal pattern, and were observed at all levels of the brain, including the 
cerebral cortex, hippocampus, midbrain, meninges, and brainstem.  Lesions were typified 
by generalized meningoencephalitis with perivascular accumulations of lymphocytes and 
heterophils, in combination with neuronal degeneration and necrosis, rarefaction of the 
neuropil, and gliosis (Fig. 2.2).  Lymphocytes and plasma cells were present in the 
meninges and in perivascular locations within the cortex.  The inflammation and 
meningitis, although multifocal, were most pronounced in the anterior and ventral areas 
of the brain.  In the most severely-affected brains, there were foci of liquefaction of the 
brain parenchyma, and the meningitis extended to the ventral brain stem area.  All 
observed lesions were characteristically similar, but were present to variable extents; 
some brains presented with markedly-diminished cellular infiltrates and observable 
reductions in the degree of meningoencephalitis and the extent of neuronal necrosis.  In 
addition, some areas of the brain were unaffected.  Confirmation of LACV-presence was 
determined by amplification and detection of LACV M-segment RNA sequences via a 
nested reverse-transcriptase polymerase chain reaction (image not available).     
Virus tissue tropisms and titer following aerosol infection. 
To investigate the pathogenesis of LACV following aerosol infection, we 
harvested tissues from challenged mice at selected time points and titrated them for 
infectious virus.  Tissues with detectable titers of infectious virus included the lung, nasal 




and brain.  Liver, spleen and kidneys did not consistently contain infectious virus, if at 
all.  Virus was not detected in the sera of challenged mice at any timepoint, suggesting 
that unlike following sc infections, the development of viremia was not a prerequisite for 
neuroinvasion following aerosol infection.  
 
LACV was first detected in lungs of 2 of 3 mice on day 4 post-challenge, at which 
time the mean virus titer was 2.5 log10 TCID50/gram of lung tissue (Fig. 2.3).  LACV was 
not detected in the lungs of any mouse at any subsequent time point, suggesting that only 
transient infection of the lungs occurs following aerosol challenge or that virus titer is 
below the level of detection.  Nasal turbinates of challenged mice were assayed in order 
to determine if LACV infection occurred first in these tissues, which could then lead 
directly to neuroinvasion and CNS infection.  The nasal turbinates are located in close 
proximity to the brain and the rest of the CNS, and it is possible that infection of 
epithelial tissue could subsequently seed the bloodstream with infectious virus and/or 
directly infect the brain via olfactory neurons, which could discount the importance of 
early infection of the lungs as a prerequisite to neuroinvasion.   
Tissue Day 2 Day 4 Day 6 Day 8 Day 10
Serum NDVb NDV NDV NDV NDV
Brain NDV NDV 5.5 6.4 8.6
Nasal
Turbinates NDV 1.2 3.0 1.4 4.9
Liver NDV NDV NDV NDV NDV
Lung NDV 2.5 NDV NDV NDV
Kidney NDV NDV NDV NDV NDV
Spleen NDV NDV NDV NDV NDV
Table 2.1.  Detection of LACV in tissues of mice following aerosol challengea
a geometric mean (n = 3) log10 TCID50 titer per gram or mL of tissue





Figure 2.3.  Viral titer in mouse tissues following aerosol challenge with LACV.  C3H mice 
(n = 15 animals) were challenged with LACV via aerosol, and geometric mean viral titer 
(expressed as log10 TCID50/gram of tissue ± SEM) were determined in the brain, nasal turbinates, 
and lung at the indicated time points after challenge, as described in Materials and Methods.  Data 
are representative of two independent experiments.   
 
Nasal turbinate infection was first detected on day 4 post-challenge (Fig. 2.3).  By 
day 10, virus replication in this tissue had reached maximum titer (4.9 log10 
TCID50/gram).  These results suggest that the major site of peripheral replication 
following aerosol challenge is the nasal turbinates. 
Virus was first detected in the brains of challenged mice on day 6 post-challenge, 
and all brains were positive for infectious virus at all later timepoints.  Brain titer 
increased steadily throughout the time course, reaching the greatest titer in any assayed 
tissue by day 10 (8.6 log10 TCID50/gram) (Fig. 2.3).   




























Intranasal infectivity of LACV in C3H mice. 
Concerns about the actual dose of virus received by individual mice and 
differences in lung infection rates in the aerosol model prompted exploration of intranasal 
inoculation as an alternative to aerosol exposure as an inhalational model of LACV 
infection.  Intranasal challenge permits administration of a more-controlled and 
consistent dose of virus to each animal.  Sequential dilutions of LACV were administered 
intranasally to C3H mice, which were then monitored for CNS disease.  Symptoms were 
more pronounced than those seen in mice infected by aerosol, with most encephalitic 
mice presenting with hind limb paralysis and/or complete inability or unwillingness to 
move.  The kinetics of disease presentation were also quite uniform in intranasally-
challenged mice. Challenge with 50 µl of inoculum containing  5 x 106, 5 x 105, or 5 x 
104 TCID50 of LACV resulted in 100% mortality in all groups, and all but one mouse 
displayed symptoms of CNS infection by day 8 post-challenge (Fig. 2.4).  This remaining 
mouse ultimately developed symptoms on day 14.  Of those challenged with the three 
lower doses of virus, only one mouse (challenged with an inoculum containing 5 x 103 
TCID50) developed neurological disease and this did not occur until day 14 post-
challenge.  All mice challenged at 5 x102 or 5 x101 TCID50 survived to day 28 without 
development of signs of CNS disease.  
 
Histological lesions following intranasal infection with LACV. 
To determine the pathogenesis of LACV in mice infected following intranasal 





Figure 2.4.  Survival of mice following intranasal challenge with LACV.  C3H mice (n = 4 
animals) were challenged intranasally with LACV (strain Lac Ori) at one of six dosages ranging 
from 5x101 to 5x106 TCID50  and survival times were determined as described in Materials and 
Methods.  Data shown are representative of two independent experiments.  
 
Histological examination of the brains of mice challenged intranasally with LACV 
revealed inflammation of the brain parenchyma and the meninges (meningoencephalitis) 
in all animals euthanized following the development of clinical signs of CNS disease.  
The inflammation was characterized by a meningeal and perivascular infiltrate of 
lymphocytes and plasma cells, with variable numbers of macrophages and neutrophils, 
depending on the severity and acuteness/chronicity of the inflammatory process (Fig. 
2.5).  Necrosis was noted in association with inflammation (necrotizing 
meningoencephalitis) and was characterized by rarefaction of the neuropil, cellular 
debris, and neuronal necrosis.  Very severe inflammation was present specifically in the 
olfactory lobes, which in some animals was so severe that there was liquefaction of the 


























parenchyma and replacement by foamy macrophages (i.e., gitter cells, which are 
microglial cells swollen with phagocytic debris from dead cells of the CNS) (Fig. 2.5B). 
 
Figure 2.5.  Histologic lesions in the CNS of intranasally-challenged animals.  C3H mice (n = 
5 animals) were challenged intranasally with 50 µL of inoculum containing 5 x104 TCID50 of 
LACV and brains were harvested at the first signs of disease. Panel A illustrates severe 
lymphocytic necrotizing meningoencephalitis with areas of parenchymal necrosis.  Panel B, at a 
higher magnification, shows inflammation, parenchymal necrosis, and accumulations of gitter 
cells.  Images are representative of results obtained from three independent experiments.  (A): 
Intranasally-challenged mouse brain, showing nasal turbinates and section 41 of the olfactory 
lobes; day 9 post-challenge.  H&E stain, 20x objective magnification.  (B): Intranasally-
challenged mouse brain, showing section 41 of the olfactory lobe; day 9 post-challenge.  H&E 
stain, 40x objective magnification. 
 
Additionally, necrotizing inflammation was most often noted in the ventral aspect of the 
rostral cerebrum (the anatomical location of the olfactory tubercles), suggesting ascent of 
the infection along the olfactory tracts.  Inflammation in the brain stem and obex was 
lower in magnitude and frequency, and active necrosis was absent in these caudal aspects 
of the brain.  No significant differences in the patterns of pathologic changes were 
observed following intranasal vs. aerosol challenge, but the former consistently caused 
more-severe pathologic changes, possibly due to a higher challenge dose.  LACV was 
confirmed to be present in the brain by amplification and detection of LACV M-segment 
RNA sequences via a nested reverse-transcriptase polymerase chain reaction (image not 





Virus tissue tropisms and titer following intranasal infection. 
Tissue tropisms and kinetics of infection following intranasal infection were 
determined.  Tissues with detectable titers of infectious virus included serum, brain, nasal 
turbinates, liver, and lung (Table 2.2).  As with aerosol infection, the greatest titers were 
detected in the nasal turbinates and brain.   
 
Virus was detectable in tissues as early as day 2 post-challenge (Fig. 2.6), in 
contrast to the aerosol-challenge model, in which infectious virus was first detected in 
any tissue on day 4 post-challenge.  
LACV was first detected in the serum of intranasally-challenged mice on day 2 
post-challenge (mean titer = 1.8 log10 TCID50 /mL) (Fig. 2.6).  By day 3, virus titer 
reached a mean titer of 2.7 log10 TCID50 /mL.  No virus was detected in the serum of any 
mouse at any subsequent time point, suggesting that viremia had been cleared or was at 
very low titer.     
Day 1 Day 2 Day 3 Day 5 Day 7 Day 8
Tissue
Serum NDVb 1.8 2.7 NDV NDV NDV
Brain NDV 2.5 1.9 5.6 5.5 6.9
Nasal
Turbinates NDV 4.3 4.3 4.7 4.9 5.4
Liver NDV 1.4 1.3 0.5 NDV NDV
Lung NDV 1.5 2.2 NDV NDV 4.3
Table 2.2.  Detection of LACV in tissues of mice following intranasal challengea
a geometric mean (n = 5) log10 TCID50 titer per gram or mL of tissue





Figure 2.6.  Viral titer in mouse tissues following intranasal challenge with LACV.  C3H 
mice (n = 5 animals) were challenged intranasally with LACV, and geometric mean viral titers 
(expressed as log10 TCID50/gram or /mL of tissue ± SEM) were determined in the brain, nasal 
turbinates, lung, liver, and serum at the indicated days post-challenge, as described in Materials 
and Methods.  Data are representative of two independent experiments.   
   
LACV was first detected in lung tissue on day 2 post-challenge (mean titer = 1.5 
log10 TCID50 /gram); by day 3, viral mean titer increased to 2.2 log10 TCID50 /gram (Fig. 
2.6).  On days 5 and 7 post-challenge, virus was not detectable in lungs; however, virus 
was again detectable in the lungs on day 8 and titered at 4.3 log10 TCID50/gram. 
Virus was detected in the livers of intranasally-challenged mice at a maximum 
titer of 1.4 log10 TCID50 /gram at 2 days post-challenge (Fig. 2.6).  Viral load in the liver 
decreased steadily on days 3 and 5 post-challenge, and was not detectable at any 
subsequently-assayed time points.   
































Nasal turbinate infection was first detected on day 2 post-challenge, and mean 
nasal turbinate titer increased throughout the time course, reaching a maximum mean titer 
of 5.4 log10 TCID50/gram on day 8 (Fig. 2.6).  The LACV titer in the nasal turbinates on 
day 8 post-challenge was the highest of any of the peripheral tissues assayed from 
intranasally-challenged mice.   
LACV was first detected in the brains of challenged mice on day 2 post-exposure; 
all assayed brains were positive for infectious virus at all subsequent time points.  In 
general, mean brain titer increased throughout the time course and reached a maximum 
mean titer of 6.9 log10 TCID50 /gram of tissue on day 8 (Fig 2.6).  This was the greatest 
titer of LACV detected in any tissue.     
Discussion 
Adult mice have been demonstrated to be very resistant to LACV infection 
following subcutaneous or intramuscular challenge, even when challenged with high 
doses of virus (Johnson, 1983; Janssen et al., 1984).  Prior studies in our laboratory have 
shown that less than 10% of adult mice develop CNS disease when injected with 1 x 105 
TCID50 of virus subcutaneously or intramuscularly (unpublished observations).  In 
contrast, the current studies demonstrate that adult mice are very susceptible to aerosol or 
intranasal challenge with LACV.  The classical model of LACV infection via peripheral 
routes involves initial replication in skeletal muscle tissue near the site of infection with 
eventual infection of the vascular endothelium and development of viremia. The virus 
may then bypass the blood-brain barrier and enter the CNS though infection of the 
vascular tissue supplying the brain (Johnson, 1983; Janssen et. al, 1984; Griot et. al, 
1993a; Griot et. al, 1993b).  High viremia titer is thought to condition neuroinvasiveness 




require a viremia to negotiate the blood-brain barrier; rather, the virus could infect tissues 
in the nasal epithelium, including olfactory neurons, and thus be transported directly into 
the CNS. 
We have demonstrated that adult mice can be infected by both aerosol and 
intranasal challenge with LACV, leading to high rates of mortality: 100% of challenged 
mice succumbed to lethal LAC encephalitis within 15 days following aerosol challenge, 
and groups of mice challenged intranasally exhibited 100% mortality as early as day 7 
post-challenge.  The faster kinetics of mortality seen following intranasal challenge are 
likely attributable to the dose of virus administered to the respective mice and the portal 
of entry for the virus following intranasal and aerosol infection.  Intranasal challenge 
would theoretically result in higher challenge doses, but might also involve a more-direct 
challenge of nasal epithelial tissues in close contact with the CNS, allowing for 
accelerated neuroinvasion and more rapid mortality.  Regardless of the route of 
challenge, the significant titers of LACV in nasal turbinate tissues likely condition 
neuroinvasiveness and may overwhelm the normal immune mechanisms that protect 
adult mice from CNS infection.  To our knowledge, this is the first report of an aerosol 
challenge with LACV leading reproducibly to the development of lethal encephalitis in 
high percentages of normally-resistant adult mice.  However, because of the ability to 
better control the dose and route of infection, the intranasal challenge route would seem 
to be the better model of inhalational infection.   
Following aerosol or intranasal challenge, LACV replicated in various peripheral 
tissues before entering the brain and causing CNS disease.  In mice challenged via 




challenge.  LACV was maintained in the nasal turbinates at high titer through day 10 of 
infection, but was not detected in lung tissues after day 4.  LACV was first detectable in 
the brains of aerosol-challenge mice on day 6 post-challenge, implying that the virus 
must infect and replicate in peripheral tissues before neuroinvasion occurs.  The virus 
replicated in the brain to the greatest titer found in any tissue in aerosol-infected mice.  
Further studies will be necessary to determine if the virus was replicating in the lungs or 
was a result of viremia or shedding of virus into the lower respiratory tract from nasal 
turbinates.   
In mice challenged via intranasal inoculation, LACV was detected in the nasal 
turbinates and brain on day 2 post-challenge and remained there at high titers throughout 
the course of infection.  LACV was also transiently detected in the lungs between days 2-
3 post challenge. In contrast to aerosol infection, LACV was also detected in the livers 
and serum of intranasally-infected mice.  Viremia was detectable between days 2 and 3 
post-challenge, while LACV was present in the liver between days 2 and 5.  The presence 
of a detectable viremia following intranasal challenge was a significant and notable 
difference between the two challenge models; viremia was not detected in the serum of 
any mouse infected following aerosol challenge.  Viremia following intranasal infection 
may have been a contributing factor to subsequent neuroinvasion in the intranasal 
challenge model.     
Intranasal infection also resulted in more rapid infection of organs and tissues.  
Following intranasal infection, LACV was detected concurrently in the CNS and in other 
tissues, in contrast to aerosol infection, in which virus was detected in peripheral tissues 




detectable in tissues as early as day 2 following intranasal challenge, but not until day 4 
following aerosol challenge.  Viral titers were greater in the nasal turbinates of 
intranasally-challenged mice than in aerosol-challenged mice.  These increased viral 
titers in the nasal turbinates of intranasally-challenged mice may have accelerated 
neuroinvasion and death.  
In summary, intranasal infection leads to accelerated infection, infection of 
additional peripheral tissues, higher viral titers in tissues, earlier CNS infection, and 
earlier time to death than aerosol infection.  Inoculation of high doses of LACV directly 
into the nasal passages may have led to rapid infection of peripheral tissues (primarily the 
nasal turbinates), where LACV was able to replicate to high titers sufficient to either seed 
the bloodstream or to ascend the olfactory neurons, allowing for quick entry to the brain 
and resulting in faster kinetics of mortality.  It is notable that in both challenge models, 
the major site of peripheral replication was the nasal turbinates.  
These patterns of LACV tissue tropism support the observations of Bennett et al., 
who showed that weanling (4 week-old) Swiss Webster mice were susceptible to lethal 
LACV infection by either the intranasal or intraperitoneal routes (2008).  Interestingly, 
this research group also found the peripheral tissue with the highest titers of virus to be 
the nasal turbinates, and suggested that LACV could presumably enter the CNS via the 
olfactory neurons that bridge the nasal olfactory epithelium and the brain.  The abnormal 
susceptibility of adult mice to intranasal and/or aerosol challenge with LACV may indeed 
be explained by the close association between these tissues of the upper respiratory tract 
and the brain/CNS.  Indeed, many other arboviruses can be aerosol transmitted and some 




Larson et al., 1980; Ryzhikov et. al, 1995a; Ryzhikov et. al, 1995b; Vogel et. al, 1996).  
Our studies suggest that many other arboviruses and rodent borne viruses may also be 
infectious to humans when delivered via aerosol and thus are of bioterrorism concern.   
Both aerosol and intranasal challenge with LACV led to the development of 
histologic lesions of encephalitis in the brains of challenged mice, typified by generalized 
meningoencephalitis with histological evidence of disease.  No significant differences in 
the patterns of pathologic changes were observed due to intranasal vs. aerosol challenge, 
but the severity of lesions was consistently worse following intranasal challenge.  In the 
aerosol model, the inflammation and meningitis, although multifocal, were most 
pronounced in the anterior and ventral areas of the brain.  In the most severely-affected 
brains of aerosol-challenged mice, there were foci of liquefaction of the brain 
parenchyma, and the meningitis extended to the ventral brain stem area.  In the intranasal 
model, very severe inflammation was noted specifically in the olfactory lobes, which in 
some animals was again so severe that there was liquefaction of the parenchyma and 
replacement by foamy macrophages.  Additionally, in the intranasal challenge model 
necrotizing inflammation was most often noted in the ventral aspect of the rostral 
cerebrum (the anatomical location of the olfactory tubercles), suggesting ascent of the 
infection along the olfactory tracts in this challenge model.  Accordingly, inflammation in 
the brain stem and obex was lower in magnitude and frequency, and active necrosis was 
absent in these caudal aspects of intranasally-challenged brains.   
The increased severity of histologic lesions in the intranasal challenge model 
might again be the result of a more-direct challenge of the nasal turbinates with a higher 




differ between the two challenge models.  It is possible that intranasal challenge provides 
for a more-direct infection of the CNS via the olfactory tract (as has been demonstrated 
with Japanese Encephalitis virus), leading to the more-localized lesions of encephalitis 
found in the rostral portions of the mouse brain.  Coupled with the histological 
observations of lesions largely confined to the anterior and ventral portions of the brains 
of intranasally-challenged mice, the observation that LACV consistently grew to its 
highest peripheral titers in the nasal turbinates strongly suggests that a direct infection of 
the CNS is occurring through the olfactory tract.  This direct intranasal infection route 
may also explain the earlier and more uniform presentation of clinical encephalitis in 
intranasally-challenged mice.   
The neurological lesions observed in the brains of mice challenged with LACV 
either intranasally or via aerosol were indistinguishable from those that have been 
observed in mice infected by vector-borne or subcutaneous routes: mainly a non-focused 
meningoencephalitis characterized by a large amount of cellular infiltrate (perivascular 
cuffing) and necrosis (Pekosz et al., 1996).  Interestingly, this pattern of pathological 
changes is not noted in the brains of younger suckling mice challenged with LACV, in 
which apoptosis is thought to be responsible for most of the neural damage and the 
associated inflammation is mild.  It has been suggested that increased cellular 
differentiation in the adult CNS, including increased expression levels of the anti-
apoptotic regulator bcl-2 (Pekosz et al., 1996) may account for this difference.  This may 
explain, in part, the normally-refractory nature of adult mice to the development of LAC 
encephalitis.  The unnatural route of infection or introduction of high titers of virus into 




protect adult mice from CNS infection.  As with mice, older (post-pubertal) humans 
become decreasingly susceptible to encephalitis, which occurs almost exclusively in 
younger patients (Johnson, 1983; McJunkin et al., 2001).  Our studies suggest that adults 
could experience severe neurological disease following aerosol exposure to LACV and 
related viruses.  This is cause for concern and requires rethinking of the process for 
inclusion and exclusion of viruses from the NIAID priority pathogens.  
In summary, inhalational (aerosol and intranasal) models of LACV infection in 
adult mice have been developed.  Following either aerosol or intranasal challenge with 
LACV, 100% of normally-refractory adult mice developed clinical and histological signs 
of LAC encephalitis.  Importantly, in the aerosol model, LACV viremia was never 
detected, suggesting that direct infection of the nasal olfactory epithelium can lead 
directly to CNS infection in absence of a viremia, which has been classically-accepted as 
a prerequisite to neuroinvasion.  This ability of aerosol- or intranasally-delivered LACV 
to cause 100% mortality in normally-resistant adult mice underscores the dangerous 
potential of members of the Bunyaviridae as possible bioterrorism agents.  These 
inhalational LACV challenge models will hopefully serve as useful tools with which to 
test the efficacy of sorely-needed vaccines and therapeutics to be used in the events of 







IMMUNOSTIMULATORY CATIONIC LIPOSOME-DNA COMPLEXES ELICIT 
PROTECTION AGAINST AEROSOLIZED LA CROSSE VIRUS CHALLENGE 
IN A MURINE MODEL 
Introduction 
 Viruses in the family Bunyaviridae designated by the National Institute of Allergy 
and Infectious Diseases (NIAID) as Category A, B, and C priority pathogens include Rift 
Valley fever virus (RVFV), Crimean-Congo hemorrhagic fever virus (CCHFV), La 
Crosse virus (LACV) and other related encephalitis viruses, as well as Sin Nombre virus 
(SNV) and other related hantaviruses (Nichol, 2001).  Many recently-emerged or 
emerging viruses also belong to the family Bunyaviridae.  Despite their significance in 
public and veterinary health (Calisher, 1994), their remarkable potential to emerge in new 
areas, and their significant potential for use as bioterrorism agents, vaccines and licensed 
antiviral treatments for many of these viruses are lacking.  Furthermore, with more than 
250 members, it is difficult to imagine developing protective vaccine formulations for all 
the many bunyaviruses that could emerge in human populations resulting from natural or 
purposeful events (Beaty and Calisher, 1991).  Novel immunological approaches are 
sorely needed to prevent and control these increasingly-important pathogens. 
LACV (family Bunyaviridae, genus Orthobunyavirus) first emerged as an 
important human pathogen in the 1960s (Thompson et al., 1965) and has since persisted 




United States (Rust et al., 1999, McJunkin et al., 2001).  In endemic areas, the incidence 
of La Crosse (LAC) encephalitis surpasses that of bacterial meningitis (McJunkin et al., 
2001), and LACV remains the leading cause of pediatric encephalitis in the United States 
with approximately 70-130 cases with severe neurological involvement diagnosed 
annually.  Significantly, the actual number of pediatric infections that occur is thought to 
be vastly underdiagnosed (Calisher, 1994).  In the past, most cases of LAC encephalitis 
have occurred in states of the upper Midwest; more recently, however, cases have been 
identified in North Carolina, West Virginia, Tennessee, and Missouri (Jones et al., 1999; 
CDC, 2010; Haddow and Odoi, 2009;  Haddow et al., 2011 ).  Aedes triseriatus (the 
Eastern Treehole mosquito) is the principal vector of LACV, efficiently transmitting 
LACV both horizontally and transovarially (Watts et al., 1973).  The recent isolation of 
LACV from field-collected larvae and male Aedes albopictus (a species introduced into 
the North American continent within the last two decades) and the connection of this 
vector to human cases in Tennessee collectively are a cause for concern to public health 
(Gerhardt et al., 2001; Erwin et al., 2002) as Ae. albopictus has been shown to be a 
competent vector of LACV (Tesh and Gubler, 1975; Hughes et al., 2006) and LAC 
encephalitis is on the rise in the South, where recent cases have been reported in 
Louisiana, Alabama, Georgia, and Florida (Lambert et al., 2010). 
Severe LACV infection of the central nervous system (CNS) in humans 
commonly presents with clinical signs of seizures and eventual coma, and the brains of 
patients display histologic lesions of meningoencephalitis consisting of cellular infiltrates 
largely confined to the cerebral cortex (McJunkin et al., 1997; Kalfayan, 1983).  Milder 




headache, fever, and vomiting (McJunkin et al., 2001).  Recovery can be associated with 
significant neurological sequelae, including learning disabilities, attention deficit 
hyperactivity disorder and seizures (McJunkin et al., 2001; Balfour et al., 1973).  At 
present there is neither a licensed vaccine nor a standard antiviral therapy for prevention 
of LACV infection or treatment of LAC encephalitis, providing impetus for the 
development of immunotherapies for treatment of this severe disease (Hollidge, 2010). 
 The data on the immunostimulatory and immunoenhancing properties of cationic 
liposome-nucleic acid complexes is well documented (Dow, 2008).  When deployed in 
combination with certain pathogen-associated molecular patterns (PAMPs), such as non-
methylated CpG motifs enriched in bacterial DNA, cationic liposomes are capable of 
facilitating endocytic uptake and markedly enhancing the innate immune stimulatory 
properties of such adsorbed molecules (Gursel et al., 2001; Krieg, 2002).  It has been 
proposed that this potentiation of the innate immune response is due to the ability of 
cationic liposomes to protect adsorbed nucleic acids from extracellular degradation while 
simultaneously localizing the complexes to the early endosomal compartment of targeted 
cells, the primary site of expression for nucleic acid pattern recognition receptors (PRRs) 
(Akira and Takeda, 2004; Akira, 2006; Zaks et al., 2006; Takeuchi and Akira, 2007).  
The first detailed description of intravenous treatment with liposome-DNA complexes 
leading to stimulation of the innate immune system resulted from investigations of these 
formulations for potential immunotherapeutic treatment of tumors (Dow et al., 1999a).  
The authors determined that the observed CLDC-induced antitumor effects were a result 
of stimulation of the innate immune system, specifically the activation of natural killer 




liposome-DNA complexes (CLDC) to stimulate the innate immune system makes them 
uniquely appealing as non-specific immunotherapeutics and vaccine adjuvants.  CLDCs 
or liposomal CpG oligodeoxynucleotide (ODN) complexes have not only been shown to 
exert notable anticancer activity in various animal tumor models (Dow et al., 1999a; 
Whitmore et al., 1999; Whitmore et al., 2001; Lanuti et al., 2000; Dow et al., 1999b), but 
have also been successfully used for immunotherapeutic treatment of acute viral (Gowen 
et al., 2006; Gowen et al., 2008; Logue et al., 2010) and bacterial infections (Goodyear et 
al., 2009; Troyer et al., 2009).  CLDCs are actively endocytosed by antigen presenting 
cells (APCs) such as plasmacytoid dendritic cells (pDCs) and target delivery of adsorbed 
and protected molecules to the cellular endosomal compartment containing Toll-like 
receptors (TLRs) such as TLR3, TLR7/8, and TLR9. These PRRs recognize molecules 
common to various microorganisms and signal for the development of a non-specific 
immune response, resulting in the release of soluble effector molecules and the activation 
of innate immune cells.  Unmethylated CpG ODNs efficiently bind to and activate TLR9, 
a signal receptor selectively expressed within the endosomal compartment of dendritic 
cells (DC), macrophages and B cells.  Ligation of TLR9 leads to prompt non-specific 
activation of the immune system, principally in the spleen and draining lymph nodes. 
This response is typified by the release of pro-inflammatory cytokines, including TNF, 
IL-1β, IL-6, IL-12, IFN-γ, IFN-α and IFN-β (Ishii et al., 2004; Klinman et al., 2004).  
The particular cytokine milieu triggered following TLR9 ligation yields an immune 
response with a clear antiviral potential and Th1-type immune bias, which (if utilized as 
an adjuvant in the context of immunization, rather than as a stand-alone 




required for clearance of intracellular pathogens and control of tumor growth (Krieg, 
2007).  In addition, ligation of TLR9 leads to prompt cellular stimulation, characterized 
by upregulation of co-stimulatory molecules on DCs and macrophages, functional 
maturation of APCs, and NK cell activation and infiltration (Dow et al., 1999b).  The 
immunostimulatory properties of CLDC have also been shown to be regulated in part by 
TLR-independent pathways and receptors, such as the cytosolic DNA sensor DAI (DNA-
dependent activator of IFN-regulatory factors) (Ishii and Akira, 2006; Stetson and 
Medzhitov, 2006b; Takaoka et al., 2007; Takaoka and Taniguchi, 2008).  Taken as a 
whole, the ability of CLDCs to selectively activate this type of an innate immune 
response suggests that they may be appropriate for use as an antiviral immunotherapy.  
For example, in a lethal mouse model of Punta Toro Virus (PTV) infection, CLDC 
administration prior to challenge was shown to increase survival, reduce viral load, and 
lessen the severity and presentation of disease symptoms (Gowen et al., 2006).  The 
absence of PTV antigen in the CLDC formulation affirms that the conferred protection 
was due to innate, non-specific antiviral effector responses.  Though the immunological 
mechanisms of protection were not determined in this study, it was hypothesized that the 
observed protection was mediated by type I interferons (IFN).  Similar CLDC-induced 
antiviral effects were more recently reported in a murine model of lethal Western equine 
encephalitis virus challenge (Logue et al, 2010). 
We examined the ability of CLDC immunotherapy to elicit protection against a 
lethal challenge with LACV, hypothesizing that CLDC treatment would protect against 
the development of lethal LAC encephalitis in adult mice following aerosol challenge 




and mouse models for parenteral LACV infection have been long established (Johnson, 
1983; Janssen et al., 1984).  However, many members of the family Bunyaviridae are 
designated as NIAID priority pathogens due to their potential to be used as agents of 
bioterrorism (Sidwell and Smee, 2003).  This is due to a number of factors, including the 
ability of LACV and other members of the Bunyaviridae to induce serious illness in 
human subjects, the ease with which large volumes of infectious material can be 
produced, their potential for transmission via aerosol, and the current lack of prophylactic 
or therapeutic approaches to treatment (Sidwell and Smee, 2003).  LACV is not only an 
important human pathogen, but also can serve as a model for development of therapeutics 
for other members of the family Bunyaviridae.  In this regard, we recently developed a 
mouse model for aerosol infection with LACV (unpublished observations, see Chapter 2) 
and have now used this model to investigate the protective efficacy of CLDC 
immunotherapy for aerosol infection by bunyaviruses.  CLDC immunotherapy protected 
mice against lethal aerosol challenge with LACV when administered pre-, co-, or post-
challenge.  CLDC immunotherapy, administered either prophylactically or 
therapeutically, provides a potential novel new approach to protect against natural or 
purposeful challenge with members of the Bunyaviridae. 
In order to determine the ability of CLDC administration to reduce viral 
replication in challenged mice, various tissues were harvested for quantification of viral 
load at various time points after challenge.  To verify the extent of infection and 
associated neuropathologic changes, brain tissues from treated and untreated mice were 
examined histologically for lesions of encephalitis.  Innate immune responses were also 




brain.  Finally, we systemically-depleted NK cells from mice prior to immunotherapeutic 
treatment in order to determine the importance of this cell type in CLDC-induced 
protection.   
Materials and Methods 
Mice. 
5-6 week old (25g) female C3H, BALB/c, and ICR outbred mice were obtained 
from Harlan Laboratories (Indianapolis, IN) and National Cancer Institute (Frederick, 
MD).  All animals were housed for a minimum of 7 days prior to respective treatments or 
challenge in order to allow for acclimation to the research facility.  All protocols and 
procedures involving animals were approved by Colorado State University’s Institutional 
Animal Care and Use Committee. 
Virus. 
La Crosse virus (wild type; wt), originally isolated from a human case in 1960 
from La Crosse, WI, was used in all experiments.  This low-passage virus stock had been 
passed three times in suckling mouse brain followed by three passages in BHK-21 cells 
maintained in Leibovitz’s L-15 (Invitrogen, Carlsbad, CA) medium supplemented with 
10% FCS (Colorado Serum Co., Denver, CO) and L-glutamine (Invitrogen).  Stock virus 
(LAC wt) was then prepared by a fourth passage in BHK-21 cells and titrated in Vero 
cells in 96-well plates.  The titer was calculated by the method of Kärber (1931).   
Aerosol challenge with LACV. 
For delivery of aerosolized LACV, mice were exposed to a 5 mL suspension of 
virus (2.32 x 108 TCID50/mL) in a Middlebrook Airborne Infection Apparatus (Glas-Col 
LLC, Terre Haute, IN) under BSL3 conditions according to the manufacturer’s 
instructions.  Conditions for all aerosol challenge experiments included a nebulizing time 




decontaminating UV exposure (Arthun et al., 2011, submitted).  Experiments typically 
involved the exposure of 30 to 40 mice per aerosolization.  Mice were then examined 
twice daily for a minimum of 28 days post-exposure (maximum of 90 days post-
exposure) for the development of signs of encephalitis (including sick rodent posture, 
repetitive behaviors, and hind limb paralysis).  All animals were humanely sacrificed 
upon development of symptoms of clinical encephalitis.    
Preparation and administration of cationic liposome-DNA complexes. 
Cationic liposomes were prepared as previously described by combining 
equimolar amounts of DOTIM [octadecanoyloxy(ethyl-2-heptadecenyl-3-hydroxyethyl) 
imidazolinium chloride] and cholesterol (Templeton et al., 1997).  Cationic liposome-
DNA complexes (CLDC) were prepared fresh immediately prior to injection by gently 
mixing cationic liposomes with plasmid DNA (pMB75.6 empty vector, 3 mg/mL) in 
sterile Tris-buffered 5% dextrose in water at room temperature.  The final concentration 
of plasmid DNA was 100 µg DNA/mL.  For treatment of mice, 250 µL of the CLDC 
formulation was injected intraperitoneally (i.p.) at the appropriate timepoint.  Control 
mice in all experiments received an i.p. sham injection of 250 µL Tris-buffered 5% 
dextrose in water (diluent).  Additional controls included mice treated with cationic 
liposomes alone or plasmid-DNA alone.   
Preparation and administration of CpG oligonucleotide constructs. 
Mice (10-20/treatment group) were injected i.p. with either 250 µL CLDC, 50 µg 
Type C CpG oligonucleotide 2395 (InvivoGen, San Diego, CA) diluted in 250 µL 
1xPBS, or 250 µL diluent 24 hours before aerosol challenge with LACV, and were then 





Histopathological examination of challenged mouse brains. 
Brains from 4 sham-treated mice were harvested at the first signs of disease and 
compared to time-matched CLDC-treated mouse brains to examine the histologic 
changes in the 2 experimental groups.  The brain of each mouse was removed 
immediately after euthanasia, fixed in 10% neutral buffered formalin, and then coronally 
sectioned.  Tissue sections were processed routinely, embedded in paraffin, sectioned at 5 
µm, and stained with hematoxylin and eosin.  Tissues were evaluated by a professional 
veterinary pathologist.    
Determination of viral titer in tissues. 
To detect and quantify viral replication, tissues were extracted from 3 mice per 
treatment group at 2, 4, 6, 8 and 10 days post-challenge.  Collected tissues included 
serum, brain, nasal turbinates, lung, spleen, liver and kidney.  Once harvested, tissues 
were placed in pre-weighed tubes containing 1 mL L-15 medium plus 10% FCS and 
stored at -70oC until homogenized using a glass dounce grinder.  To determine viral 
titers, homogenates were briefly centrifuged (2 minutes at 14,000 rpm), diluted serially 
1:10 in triplicate and added to Vero cells in a 96-well microplate format to determine end 
point dilution titer (TCID50) via the method of Kärber (Kärber 1931).  
Sample preparation for cytokine gene expression analysis. 
Tissues were extracted from 3 mice per treatment group at days 2 and 4 post-
challenge.  Collected tissues included brain, lung and spleen.  Tissues were placed in 1 
mL green bead tubes (Roche, Switzerland) containing 500 µL TRIzol Reagent 
(Invitrogen, Carlsbad, CA) and homogenized in a Roche Magna Lyser.  Lungs and 
spleens were initially homogenized using two primary pulses of 30 seconds at 3500 g, 
while brains were initially homogenized using two primary pulses of 20 seconds at 3000 




was added to each green bead tube, followed by two additional pulses as described above.  
Secondary tissue homogenates were collected, pooled with the primary samples, and 
stored at –80 °C.  Total RNA was extracted following the manufacturer’s protocol for 
TRIzol Reagent.  Residual DNA was then removed via treatment with 4U of DNase I 
Amplification Grade (Invitrogen) in a 100 µL volume.  Further RNA purification was 
performed using the RNeasy Mini Kit (Qiagen, Valencia, CA) RNA cleanup protocol.  
RNA preparations were quantified using a SmartSpec 3000 Spectrophotometer (Bio-Rad, 
Hercules, CA) at OD260. 
Cytokine gene expression analysis via quantitative reverse transcription-PCR. 
5 µg total RNA was reverse transcribed to cDNA using the SuperScript III First-
Strand Synthesis Kit for RT-PCR (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol.  The provided oligo dT was used to prime the reverse 
transcription reaction.  Cytokine-specific DNA levels were determined using FAM dye-
labeled Taq-Man probes, specific primers, and Taqman Universal PCR Master Mix 
(Applied Biosystems Inc., Foster City, CA).  Polymerase chain reactions were prepared 
in a 96-well format and run on an iCycler (Bio-Rad, Hercules, CA).  In order to control 
for differing levels of mRNA between individual samples, expression of cytokine mRNA 
was normalized to the expression of the hypoxanthine guanine phosphoribosyl transferase 
1 (HPRT1) housekeeping gene.  Fold-changes in cytokine transcript levels between 
individual samples were calculated using the ΔΔCt method of relative quantification. 
Natural killer cell depletion. 
Systemic depletion of murine natural killer cells was accomplished by i.p. 
injection of 50 µg anti-asialo-GM1 antibody (Wako, Osaka, Japan).  Anti-asialo-GM1 




order to maintain continuous depletion of the natural killer cell population.  Antibody 
treatment resulted in 80% decreases in both lung and splenic natural killer cell counts at 
24 hours post-depletion.  The mice were then challenged with aerosolized LACV 24 
hours after CLDC treatment.  Control mice were injected i.p. with 50 µg ChromPure 
rabbit IgG antibody (Jackson ImmunoResearch, West Grove, PA).   
Statistical analysis. 
Statistical analyses were conducted using Prism 5.0 software (GraphPad, La Jolla, 
CA).  Kaplan-Meier curves and the log-rank test were used for comparison of survival 
times.  For survival comparison of more than two groups, the Bonferroni correction was 
applied.  For comparisons between two groups, two-tailed t tests were performed.  Data 






Intraperitoneal administration of CLDC protects mice from the development of LAC 
encephalitis when administered prophylactically and therapeutically. 
We recently developed a murine model of aerosol-delivered LACV challenge that 
results in the development of LAC encephalitis in adult mice (unpublished observations, 
see Chapter 2).  In order to examine the protective potential of prophylactic CLDC 
immunotherapy in this challenge model, mice were injected i.p. with CLDC at 24 hours 
prior to or immediately prior to aerosolized LACV challenge.  To ensure that any 
protective CLDC effect was not merely a delay of symptom onset, mice were observed 
for the development of symptoms of LAC encephalitis up to 90 days post-challenge.  In 
contrast to the cumulative survival rate of sham-treated control mice (24.5%; 13/53 mice 
in 3 independent experiments), the overall survival rate for mice pretreated with CLDC 
was 95.8% (23/24; p = 0.0001) for those treated 24 hours prior to challenge, and 90% 
(18/20; p = 0.0001) for those treated immediately prior to challenge (Fig. 3.1).  
Additional controls included mice treated with plasmid DNA alone or cationic liposomes 
alone.  Neither of these control groups was protected to the extent of the complete CLDC 
formulation.  In contrast to the cumulative survival rate of mice treated with CLDC 24 
hours prior to challenge (95.8%), the overall survival rate was 20% for control mice 
treated with either plasmid DNA alone (4/5; p < 0.0001) or cationic liposomes alone 
(4/5; p < 0.0001), indicating that both components are required for elicitation of complete 





Figure 2.1.  Prophylactic CLDC-induced protection against aerosolized LACV challenge.  
(A) C3H mice (n = 5-10 animals per group) were challenged via aerosol with a suspension (5.0 
mL) of LACV (2.32 x 108 TCID50/mL) and the effects of the timing of administration of 
prophylactic CLDC immunotherapy were determined.  Mice were sham-injected (untreated) or 
were treated with CLDC 24 h prior to challenge (-24h) or immediately prior to challenge (0h), 
and survival times were determined as described in Materials and Methods.  Groups of control 
mice (n = 5 animals) were treated with plasmid DNA alone or liposomes alone at 24 h prior to 
challenge.  Statistical differences in survivorship were determined by Kaplan-Meier analysis, 
followed by a log-rank test (***, P ≤ 0.0001).  Data shown are cumulative data from three 
independent experiments.   
 
  CLDC-treated mice that eventually developed encephalitis survived markedly 
longer than the majority of those in the sham-treated control group (Fig. 3.1), 
demonstrating that CLDC pre-treatment both increased survival and delayed disease 
onset.  Additional challenge experiments performed with either BALB/c or ICR outbred 
mice yielded similar protective results, regardless of mouse strain.  Overall, prophylactic 
treatment with CLDC induced significant innate immune protection against an otherwise 
lethal aerosol challenge with LACV.   
 In order to examine the protective potential of therapeutic CLDC immunotherapy 
following aerosol infection, mice were injected i.p. with CLDC at 12, 36, or 72 hours 
following aerosolized LACV challenge (as above) and were observed for morbidity and 
























clinical outcome.  Administration of CLDC within two days following aerosol infection 
provided significant protection against the development of clinical signs of encephalitis 
(Fig. 3.2).   
 
Figure 3.2.  Therapeutic CLDC-induced protection against aerosolized LACV challenge is 
dependent on the timing of CLDC administration.  (B) C3H mice (n = 5-10 animals per 
group) were challenged via aerosol with a suspension (5.0 mL) of LACV (2.32 x 108 TCID50/mL) 
and the effects of the timing of administration of therapeutic CLDC immunotherapy were 
determined.  Mice were sham-treated (untreated) or were treated with CLDC 12 h, 36 h, or 72 h 
after challenge, and survival times were determined as described in Materials and Methods.  
Statistical differences in survivorship were determined by Kaplan-Meier analysis, followed by a 
log-rank test (**, P = 0.0003; *, P = .0034).  Data shown are cumulative data from three 
independent experiments.   
 
Following therapeutic administration of CLDC at 12 hours post exposure, 63.2% 
of mice (12/19 in 3 independent experiments) survived (p = 0.0003), following treatment 
at 36 hours post-exposure, 60% of mice (12/20) survived (p = 0.0034), and following 
treatment at 72 hours post-exposure, only 35% of mice (7/20) survived (p = 0.08).  The 
cumulative survival rate of sham-injected mice was 25% (31/124).  Therapeutic CLDC 
immunotherapy was therefore most effective at time points closest to challenge, with 
protective efficacy waning closer to background levels in the 72 hour post-exposure 

























treatment groups.  In contrast to the prophylactic treatment (Fig. 3.1), therapeutic CLDC 
treatment (Fig. 3.2) did not delay disease onset. 
 In order to investigate the mechanisms that condition the protective efficacy of 
CLDC treatment against aerosolized LACV challenge, we compared CLDC-induced 
protection to that induced by treatment with synthetic CpG-containing oligonucleotides 
as alternative TLR9 agonists.  Mice were injected i.p. with equivalent amounts of either 
CLDC, Type C CpG oligonucleotide 2395, or diluent 24 hours prior to challenge with 
aerosolized LACV and then observed for the development of clinical signs of 
encephalitis.  CLDC treatment yielded the highest survival rate observed (80%, p < 
0.0001), while CpG oligonucleotide or diluent treatment yielded only 50% (p < 0.0001) 
and 10% survival rates, respectively (Fig. 3.3). 
 
Figure 3.3.  CLDC immunotherapy elicits protection against aerosolized LACV challenge 
exceeding that induced by CpG oligonucleotide constructs alone.  C3H mice (n = 10-20 
animals) were injected i.p. with either 250 μL CLDC, 50 μg CpG oligonucleotide 2395 diluted in 
250 μL 1x PBS, or were sham-injected (untreated) 24 hours before aerosol challenge with LACV, 
and survival times were determined as described in Materials and Methods.  Statistical 
differences in survivorship were determined by Kaplan-Meier analysis, followed by a log-rank 
test.  Mice treated with either CLDC or CpG survived at significantly higher percentages than 























untreated control mice (p < 0.0001).  Mice treated with CLDC survived at significantly higher 
percentages than mice treated with CpG (*; p = 0.0252).  Data shown are cumulative data from 
two independent experiments.    
 
CLDC immunotherapy elicits protection (p = 0.0252) against aerosolized LACV 
challenge exceeding that induced by conventional immunotherapy using synthetic Type 
C CpG oligonucleotides alone.   
CLDC reduces the severity of histological lesions in the central nervous system of 
challenged animals. 
In order to clarify the mechanism(s) of the protection elicited by CLDC 
immunotherapy against lethal aerosol challenge with LACV, we next investigated 
whether there was a reduction in pathological changes in the brains of challenged mice 
due to CLDC administration.  Examination of brain tissues revealed histologic lesions of 
meningoencephalitis in all aerosolized LACV-challenged animals, regardless of 
treatment or lack thereof (Fig. 3.4).   
 
Figure 3.4.  CLDC pre-treatment reduces the severity of histologic lesions in the CNS of 
challenged animals.  C3H mice (n = 4 animals) were challenged via aerosol with a suspension 
(5.0 mL) of LACV (2.32 x 108 TCID50/mL) and the effects of prophylactic CLDC administration 
on histologic changes in the brain were determined.  Mice were sham-injected (untreated) or were 
treated with CLDC 24 h prior to challenge.  Brains from four untreated mice were harvested at 
the first signs of disease and compared to time-matched CLDC-treated mouse brains.  Direct 




comparison of representative brain sections of untreated (A) vs. CLDC-treated (B) mice reveals 
significant differences in the severity of histological lesions of encephalitis, typified by 
meningitis (thick arrow), lymphocytic infiltration, and necrosis (thin lines).  Images are 
representative of results obtained from three independent experiments.  (A): Untreated mouse 
brain, day 18 post-challenge.  H&E stain, 20x objective magnification.  (B): CLDC-treated mouse 
brain, day 18 post-challenge.  H&E stain, 20x objective magnification. 
 
Lesions presented in a multifocal pattern, and were observed at all levels of the 
brain, including the cerebral cortex, hippocampus, midbrain, meninges, and brainstem.  
Lesions were typified by generalized meningoencephalitis with perivascular 
accumulations of lymphocytes and heterophils, in combination with neuronal 
degeneration and necrosis, rarefaction of the neuropil, and gliosis.  Lymphocytes and 
plasma cells were present in the meninges and in perivascular locations within the cortex.  
The inflammation and meningitis, although multifocal, were most pronounced in the 
anterior and ventral areas of the brain.  In the most severely-affected brains, there were 
foci of liquefaction of the brain parenchyma, and the meningitis extended to the ventral 
brain stem area.  All observed lesions were characteristically similar, but were present to 
variable extents depending on CLDC treatment or lack thereof (Fig. 3.4).  Lesions were 
categorized as extensive and severe in the brains of sham-treated mice, while those in the 
brains of CLDC-treated animals were consistently smaller and less severe, categorized as 
mild to moderate, with markedly-diminished cellular infiltrates and observable reductions 
in the degree of meningoencephalitis and the extent of neuronal necrosis.  The presence 
of obvious neurological involvement in both groups demonstrated that CLDC treatment 
did not completely prevent invasion of the CNS by LACV, but rather lessened the 
neuropathology to the point that most mice did not display clinical symptoms of CNS 





Comparison of viral titer and tissue tropism in challenged animals.   
The previous experiment revealed that CLDC treatment increased survival and 
reduced disease severity in LACV-infected mice.  To investigate the pathogenesis and 
tissue tropisms of LACV in CLDC- and sham-treated mice that condition the differences 
in disease outcomes, organs were harvested at selected time points post-infection, and 
virus infection kinetics and titers were determined in mice in the two treatment groups 
(Fig. 3.5). 
 
Figure 3.5.  Effects of CLDC immunotherapy on viral load in mouse tissues following 
aerosol challenge with LACV.  C3H mice (n = 15 animals) were sham-injected (untreated) or 
treated with CLDC 24 h prior to aerosol challenge with LACV.  Geometric mean viral titers 
(expressed as log10 TCID50/gram or /mL of tissue ± SEM) were determined in the serum (A), lung 
(B), nasal turbinates (C), and brain (D) at the indicated time points after LACV challenge, as 
described in Materials and Methods.  Data are representative of two independent experiments.   
 


























































































amA.  Serum  





Infectious virus was transiently found in serum and lung tissues, and once 
infected, persistently found in the nasal turbinates and brain (Fig. 3.5) in CLDC- and 
sham-treated mice.  Spleen, liver, and kidneys were not consistently infected in either 
treatment group.  Tissue tropisms were generally the same in both groups; however, viral 
infection of specific tissues was delayed and titers were reduced in CLDC-treated mouse 
tissues (Fig. 3.5A-D).  In fact, all sham-treated control mice developed clinical signs of 
LAC encephalitis by day 8 post-challenge and were humanely sacrificed.  Thus we were 
unable to collect tissues on day 10 for comparison to CLDC-treated mice. 
LACV was transiently detected in sera of sham-treated control mice at 2 days 
post-challenge (2.5 log10 TCID50 /mL), but viremia declined to undetectable levels by day 
4 (Fig. 3.5A).  LACV viremia was never detected in CLDC-treated mice at any time 
point post-challenge, demonstrating that a high-titered viremia is not necessary for 
neuroinvasion. 
LACV was detected in lungs.  The highest titers were detected in lungs of sham-
treated control mice at day 2 post-challenge (2.9 log10 TCID50 /gram).  Viral titer declined 
in this group on days 4 and 6 post-challenge, and was undetectable by day 8 (Fig. 3.5B).  
Conversely, no infectious virus was detected in the lungs of CLDC-treated mice during 
the first 6 days post-challenge.  Strangely, virus was detected in the lungs of 2 of 3 mice 
on day 8 post-challenge (2.8 log10 TCID50 /gram), but on day 10 post-challenge virus was 
not detectable.  The reason for this is unknown and could be attributable to CLDC 
treatment preventing or delaying lung infection in the majority of infected mice, or 




LACV was also detected in the nasal turbinates of infected animals (Fig. 3.5C).  
At every time point, the nasal turbinates of all sham-injected mice contained infectious 
virus.  Nasal turbinate infection was detected at day 2 post-challenge, and LACV titer 
increased to a maximum titer on day 6 (6.0 log10 TCID50 /gram) (Fig. 3.5C).  Conversely, 
the nasal turbinates of CLDC-treated mice had no detectable LACV until day 4 post-
challenge.  Mean viral titers were lower in the nasal turbinates of CLDC-treated mice 
than in the sham-treated mice at all assayed timepoints.  The maximum mean titer found 
in the nasal turbinates of CLDC-treated mice was 4.0 log10 TCID50 /gram (day 8 post-
challenge) and was notably lower than the maximum titer of 6.0 log10 TCID50 /gram (day 
6 post-challenge) in the sham-treated mice.  Further, the nasal turbinates of all sham-
injected control mice contained infectious virus, but only 1 of 3 CLDC-treated mice had 
detectable virus in nasal turbinates on days 6 and 10 post-challenge, and only 2 of 3 
CLDC-treated mice yielded virus on days 4 and 8.  These results again suggest that 
CLDC treatment both delayed and prevented or reduced LACV infection of tissues.   
A similar trend of viral infection kinetics was observed in the brains of challenged 
mice (Fig. 3.5D).  Virus was detected in the brains of all sham-treated control mice on 
day 6 post exposure, and maximum mean brain titer (7.1 log10 TCID50 /gram), which was 
the greatest titer seen in any assayed tissue, was detected on day 8 (Fig. 3.5D).  In 
contrast, virus was not detected in the brains of any CLDC-treated mouse until day 8 
post-challenge.  This titer was lower than those in the brains of sham-treated control mice 
at days 6 or 8 post-challenge.  By day 10, the mean viral titer in the brains of CLDC-
treated mice had peaked at 2.8 log10 TCID50 /gram.  These data suggest that CLDC 




tissues and the central nervous system.  These results are supported by our observation 
that a significantly higher percentage of mice in the sham-treated group had 
seroconverted to LACV than in the CLDC-treated group; this suggested that CLDC 
immunotherapy was either preventing infection or limiting viral replication to an 
immunologically undetectable level in treated mice, and demonstrated that a higher 
proportion of sham-injected mice were indeed infected with LACV (data not shown).     
CLDC elicits interferon responses in the context of LACV challenge. 
The observations that CLDC treatment both delayed virus infection and restricted 
viral replication in challenged animals suggested induction of a protective antiviral innate 
immune response in CLDC-treated animals.  In order to characterize the nature of this 
immune response and to identify potential cytokines involved, we determined whether 
CLDC administration would lead to increased interferon (IFN) gene expression in either 
peripheral tissues or the CNS of challenged animals.  Levels of mRNA expression of two 
type I interferons (IFN-α5 and IFN-β1) and type II IFN-γ were compared between 
CLDC-treated and untreated animals using quantitative reverse transcriptase PCR (qRT-
PCR).  This approach allowed us to quantitatively determine the fold-differences in type I 
and II IFN mRNA expression in the spleens and brains of CLDC-treated and untreated 
mice (Fig. 3.6).   
At both days 2 and 4 post-challenge, spleens from CLDC-treated mice (n = 3 per 
group) expressed significantly increased levels of both IFN-α5 and IFN-β1 mRNA 
transcripts (Fig. 3.6A and 3.6B).  IFN-α5 expression in the CLDC-treated group was 
increased 36-fold over the levels in the control group on day 2 post-challenge, and on day 





Figure 3.6.  Expression of cytokine genes in the spleen and brain following CLDC 
administration and aerosolized LACV challenge. C3H mice (n = 15 animals) were sham-
injected (untreated) or were treated with CLDC 24 h prior to aerosol challenge with LACV, and 
tissues were harvested at days 2 and 4 post-challenge.  Cytokine gene expression in spleen and 
brain tissues of  untreated and CLDC-treated mice (n = 3 per group) was determined via 
quantitative real-time PCR, as described in Materials and Methods.  The mean fold change 
(+SEM) in mRNA expression between untreated and CLDC-treated mice is shown for IFN-α5 
(A) and IFN-β1 (B) in the spleen, and for IFN-𝛾 (C) in the brain.  Statistical differences were 
determined using a nonparametric two-tailed Mann-Whitney test (*, P < 0.05).  Data are 
representative of two independent experiments.   
 
Mice in the CLDC-treated group expressed 19-fold more IFN-β1 mRNA than 
controls on day 2, and these levels were still 11-fold higher than that found in control 
mice on day 4 post-challenge (Fig. 3.6B).  These increases in peripheral type I IFN 
expression were also found to be associated with elevated IFN-γ levels in the brains of 
CLDC-treated mice at both 2 and 4 days post-challenge (Fig. 3.6C).  On day 2, IFN-γ 
levels were 3-fold higher in the brains of CLDC-treated mice than untreated mice, and by 









































































These observations provide evidence that CLDC treatment induces transcription of 
important antiviral cytokines that could account for the protective effects observed in 
treated mice.    
Systemic depletion of natural killer cells abrogates CLDC-induced protection. 
Previously-published studies using CLDC immunotherapy identified NK cells as 
the major cell type responsible for the production of IFN-γ (Dow et al., 1999a; Dow et 
al., 1999b; U’Ren et al., 2006; Goodyear et al., 2009; Troyer et al., 2009).  In order to 
determine the importance of NK cells in the protection elicited by CLDC treatment in the 
aerosolized LACV model, anti-asialo GM1 antibodies were used to systemically deplete 
NK cells prior to treatment with CLDC and aerosol challenge (Fig. 3.7).  This antibody 
preparation results in systemic NK cell depletion that lasts for at least 5 days (Habu et al., 
1981; Kasai et al., 1980).  Flow cytometric analysis of cells from the lungs and spleens of 
NK-depleted mice revealed the NK-depletion efficiency to be ~80% (data not shown). 
 
Figure 3.7.  Depletion of NK cells significantly reduces survival in CLDC-pre-treated mice.    
C3H mice (n = 9-10 per group) were depleted of NK cells via i.p. injection of anti-asialo-GM1 
antibody 24 hours prior to CLDC treatment and again 5 days later, as described in Materials and 
Methods.  A control group received an irrelevant rabbit IgG control antibody.  Mice were sham-
injected (untreated) or were treated with CLDC and then challenged 24 hours later with 























aerosolized LACV, and survival times were determined.  CLDC-treated non-NK-depleted mice 
survived at significantly higher percentages than CLDC-treated NK-depleted mice (*;p < 0.05).  
Statistical differences were determined using Kaplan-Meier analysis followed by the log-rank test 
(*, P < 0.05).  Data are representative of two independent experiments.     
 
100% of CLDC-treated mice which had not had their NK cells depleted survived 
aerosol challenge, while only 33.3% of mice depleted of NK cells prior to CLDC 
treatment survived to 28 days post-challenge (Fig. 3.7; *; p < 0.05).  This observation 
suggests that NK cells play an important role in CLDC-induced protection against aerosol 
challenge, and are necessary for the induction of complete protection.  It is notable that 
the CLDC-treated, NK cell-depleted mice had a significantly higher survival rate (33.3%) 




 In this study, we investigated both the prophylactic and therapeutic efficacy of 
CLDC immunotherapy and assessed its ability to (a) prevent lethality in mice challenged 
by aerosol with LACV (Figs. 3.1, 3.2, and 3.3), (b) reduce the severity of CNS lesions in 
challenged mice (Fig. 3.4), (c) prevent, reduce, or delay infection of the sera, lungs, nasal 
turbinates and brain (Fig. 3.5), and (d) induce the expression of antiviral type I and II 
IFNs (Fig. 3.6).  Adult mice are normally refractive to LACV infection when challenged 
peripherally, even with quite high subcutaneous doses (Johnson, 1983; Janssen et al., 
1984).  Previous studies in our lab have shown that less than 10% of adult mice develop 
neurological disease when given as much as 1 x105 TCID50 of LACV subcutaneously or 
intramuscularly (unpublished observations).  The classical model of LACV infection via 
peripheral routes involves initial replication in skeletal muscle tissue near the site of 




endothelium. The virus is then thought to bypass the blood-brain barrier and enter the 
CNS through infection of this vascular tissue supplying the brain (Johnson, 1983; Janssen 
et. al, 1984; Griot et. al, 1993a; Griot et. al, 1993b).  More recent studies involving 
intraperitoneal and intranasal inoculation of weanling mice with LACV have proposed 
that invasion of the CNS might alternatively occur via infection of the nasal turbinates 
and subsequent utilization of olfactory neurons as a means of gaining entry to the brain 
(Bennett et al., 2008).  Our recently-developed aerosol- or intranasally-delivered LACV 
challenge models have also identified infection of the nasal turbinates as an important 
prerequisite for subsequent CNS infection (unpublished observations, see Chapter 2).   
In contrast to parenteral infection, adult mice are very susceptible to LACV 
infection via aerosol.  Aerosol challenge with LACV results in nearly 100% morbidity 
and mortality within two weeks of challenge.  Neurological lesions are indistinguishable 
from those that have been observed in mice infected by vector-borne or subcutaneous 
routes, mainly a multifocal meningioencephalitis characterized by a large amount of 
cellular infiltrate (perivascular cuffing) and necrosis (Pekosz et al., 1996; unpublished 
observations, see Chapter 2).  Interestingly, this pattern of neurological lesions is not 
noted in younger suckling mice, in which apoptosis is thought to be responsible for most 
of the neural damage and inflammation is mild.  It has been suggested that increased 
cellular differentiation in the adult CNS, including increased expression levels of the anti-
apoptotic regulator bcl-2 (Pekosz et al. 1996) may account for this difference.  This 
reduction in neuronal apoptosis may explain, in part, the typically-refractory nature of 
adult mice to the development of LAC encephalitis.  Aerosol delivery of LACV may 




kinetics of infection and potentially high dosages of virus may then overwhelm the 
normal mechanisms that protect adult mice from a damaging inflammatory response that 
results in meningioencephalitis. The near 100% morbidity and mortality seen in 
normally-refractory adult mice when challenged via aerosol underscores the danger of 
these pathogens as possible bioterrorism agents. 
 Prior studies have successfully demonstrated the antiviral capacity and protective 
effects of CLDC administration against lethal subcutaneous challenge with members of 
the Bunyaviridae and Togaviridae (Gowen et al., 2006; Gowen et al., 2008; Logue et al., 
2010).  In addition, CLDC immunotherapy has been shown to significantly reduce the 
quantity of hepatitis B viral transcripts in a transgenic mouse model (Morrey et al., 2008).  
To our knowledge, however, this is the first published report of CLDC administration 
eliciting protection in an aerosolized virus challenge model.  Prophylactic treatment with 
CLDC greatly increased the survival of mice challenged with aerosolized LACV (>95% 
compared to <25% in controls; Fig. 3.1).  Therapeutic administration was found to be 
most protective when given at time points closest to challenge, with 60% survival seen as 
far out as 36 hours post-exposure.  However, by 72 hours post-challenge, protective 
efficacy was reduced to non-significant levels (p = 0.08), indicating that once infection is 
well-established CLDC immunotherapy can no longer affect outcome (Fig. 3.2).  
Nonetheless, the therapeutic window for post-exposure treatment of inhalational LACV 
infection suggests the feasibility of CLDC treatment as a possible immunotherapeutic 
intervention in the event of a bioterrorist attack employing aerosolized members of the 
Bunyaviridae.  The protection elicited by the complete CLDC formulation exceeded that 




3.1) or with synthetic CpG-containing oligonucleotides alone (Fig. 3.3).  The inclusion of 
cationic liposomes in the complete CLDC formulation likely serves to both protect the 
plasmid DNA from extracellular degradation and to localize the complexes to the early 
endosomal compartment, allowing for maximal and targeted enhancement of the intended 
innate immune response.    
Histological examination of the brains of CLDC-treated mice showed only mild 
pathological changes in the CNS compared to a severe inflammatory response in sham-
treated controls (Fig. 3.4).  Encephalitic lesions in CLDC-treated mice were consistently 
smaller and less severe, with considerably-diminished cellular infiltrates and significant 
reductions in the degree of meningoencephalitis and the magnitude of neuronal necrosis.  
Presumably, CLDC treatment reduced infection of the CNS and/or lessened the 
associated neuropathology to the point that most mice did not develop clinical symptoms 
of LAC encephalitis, thereby increasing the chances of recovery.   
Pathogenesis studies (Fig. 3.5A-D) revealed that viral infection and titers in 
peripheral tissues and the brains of CLDC-treated animals were both delayed in initial 
appearance and reduced in titer in all assayed tissues.  Viremia was not detected in the 
serum of any CLDC-treated mouse at any assayed time point.  In addition, in CLDC-
treated mice, lung infection was both delayed and decreased in titer following CLDC 
treatment, and in some cases virus infection was not detected.  It is possible that CLDC-
induced innate immune activation either dampens or prevents initial infection and 
subsequent replication of virus in the lungs (and other peripheral tissues), allowing for a 
delayed dissemination to other tissues (as seen in Fig. 3.5).  LACV was detected in the 




CLDC-treated mice.  Presumably, CLDC treatment reduces viral replication kinetics and 
titer and associated neuropathology to levels that allow mice to survive LACV infection 
and to avoid development of lethal LAC encephalitis.   
This conclusion is further supported by our observation that sham-treated mice 
seroconverted to produce LACV-neutralizing antibodies at a notably-higher percentage 
than CLDC-treated mice (data not shown), demonstrating that a higher proportion of 
untreated mice were indeed infected with LACV, and suggesting again that CLDC 
immunotherapy either prevents infection or delays and limits viral replication in treated 
mice. 
A particularly striking result of the pathogenesis studies was the lack of detectable 
viremia at any time point in all CLDC-treated mice.  The classically-accepted murine 
model of peripheral LACV infection assumes that the generation of a high viremia is 
required for subsequent invasion and infection of the CNS (Janssen et al., 1984).  
However, despite the lack of detectable viremia in CLDC-treated mice, infectious virus 
was detectable in the brains of CLDC-treated mice on days 8 and 10 post-challenge (Fig. 
3.5D).  These results suggest that high titered viremia is not a prerequisite for 
neuroinvasion in our aerosol infection model.  LACV could directly infect the nasal 
turbinate epithelium and olfactory nerves for transport into the CNS.   The observation 
that aerosol-challenged mice that subsequently develop CNS infection did not have a 
detectable viremia is in contrast to the classically-accepted murine model of peripheral 
LACV infection, and challenges our present notions concerning the mechanism(s) of 
neuroinvasion by LACV and the subsequent development of LAC encephalitis in both 




adult mice are very susceptible to LACV infection and severe disease outcome when 
infected via aerosol and intranasally (unpublished observations, see Chapter 2).  Perhaps 
virus infection of the olfactory neurons results in more rapid infection, different routes of 
infection, or greater doses of LACV being introduced into the CNS, thereby 
overwhelming the immune and/or molecular mechanisms that protect adult mice from 
lethal encephalitis when infected parenterally.  Regardless, the demonstration that LACV 
aerosol infection results in LAC encephalitis, even in adults, underscores the potential 
danger of the use of LACV and/or other members of the Bunyaviridae as agents of 
bioterrorism.  
Previous studies have identified both IFN-α and IFN-β as important mediators of 
protection against murine LACV infection (Blakqori et al., 2007).  In addition, 
production of IFN-γ is known to exert direct antiviral responses through the induction of 
various antiviral effectors, including double-stranded RNA-activated protein kinase 
(PKR), 2’-5’ oligoadenylate synthetase (2-5A synthetase), and dsRNA-specific adenosine 
deaminase (dsRAD) (Boehm et al., 1997).  In fact, IFN-γ is critical for antiviral responses 
in the CNS, in which non-cytolytic clearance of intracellular viruses is required for 
preservation of neuronal function (Chesler and Reiss, 2002).  CLDC treatment prior to 
aerosolized LACV challenge elicited significant fold-increases in expression of both IFN-
α5 and IFN-β1 in the spleen and IFN-γ in the brain during the first 48 hours following 
challenge (Fig. 3.6).  These observed increases in expression of important antiviral 
cytokines could very well account for the reductions in viral load and lessened 
neuropathologic changes in this treatment group, as the establishment of a type I IFN-




interfere with initial viral infection, propagation and spread to neighboring tissues.  
Additionally, the increased expression of IFN-γ in the brains of CLDC-treated mice 
might serve to simultaneously control CNS infections and preserve neuronal function in 
those mice that did not successfully prevent LACV neuroinvasion.  The importance of the 
IFN response in protection against infection with LACV is further highlighted by results 
from in vivo studies that have shown that LACV nonstructural protein NSs modulates the 
antiviral type I IFN response in mammalian hosts (Blakqori et al., 2007).  The increases 
in IFN expression induced by CLDC administration may serve to overcome this viral 
defense strategy evolved to disarm important and effective antiviral innate immune 
responses of the mammalian host.   
NK cells have been identified in previous studies utilizing CLDC immunotherapy 
as the major cell type responsible for the production of IFN-γ (Dow et al., 1999a; Dow et 
al., 1999b; U’Ren et al., 2006; Goodyear et al., 2009; Troyer et al., 2009).  In our 
experiments, depletion of NK cells prior to treatment with CLDC and subsequent aerosol 
challenge significantly reduced survival percentages (Fig. 3.7), identifying an integral 
role played by NK cells in complete CLDC-induced protection in this challenge model.  
The additional observation that a small subset of NK-depleted, CLDC-treated mice were 
still protected from the development of LAC encephalitis suggests that other cell types or 
other IFN-γ-producing cells may also serve an integral function alongside NK cells in 
complete CLDC-induced protection.  An alternative hypothesis is that as the depletion 
efficiency of NK cells was found not to be wholly complete (~80%, data not shown), 
production of IFN-γ by the remaining NK cell population in the depleted group might 




To our knowledge, this is the first published report of CLDC-induced protection 
in an aerosolized viral infection model, which highlights the protective potential of both 
prophylactic and therapeutic CLDC administration in response to a purposeful 
bioterrorism event using aerosolized viral pathogens.  A plausible protective mechanism 
in this experimental system is the combination of antiviral type I and II IFN production 
and NK cell activation, which together lead to the development of an antiviral 
immunological state paired with non-cytolytic clearance of intracellular LACV in the 
CNS.  This immunological environment has the potential to significantly interfere with 
initial viral propagation and subsequent spread to neighboring tissues, effectively 
reducing viral load and associated neuropathology to levels that allow for control of 
and/or recovery from LACV infection.  While the exact mechanism of protection has yet 
to be determined, the observation that non-specific CLDC treatment can be 
prophylactically and therapeutically used to prevent and treat LAC encephalitis is 
provocative.  CLDC immunotherapy may be an innovative new approach for preventing 
and treating aerosol and conventional infections by members of the Bunyaviridae and 






CATIONIC LIPOSOME-DNA COMPLEX (CLDC)-BASED IMMUNIZATION 
AGAINST THE SAND FLY SALIVARY PEPTIDE MAXADILAN PROTECTS 
AGAINST LEISHMANIA MAJOR INFECTION 
Introduction 
 The leishmaniases are a group of vector-borne diseases caused by infection with 
obligate intracellular protozoan parasites of the genus Leishmania, transmitted to 
vertebrate hosts by the bite of infected female phlebotomine sand flies of the genera 
Phlebotomus and Lutzomyia.  Within vertebrates, the infective stage metacyclic 
promastigotes are phagocytized by macrophages, in which they differentiate into the 
intracellular amastigote form and replicate within phagolysosomes, leading to the 
development of a spectrum of diseases extending from mild cutaneous forms to lethal 
visceral infections (Herwaldt, 1999).  More than 350 million people living in endemic 
regions in 88 different countries are at risk for infection, and more than 12 million people 
are thought to be presently infected, with an estimated 1.5-2 million new cases arising 
each year (World Health Organization, Leishmaniasis home page: 
http://www.who.int/leishmaniasis/en/; Desjeux, 2004).  In addition, Leishmania infection 
of United States military personnel deployed to Afghanistan, Iraq, and Kuwait is cause 
for domestic concern (Centers for Disease Control and Prevention, 2004).     
Infection with Leishmania major (L. major) leads to the development of Old 




develop a protective immune response capable of clearing the cutaneous infection and 
ultimately rendering the host immune to reinfection (Neva and Brown, 1994), 
characterizing cutaneous leishmaniasis as one of the few parasitic diseases of humans for 
which a protective vaccine could be developed with a reasonable expectation of success.  
Unfortunately, there exists no innocuous and useful human vaccine for prevention of 
cutaneous leishmaniasis.  In addition, as there are 20 different species of Leishmania 
categorized as human pathogens (Cupolillo et al., 2000), the development of multiple 
stand-alone vaccines that target individual species themselves is a monumental task.  
Novel approaches toward immunizing against infection with Leishmania parasites that 
target more general and common requirements for host infection are direly needed.         
Control of infection with L. major is dependent upon the development of a robust 
CD4+ mediated type 1 (Th1) cellular immune response that supports the production of 
cytokines (e.g., IL-12, IFN-γ and TNF-α) that activate infected macrophages to produce 
nitric oxide (NO), which results in killing of intracellular parasites (Reiner and Locksley, 
1995).  In contrast, progressive disease is correlated with development of a CD4+ 
mediated type 2 (Th2) cellular immune response characterized by the production of 
regulatory and Th2-biased cytokines (e.g., IL-10, TGF-β, IL-4, and IL-13) ineffective for 
activation of macrophages, which instead support the development of an antibody-
mediated response inadequate for clearance of intracellular organisms (Reiner and 
Locksley, 1995; Matthews et al., 2000).  Therefore, proper defense against L. major 
infection is crucially-dependent upon priming of a Th1-biased adaptive immune response 
(Liese et al., 2008).  Development of protective cell-mediated immune responses is 




sand fly salivary components co-injected during natural transmission (Brittingham et al., 
1995; Mosser and Edelson, 1987; Brandonisio et al., 2004; Belkaid et al., 2002a; Peters 
and Sacks, 2006; Nylen et al., 2007; van Zandbergen et al., 2004).        
The saliva of blood-feeding arthropods contains numerous bioactive molecules 
that facilitate the acquisition of a blood meal, including anesthetics, vasodilators, and 
components that inhibit hemostasis and modulate the development of host immune 
responses (Kamhawi, 2000; Schoeler and Wikel, 2001; Rogers et al., 2002a; Titus et al., 
2006).  Depending on the quality of the immune environment induced at the bite site by 
salivary immunomodulation, co-injected pathogens might benefit from salivary-imposed 
immunological alterations.  It is now widely-accepted that arthropod saliva enhances the 
infectivity of pathogens transmitted to vertebrate hosts during the bloodmeal (Titus and 
Ribeiro, 1988; Mbow et al., 1998; Belkaid et al., 1998; Jones et al., 1989; Labuda et al., 
1993; Edwards et al., 1998).  This phenomenon may, in part, account for the impressive 
ability of many arthropods to so effectively transmit such a wide variety of pathogens.   
The immunomodulatory role of sand fly saliva in the transmission of Leishmania 
parasites was first demonstrated by co-injection of mice with L. major and salivary gland 
lysates (SGL) from the New World sand fly Lutzomyia longipalpis.  Cutaneous lesions of 
mice challenged with both parasites and SGL grew several-fold larger than lesions of 
mice challenged without SGL, and the parasite loads within the lesions were increased by 
several thousand-fold (Titus and Ribeiro, 1988).  This dramatic exacerbation of infection 
was attributed to the immunodulatory actions of maxadilan (MAX), a 63-amino acid 
vasodilatory salivary peptide of Lu. longipalpis (Lerner et al., 1991; Lerner and 




mediated through activation of the mammalian type I receptor for the pituitary adenylate 
cyclase-activating neuropeptide (PACAP), expressed on vascular and neural tissues 
(Moro et al., 1996; Moro and Lerner, 1997; Eggenberger et al., 1999), as well as on 
macrophages, immature dendritic cells (DC), and T cells (Arimura and Said, 1996; Torii 
et al., 1998).  MAX elicits potent immunosuppressive and anti-inflammatory effects 
capable of exacerbating infection with Leishmania parasites, including modulation of DC 
functions required for instruction of Th1 cell development, inhibition of T cell activation, 
decreased production of protective Th1-biasing cytokines, increased production of 
exacerbative Th2-biasing cytokines, and inhibition of macrophage functions required for 
clearance of intracellular parasites (Bozza et al., 1998; Brodie et al., 2007; Guilpin et al., 
2002; Wheat et al., 2008; Qureshi et al., 1996; Gillespie et al., 2000; Soares et al., 1998).  
These collective results strongly suggest that MAX-mediated immunomodulation at the 
inoculation site leads to the development of an immune environment in which parasites 
thrive and successfully develop an initial focus of infection.  In fact, successful natural 
transmission of L. major may literally be dependent upon salivary immunomodulation 
(Titus and Ribeiro, 1988).  A novel approach proven to protect against infection is to 
alternatively direct the host immune response against co-injected immunomodulatory 
vector salivary components that are necessary for successful bloodfeeding and enhanced 
pathogen transmission (Titus et al., 2006).                          
The immunomodulatory effects of Lu. longipalpis SGLs can notably exacerbate 
infection with various Leishmania species of both New and Old World origin (Titus and 
Ribeiro, 1988; Samuelson et al., 1991; Warburg et al., 1994), and MAX alone can 




is a convincing catalog of evidence suggesting that the salivary approach towards 
immunization is a realistic option for prevention of leishmaniasis.  Immunization with 
salivary proteins, whole saliva, or via pre-exposure to uninfected sand fly bites have all 
elicited significant protective immunity against infection with L. major and the 
subsequent development of cutaneous disease, typified by the production of anti-saliva 
antibodies and/or a cellular immune response characterized by high levels of IFN-γ 
production (Morris et al., 2001; Valenzuela et al., 2001; Kamhawi, 2000; Belkaid et al., 
1998; Oliveira et al., 2008).  The results from these vector-saliva-based approaches to 
immunizing against infection with L. major are impressive and convincing, and warrant 
further investigation and characterization of the protective immune responses induced.      
Cationic liposome-DNA complexes (CLDCs) are potent activators of innate 
immunity whose immunostimulatory properties are mediated, in part, via activation of 
Toll-like receptor (TLR) 9 and the cytosolic DNA sensor DAI (DNA-dependent activator 
of IFN-regulatory factors) (Dow, 2008; Ishii and Akira, 2006; Stetson and Medzhitov, 
2006b).  In addition to their successful application as immunotherapy for  acute viral 
(Gowen et al., 2006; Gowen et al., 2008; Logue et al., 2010) and bacterial infections 
(Goodyear et al., 2009; Troyer et al., 2009), the ability of CLDCs to bind and target 
antigens directly to antigen presenting cells (APC) make them uniquely appealing as 
vaccine adjuvants (Dow, 2008).  CLDC-based vaccines induce balanced cellular and 
humoral immunity, eliciting strong responses from both CD4+ and CD8+ T cells, as well 
as inducing antibody responses either comparable to or exceeding those induced by 
Freund’s complete adjuvant or aluminum hydroxide adjuvants (Chen, et al., 2008; Zaks, 




production of pro-inflammatory Th1 cytokines effective for promotion of cell-mediated 
immune responses required for clearance of intracellular pathogens (Krieg, 2007; Dow, 
2008), such as L. major.  In addition, CLDC administration leads to prompt cellular 
stimulation, characterized by upregulation of co-stimulatory molecules on DCs and 
macrophages, generalized functional maturation of APCs, and natural killer (NK) cell 
activation and infiltration (Dow et al. 1999b), all of which are important for effective 
immune clearance of L. major.  Due to the Th1-biasing of CLDC-stimulated immune 
responses, we speculated that CLDC might be an effective vaccine adjuvant for 
generating both innate and adaptive immune responses appropriate for neutralization of 
MAX-potentiation and subsequent control of infection with L. major.  We hypothesized 
that immunization against MAX using CLDC as adjuvant would protect mice against the 
development of cutaneous lesions following challenge with L. major + MAX.   
The studies described in Chapter 4 of this dissertation show that CLDC-based 
MAX-immunization induces significant protection against challenge with L. major + 
MAX.  Lesion sizes and associated parasite burdens in the infected footpads of MAX-
immunized mice were significantly reduced in comparison to those of non-immunized 
mice.  The degree of protection elicited using CLDC as adjuvant not only exceeded that 
elicited using a human-approved aluminum hydroxide adjuvant (Alhydrogel®), but was 
induced without causing the long-term inflammation and tissue damage at the site of 
immunization observed in Alhydrogel® + MAX-immunized mice.  Intracellular cytokine 
staining of CD4+ lymphocytes of MAX-immunized challenged mice revealed an increase 
in the percentage ratio of IFN-γ- vs. IL-4-producing CD4+ cells, suggesting induction of 




These results indicate that CLDC is an effective adjuvant for the induction of Th1-biased 
immune responses required for control of intracellular pathogens, and further emphasize 
the importance of targeting salivary immunomodulation in thwarting establishment of 
infection with vector-borne pathogens.  
Materials and Methods 
Mice. 
5-6 week old (25g) female BALB/c mice were obtained from Harlan Laboratories 
(Indianapolis, IN) and National Cancer Institute (Frederick, MD).  All animals were 
housed for a minimum of 7 days prior to manipulation in order to allow for acclimation to 
the research facility.  Mice were maintained at the Laboratory Animal Resources facility 
at Colorado State University, Fort Collins, CO.  Animal maintenance and care complied 
with National Institutes of Health Guidelines (under pathogen-free conditions) for the 
humane use of laboratory animals and institutional policies as described in the American 
Association of Laboratory Animal Care and Institutional Guidelines.  All protocols and 
procedures involving animals were approved by the Colorado State University Animal 
Care and Use Committee. 
L. major and infection with the parasite. 
Stationary phase promastigotes of L. major (LV39 (MRHO/Sv/59/P)) were used 
for all challenge experiments, and were maintained as described previously (Titus, et al., 
1984).  Briefly, when used in experiments, the parasites were harvested from stationary-
phase cultures (Sacks, et al., 1985).  The virulence of L. major parasites was maintained 
by infecting mice with parasites and re-isolating these virulent parasites from the infected 
mice.  Prior to challenge, mice were anesthetized with ketamine (100 mg/kg; Fort Dodge 




Bedford, OH).  Anesthetized mice were injected subcutaneously with 103-104 L. major 
metacyclic promastigotes ± 10 ng synthetic MAX in one hind footpad.     
Synthetic maxadilan. 
Synthetic maxadilan was prepared by Twentyfirst Century Biochemicals, Inc. 
(Marlboro, MA).  The 63-mer amino acid sequence used was based on the predicted 
sequence of mature, secreted MAX (Lanzaro et al., 1999; 
CDATCQFRKAIEDCRKKAHHSDVLQTSVQTTATFTSMDTSQLPGSGVFKECMKE
KAKEFKAGK). 
Monitoring lesion development and parasite burden in lesions. 
Lesion development was followed by measuring with a Vernier digital caliper the 
thickness of the infected footpad compared to the thickness of uninfected footpads of 
control mice.  Parasite numbers in infected footpads were determined using a published 
limiting dilution assay (Lima et al., 1997). 
Preparation of CLDC adjuvant. 
Cationic liposomes were prepared as previously described by combining 
equimolar amounts of DOTIM [octadecanoyloxy(ethyl-2-heptadecenyl-3-hydroxyethyl) 
imidazolinium chloride] and cholesterol (Templeton et al., 1997).  Cationic liposome-
DNA complexes (CLDC) were prepared fresh immediately prior to injection by gently 
mixing cationic liposomes with plasmid DNA (pMB75.6 empty vector, 3 mg/mL) in 
sterile Tris-buffered 5% dextrose in water at room temperature.  The final concentration 
of plasmid DNA was 100 µg DNA/mL. 
Immunizing against MAX. 
Groups of mice (n = 5-8) were injected i.p. or s.c. at the base of the tail with 5 µg 
of synthetic MAX admixed with 250 µL (i.p.) or 200 µL (s.c.) CLDC adjuvant.  For 




of synthetic MAX admixed with Alhydrogel® aluminum hydroxide gel adjuvant 
(Brenntag Biosector, Frederikssund, Denmark) for 60 minutes on a rocking platform.  
Other groups of control mice (n = 5-8) were immunized with an irrelevant control 
antigen, lysozyme from chicken egg white (HEL; catalog no. L6876; Sigma Aldrich, St. 
Louis, MO), or were sham-injected with adjuvant or antigen alone.  Fourteen days later, 
the mice were boosted in an identical fashion.  Fourteen days following the boost, mice 
were challenged with 103-104 L. major metacyclic promastigotes ± 10 ng MAX. 
Histopathological examination of immunization site. 
Tails from 2-3 control mice, CLDC-adjuvanted MAX-immunized mice, and 
Alhydrogel®-adjuvanted MAX-immunized mice were harvested at 14, 42, 57, 69, and 
245 days following immunization to examine the histologic changes in the 3 
experimental groups.  The tail of each mouse was removed immediately after euthanasia, 
fixed in 10% neutral buffered formalin, and then sectioned.  Tissue sections were 
processed routinely, embedded in paraffin, sectioned at 5 µm, and stained with 
hematoxylin and eosin. 
 
Anti-MAX ELISA. 
Blood was collected from mice via tail bleed at 7, 14, 21, and 28 days following 
initial immunization, and the anti-MAX serum titer was determined by an ELISA.  
Briefly, ELISA plates were coated with synthetic MAX (10 µg/mL) using standard 
techniques (Shankar and Titus, 1995) and developed with either horseradish peroxidase 
(HRP)-labeled goat anti-mouse IgG (H and L chain) (catalog no. 074-1806; Kirkegaard 
& Perry Laboratories, Gaithersburg, MD), HRP-labeled rat anti-mouse IgG2a (material 




IgG1 (material no. 559626; Becton Dickinson Biosciences Pharmingen) and the TMB 
substrate reagent set (material no. 555214; Becton Dickinson Biosciences).   
Isolation and stimulation of lymphocytes. 
Following euthanasia, the popliteal and para-aortic lymph nodes were harvested 
from groups of experimental mice (n = 5-8) and mechanically disrupted to prepare 
separate single-cell suspensions in complete RPMI medium.  1 x 106 cells were added to 
each well of a 48-well plate in a volume of 500 µL complete RPMI medium.  1 µL of 
both Cell Stimulation Cocktail (500x; catalog no. 00-4970-93; eBioscience) and 
GolgiPlug™ Protein Transport Inhibitor (catalog no. 51-2301KZ (555029); BD 
Biosciences Pharmingen, San Diego, CA) were added to each well, and cells were then 
incubated for 5 h at 37ºC.     
Intracellular cytokine staining and flow cytometry. 
Following stimulation, cells were suspended in FACS staining buffer (PBS, 0.5% 
BSA, and 0.01% azide) and treated with Fc receptor block (Miltenyi Biotec).  Cells were 
surface-labeled with PE- or APC-conjugated Abs for 20 min at 4ºC, and washed with 
FACS staining buffer.  Cells were permeabilized via resuspension in 100 µL 
Cytofix/Cytoperm™ fixation and permeabilization solution (catalog no. 51-2090KZ 
(554722); BD Biosciences Pharmingen, San Diego, CA) for 20 min at 4ºC, and washed 
with 1x Perm/Wash™ buffer (catalog no. 51-2091KZ (554723); BD Biosciences 
Pharmingen, San Diego, CA).  Intracellularly-retained cytokines (IFN-γ or IL-4) were 
stained with FITC-conjugated Abs for 30 min at 4ºC and washed with 1x Perm/Wash™ 
buffer and FACS staining buffer.  Cells were analyzed by flow cytometry, conducted on a 
CyAn flow cytometer (DakoCytomation, Colorado, USA) using Summit Acquisition 




and resolved based on geometric mean fluorescence intensity (MFI) emissions generated 
via excitation of PE-, APC-, or FITC-conjugated Abs using a 488 nm laser.   
Reagents. 
The following Abs were purchased from eBioscience and used for flow 
cytometry: PE-conjugated anti-mouse CD4, APC-conjugated anti-mouse CD8a (Ly-2), 
FITC-conjugated anti-mouse IFN-γ and FITC-conjugated anti-mouse IL-4 (catalog no. 
12-0041-81, 17-0081-81, 11-7311-71, and 11-7042-71, respectively).  Fc receptor block 
was purchased from Miltenyi Biotec. 
Statistical analysis. 
 Data for lesion progression were analyzed using ANOVA for repeated measure.   





L. major dose-challenge response in BALB/c mice. 
 In order to determine the lower limits of L. major challenge that would lead to 
detectable infection and lesion development, BALB/c mice (n = 5) were challenged 
subcutaneously in one hind footpad with increasing log increments of L. major (Fig. 4.1).  
Lesion development was not detected in any mouse challenged with the lowest two doses 
of L. major (1x101 and 1x102 metacyclic promastigotes).  In contrast, by 4-weeks post-
infection mice challenged with the highest dose of parasites (1x105 metacyclic 
promastigotes) had developed ulcerating lesions larger than those detected in other 
challenge groups at any timepoint.  Mice challenged with either of the two intermediate 
doses of parasites (1x103 and 1x104 metacyclic promastigotes) gradually developed 




containing 1x103 - 1x104 metacyclic promastigotes in all subsequent challenge 
experiments. 
 
Figure 3.1.  L. major dose-challenge response in BALB/c mice.  BALB/c mice (n = 5 animals) 
were challenged subcutaneously in one hind foot pad with increasing log-increments of L. major 
between 1 x 101 and 1 x 105 infective-stage metacyclic promastigotes.  Mean footpad lesion size 
(±SEM) was determined by measurement of footpad swelling using a digital caliper as described 
in Materials and Methods.  Data shown are representative of two independent experiments.   
         
MAX exacerbates L. major infection in BALB/c mice. 
 In order to investigate whether intermediate-dose L. major infection was 
exacerbated by co-injection of MAX, BALB/c mice (n = 5) were challenged 
subcutaneously in one hind footpad with 104 L. major metacyclic promastigotes ± 10 ng 
of MAX (an amount experimentally determined to be present in 2 Lu. longipalpis 
salivary glands).  Mice co-injected with both L. major and MAX developed lesions that 
were significantly larger (2-3 fold; p < 0.001) than lesions of mice challenged with L. 
major alone (Fig. 4.2).   

































Figure 4.2.  MAX exacerbates infection with L. major.  BALB/c mice (n = 5 animals) were 
challenged subcutaneously in one hind foot pad with 1 x 104 L. major  metacyclic promastigotes 
± 10 ng synthetic MAX.  Mean footpad lesion size (±SEM) was determined by measurement of 
footpad swelling using a digital caliper as described in Materials and Methods.  Cutaneous lesions 
of mice challenged with L. major + MAX (■) were 2 to 3-fold larger than those of mice 
challenged with L. major alone (●).  The asterisks denote that mice challenged with L. major + 
MAX developed lesions that were significantly larger (p < 0.001) than lesions that developed on 
mice challenged with L. major alone.  Statistical differences in lesion progression were calculated 
using ANOVA for repeated measure.  Data shown are representative of two independent 
experiments. 
In addition, the parasite burden in the lesions of mice challenged with both L. 
major and MAX was increased 57-fold over that in lesions of mice challenged with L. 
major alone (Table 4.1).  Thus, co-injection of synthetic MAX exacerbated infection with 
intermediate dose challenges of L. major. 
Table 4.1.  MAX exacerbates L. major infection in BALB/c micea 
 
Challenge 
# of L.major/footpad  
(mean ± SEM) 
Fold Increase in 
Parasite # 
L. major 1,576,000 ± 665,750 Not applicable 
L. major + MAX 90,422,000 ± 34,972,000 57 
a At 8 weeks post-challenge, infected footpads from triplicate mice were combined and analyzed 
as a group for determination of the number of parasites in their footpad lesions (mean ± SEM).  
Results are representative of data obtained in three independent experiments. 




























Footpad lesion size and parasite burden are reduced in MAX-immunized BALB/c 
mice. 
 Prior studies from our laboratory concluded that MAX-immunized CBA/CaH-T6J 
mice were protected against challenge with L. major co-injected with sand fly saliva or 
synthetic MAX, and that protection correlated with anti-MAX antibody production and 
secretion of IFN-γ by CD4+ and CD8+ T cells (Morris et al., 2001); however, MAX was 
delivered in complete Freund’s adjuvant (not suitable for use in humans), and induction 
of protection required multiple immunizations with large amounts of antigen (25 µg 
MAX per treatment).  Therefore, CLDCs were utilized as an alternative adjuvant in order 
to expand on these previous results and investigate the protective potential of anti-MAX 
immunization.  Mice (n = 5) were immunized i.p. with CLDC+MAX or treated with 
CLDC alone, followed by challenge with L. major + MAX (Fig. 4.3).  Footpad lesions of 
MAX-immunized mice were significantly smaller (p < 0.001) than those of mice treated 
with CLDC alone at 6 weeks post-infection, and remained between 2- and 7-fold smaller 





Figure 4.3.  Immunization against MAX protects against infection with L. major + MAX.  
BALB/c mice (n = 5 animals) were immunized with CLDC + MAX or treated with CLDC alone, 
and were then challenged subcutaneously in one hind foot pad with 1 x 104 L. major  metacyclic 
promastigotes + 10 ng synthetic MAX.  Mean footpad lesion size (±SEM) was determined by 
measurement of footpad swelling using a digital caliper as described in Materials and Methods.  
Cutaneous lesions of MAX-immunized mice (●) were 2- to 7-fold smaller than those of mice 
receiving CLDC adjuvant only (■). The asterisks denote that mice treated with CLDC alone 
developed lesions that were significantly larger (p < 0.001) than lesions that developed on mice 
immunized with CLDC + MAX.  Statistical differences in lesion progression were calculated 
using ANOVA for repeated measure. Data shown are representative of two independent 
experiments.   
 
Visual comparison of time-matched footpads of both groups clearly revealed the 
significant reductions in footpad lesion size induced by MAX-immunization (Fig. 4.4).  
Parasite burden in lesions of MAX-immunized mice was also greatly reduced in 
comparison to the burden in lesions of mice treated with CLDC alone, with a 38,707-fold 
reduction in parasite load at day 63 post-infection (Table 4.2). 



























Figure 4.4.  Immunization against MAX elicits reductions in footpad swelling size following 
challenge with L. major + MAX.  BALB/c mice (n = 5 animals) were challenged 
subcutaneously in one hind foot pad with 1 x 104 L. major  metacyclic promastigotes + 10 ng 
synthetic MAX, and the effects of immunization with CLDC + MAX on footpad lesion 
development were determined.  Footpad lesion size was determined by measurement of footpad 
swelling using a digital caliper as described in Materials and Methods.  Comparison of 
representative footpad lesions of mice immunized with CLDC+MAX (A) vs. mice treated with 
CLDC alone (B) reveals significant reductions in cutaneous lesion sizes of MAX-immunized 
mice (2 to 7-fold smaller than those of mice receiving CLDC adjuvant only).   Images are 
representative of results obtained from 5 independent experiments.  (A): MAX-immunized mouse 
footpad, day 66 post-challenge.  (B): CLDC-treated mouse footpad, day 66 post-challenge. 
   




# of L.major/footpad  
(mean ± SEM) 
Fold Increase in 
Parasite # 
CLDC + MAX 2,608 ± 1,100 Not applicable 
CLDC 100,950,000 ± 39,045,000 38,707 
a At 9 weeks post-challenge, infected footpads from triplicate mice were combined and analyzed 
as a group for determination of the number of parasites in their footpad lesions (mean ± SEM).  
Results are representative of data obtained in three independent experiments. 
 
These results strongly support the premise that immunization against MAX using 
CLDC as adjuvant protects against challenge with L. major + MAX, as evidenced by 
reductions in both footpad lesion size and parasite burden.   




S.C. immunization elicits protection exceeding that induced by  I.P. immunization. 
In order to investigate the importance of the site of immunization and thus 
determine the immunization route that would induce optimal levels of protection against 
challenge with L. major + MAX, the protection elicited by i.p. immunization was 
compared to that elicited by s.c. immunization at the base of the tail (Fig. 4.5).   
 
Figure 4.5.  Protection elicited against infection with L. major + MAX by s.c. immunization 
exceeds that elicited by i.p. immunization.  BALB/c mice (n = 5 animals) were untreated or 
immunized either s.c. or i.p. with CLDC + MAX, and were challenged subcutaneously in one 
hind foot pad with 1 x 104 L. major  metacyclic promastigotes + 10 ng synthetic MAX.  Mean 
footpad lesion size (±SEM) was determined by measurement of footpad swelling using a digital 
caliper as described in Materials and Methods.  Cutaneous lesions of mice immunized by either 
route were significantly (**; p < 0.01) smaller than those of non-immunized mice. Cutaneous 
lesions of mice s.c.-immunized were significantly (p < 0.01) smaller than those of i.p.-immunized 
mice.  Statistical differences in lesion progression were calculated using ANOVA for repeated 
measure. Data shown are representative of two independent experiments.   
 
Footpad lesion sizes of mice immunized by either route were significantly smaller 
(p < 0.01) than those of untreated control mice, and parasite burdens in the lesions of 
immunized mice were also markedly reduced in comparison to those in lesions of 
untreated control mice (Table 4.3).   




























Table 4.3.  S.C. MAX-immunization elicits protection exceeding that of 
I.P. MAX-immunization a 
 
Treatment 
# of L.major/footpad  
(mean ± SEM) 
Fold Increase in 
Parasite # 
MAX-immunized (s.c.) 2,847,500 ± 455,250 Not applicable 
MAX-immunized (i.p.) 5,295,000 ± 933,500 1.9 
Untreated Controls 37,305,000 ± 5,937,500 13.1 
a At 5 weeks post-challenge, infected footpads from triplicate mice were combined and analyzed 
as a group for determination of the number of parasites in their footpad lesions (mean ± SEM).  
Results are representative of data obtained in two independent experiments. 
 
These results indicate that both i.p. and s.c. MAX-immunization protects against 
challenge with L. major + MAX and elicits reductions in both footpad lesion size and 
parasite burden.  However, footpad lesions of s.c.-immunized mice were significantly 
smaller (p < 0.01) than those of mice immunized via the i.p. route (Fig. 4.5), and the 
associated parasite loads were reduced 1.9-fold in s.c.-immunized mice (Table 4.3).  
Accordingly, the s.c. route of immunization was used in all subsequent experiments.   
CLDC adjuvant elicits protection exceeding that induced by Alhydrogel®. 
 In order to ascertain whether the protection elicited by MAX-immunization 
utilizing CLDC as adjuvant was comparable to that elicited by a vaccine employing a 
human-approved aluminum hydroxide gel adjuvant (Alhydrogel®), the protection elicited 
by both formulations was compared.  Mice were untreated or immunized with either 
CLDC+MAX or Alhydrogel®+MAX and then challenged with L. major + MAX as 
described above (Fig. 4.6).  
Cutaneous lesions of mice immunized with Alhydrogel®+MAX were not 
significantly different than those of non-immunized mice (p = 0.1003), indicating that 
MAX-immunization utilizing Alhydrogel® as adjuvant does not elicit significant 





Figure 4.6.  Protection elicited against infection with L. major + MAX by immunization with 
CLDC + MAX exceeds that elicited by immunization with Alhydrogel® + MAX.  BALB/c 
mice (n = 5 animals) were untreated or immunized with either CLDC + MAX or Alhydrogel® + 
MAX and were challenged subcutaneously in one hind foot pad with 1 x 104 L. major  metacyclic 
promastigotes + 10 ng synthetic MAX.  Mean footpad lesion size (±SEM) was determined by 
measurement of footpad swelling using a digital caliper as described in Materials and Methods.  
Cutaneous lesions of mice immunized with CLDC adjuvant were significantly smaller than those 
of both non-immunized mice (p < 0.01) and those of mice immunized with Alhydrogel® adjuvant 
(*; p < 0.05).  Lesions of mice immunized with Alhydrogel® adjuvant were not significantly 
different than those of non-immunized mice (p = 0.1003).  Statistical differences in lesion 
progression were calculated using ANOVA for repeated measure. Data shown are representative 
of two independent experiments. 
 
In contrast, cutaneous lesions of mice immunized with CLDC+MAX were 
significantly smaller than those of both non-immunized mice (p < 0.01) and mice 
immunized with Alhydrogel®+MAX (*; p < 0.05).  Accordingly, the parasite burden in 
the lesions of mice immunized with CLDC+MAX was reduced 17-fold in comparison to 
non-immunized mice and 1.3-fold in comparison to mice immunized with 
Alhydrogel®+MAX (Table 4.4). 




























Table 4.4.  MAX-immunization using CLDC as adjuvant elicits 
protection exceeding that induced by Alhydrogel®a 
 
Treatment 
# of L.major/footpad  
(mean ± SEM) 
Fold Increase in 
Parasite # 
CLDC + MAX 2,095,000 ± 221,250 Not applicable 
Alhydrogel + MAX 2,751,500 ± 290,500 1.3 
Untreated Controls 35,515,000 ± 3,750,750 17 
a At 8 weeks post-challenge, infected footpads from triplicate mice were combined and analyzed 
as a group for determination of the number of parasites in their footpad lesions (mean ± SEM).  
Results are representative of data obtained in two independent experiments. 
 
It was notable that although MAX-immunization with Alhydrogel® adjuvant did 
not significantly reduce footpad lesion size (Fig. 4.6), parasite burden in lesions was still 
markedly-reduced (13-fold) in comparison to non-immunized mice, suggesting that 
immunization with Alhydrogel®+MAX elicited some degree of protection against 
challenge with L. major + MAX.  Collectively, these results indicated that MAX-
immunization with CLDC as adjuvant elicits protection against challenge with L. major + 
MAX exceeding that induced by an aluminum hydroxide gel adjuvant.   
MAX-immunization with Alhydrogel® adjuvant induces tissue damage at the site of 
immunization. 
 The previous experiments revealed that although MAX-immunization using either 
CLDC or Alhydrogel® as adjuvant elicited reductions in parasite burden following 
challenge with L. major + MAX, CLDC-adjuvanted immunization not only induced a 
higher degree of protection, but also elicited significant reductions in footpad lesion size.  
Furthermore, examination of the base-of-tail immunization site of mice immunized with 
Alhydrogel® + MAX indicated the presence of significant tissue damage.  In order to 
ascertain any adjuvant-dependent differences in histopathologic changes at the site of 




comparison.  At 69 days post-boost, tail sections of mice immunized with CLDC+MAX 
appeared normal in comparison to tail sections from non-immunized mice.  In contrast, 
tail sections of mice immunized with Alhydrogel®+MAX contained a severe 
inflammatory infiltrate of macrophages and lymphocytes and exhibited collateral damage 
to muscle tissue (Fig. 4.7).   
 
Figure 4.7.  The base-of-tail immunization site of mice treated with Alhydrogel® adjuvant 
contains a severe inflammatory infiltrate that is absent at the immunization site of mice 
treated with CLDC adjuvant.  BALB/c mice (n = 8 animals) were immunized s.c. at the base of 
the tail with MAX using either Alhydrogel® or CLDC as adjuvant, and were challenged 
subcutaneously in one hind foot pad with 1 x 104 L. major  metacyclic promastigotes + 10 ng 
synthetic MAX.  At various time points following immunization, tails were harvested, sectioned, 
and prepared for observation of histopathologic changes at the site of immunization.  Comparison 
of representative tail sections of mice receiving Alhydrogel® adjuvant (A) vs. mice receiving 
CLDC adjuvant mice (B) revealed the presence of a severe inflammatory infiltrate and tissue 
damage at the site of immunization in group A that was absent in group B.  The tail section from 
the CLDC-adjuvanted group appeared normal in comparison to tail sections from un-immunized 
control mice (not shown).  Images are representative of results obtained from three independent 
experiments.  (A): MAX-immunized mouse tail section, Alhydrogel® adjuvant, day 69 post-
boost.  (B): MAX-immunized mouse tail section, CLDC adjuvant, day 69 post-boost.   
 
It was notable that this inflammatory infiltrate was present until at least 245 days 
post-boost, indicative of permanent tissue damage.  These results indicate that MAX-
immunization using a CLDC adjuvant avoids an unwanted, long-term side effect of 




MAX-immunization using an aluminum hydroxide adjuvant already approved for use in 
humans, and warrant subsequent investigation of its approval for human usage. 
Mechanism(s) of protection induced by immunization with CLDC+MAX. 
 Experiments were conducted to identify the immune mechanism(s) of protection 
against challenge with L. major + MAX induced by immunization with CLDC+MAX.  
As previous studies from our laboratory concluded that protection induced by MAX-
immunization correlated with the production of anti-MAX antibodies and secretion of 
IFN-γ by CD4+ and CD8+ T cells (Morris et al., 2001), we assayed for the presence of 
anti-MAX antibodies in the sera of mice immunized with CLDC+MAX.  Sera of mice 
immunized with CLDC+MAX did not contain detectable titers of anti-MAX IgG, IgG1, 
or IgG2a at any time-point following immunization, while immunization with CLDC + 
an irrelevant control antigen (hen egg lysozyme; HEL) elicited the production of high 
titers of anti-HEL IgG (Table 4.5).  
Table 4.5.  Mice immunized with CLDC + MAX do not produce 





Anti-MAX antibody titer, 
(negative control values) a 
CLDC + MAX IgG 0 (zero) 
Positive Control IgG 1/12,800 – 1/25,600 
CLDC + MAX IgG1 0 (zero) 
Positive Control IgG1 1/6,400 – 1/12,800 
CLDC + MAX IgG2a 0 (zero) 





Anti-HEL antibody titer, 
(negative control values) 
CLDC + HEL IgG 1/6,400 – 1/12,800, (zero) 
a Negative control mice were not immunized with MAX or HEL.  Sera from non-immunized mice 





These findings indicated that protection against infection with L. major + MAX induced 
by immunization with CLDC+MAX was not likely mediated by anti-MAX antibodies.  
In order to ascertain whether the protection elicited by MAX-immunization was 
instead mediated by a CD4+ cellular immune response, the production of cytokines by 
CD4+ cells harvested from immunized mice following challenge with L. major + MAX 
was investigated.  Lymphocytes from challenged mice were harvested from the draining 
lymph nodes of MAX-immunized, HEL-immunized and non-immunized mice, were 
stimulated in vitro and stained for intracellular cytokines indicative of a protective Th1- 
or exacerbative Th2-biased immune response (IFN-γ and IL-4, respectively)  (Fig. 4.8). 
Flow-cytometric analysis indicated 33% and 35% increases in the percentages of 
IFN-γ-producing CD4+ cells in draining lymph nodes (popliteal and para-aortic, 
respectively) of challenged MAX-immunized mice when compared to CD4+ cells of 
challenged HEL-immunized mice; in comparison to non-immunized mice, the 
percentages of IFN-γ-producing CD4+ cells in the popliteal and para-aortic lymph nodes 
of MAX-immunized mice were increased 65% and 39%, respectively (Fig. 4.8A).  
Conversely, the para-aortic lymph nodes of MAX-immunized mice contained 32% fewer 
IL-4-producing CD4+ cells than para-aortic lymph nodes of non-immunized mice and 
69% fewer IL-4-producing CD4+ cells than para-aortic lymph nodes of HEL-immunized 
mice (Fig. 4.8B).  The percentage ratio of IFN-γ- vs. IL-4-producing CD4+ cells in 
MAX-immunized mice was 2.53, in comparison to a ratio of 1.13 in non-immunized 
mice, suggesting an increased Th1-bias due to immunization with CLDC+MAX.  An 
increased percentage ratio of IFN-γ- vs. IL-4-producing CD4+ cells is an indicator of a 





Figure 4.8.  Intracellular staining of IFN-γ- and IL-4-producing CD4+ cells of MAX-
immunized and non-immunized mice.  Following challenge with L. major + MAX, popliteal 
and para-aortic lymph nodes were harvested from BALB/c mice (n = 5-8 animals) that were 
previously untreated (control), or immunized with either MAX + CLDC or HEL + CLDC.  Single 
cell suspensions were stimulated in vitro, surface stained for CD4, and then stained for 
intracellular IFN-γ (Fig. 4.8A) and IL-4 (Fig. 4.8B), as described in Materials and Methods. 
Flow-cytometric analysis indicated 33% (popliteal) and 35% (para-aortic) increases in the 
percentages of IFN-γ-producing CD4+ cells in the draining lymph nodes of MAX-immunized 
mice when compared to CD4+ cells of HEL-immunized mice; in comparison to non-immunized 
mice, the percentages of IFN-γ-producing CD4+ cells in the popliteal and para-aortic lymph 
nodes of MAX-immunized mice were increased 65% and 39%, respectively (Fig. 4.8A).  
Conversely, the para-aortic lymph nodes of MAX-immunized mice contained 32% fewer IL-4-
producing CD4+ cells than lymph nodes of non-immunized mice and 69% fewer IL-4-producing 
CD4+ cells than lymph nodes of HEL-immunized mice (Fig. 4.8B).  The percentage ratio of IFN-
γ- vs. IL-4-producing CD4+ cells in MAX-immunized mice was 2.53, in comparison to a ratio of 
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intracellular L. major infection; thus, the pattern of cytokine production identified in the 
draining lymph nodes of MAX-immunized mice challenged with L. major + MAX might 
account, in part, for the protection induced against challenge.          
Discussion 
In order for vertebrate hosts to effectively control infection with L. major, they 
must develop a Th1-biased cellular immune response capable of activating infected 
macrophages to kill intracellular parasites (Reiner and Locksley, 1995).  It is of 
significant evolutionary interest that a salivary vasodilator (MAX) utilized by sand fly 
vectors to maintain blood flow and ensure a successful blood meal also modulates the 
immune response of the vertebrate host at the bite site, effectively interfering with the 
early development of protective immunity against a co-injected pathogen.  Successful 
transmission and survival of L. major parasites in vertebrate hosts is strikingly dependent 
upon this altered immune environment at the bite site, as murine challenge with a low, 
biologically-relevant dose (10-100) of L. major in the absence of sand fly saliva does not 
lead to sustained infection, while an identical dose of parasites co-injected with sand fly 
saliva leads to progressive infection and disease (Titus and Ribeiro, 1988).  These 
observations led to the now-proven hypothesis that immunization against sand fly 
salivary components elicits protection against challenge with L. major + sand fly saliva 
(Morris et al., 2001).   
Recent studies have highlighted the importance of considering salivary 
immunomodulation during the development of vaccines intended to protect against 
infection with Leishmania parasites: vaccines which normally protect mice against 
needle-inoculation with L. major alone fail to protect against natural transmission via 




components (Peters et al., 2009).   The short-sighted goal of eliciting immune responses 
against vector-borne pathogens alone ignores the importance of salivary 
immunomodulation in allowing for initial and continued infection of vertebrate hosts.  As 
a result, it is of paramount importance to consider the influence of salivary potentiation 
when formulating and developing vaccines to protect against natural, vector-borne 
transmission of L. major or any other arthropod-borne pathogen. 
In this study, we investigated the ability of immunization with CLDC+MAX to 
protect against challenge with L. major + MAX, compared the elicited protection to that 
induced using a human-approved aluminum hydroxide gel adjuvant, and investigated the 
immune mechanism(s) of protection induced by CLDC + MAX immunization.  Mice 
were challenged with L. major ± synthetic MAX, and the effects of MAX co-
administration on infection and disease development were assessed.  Co-injection of 
MAX elicited increases in both footpad lesion size (Fig. 4.2) and parasite burden (Table 
4.1), and immunization against MAX elicited significant reductions in both lesion size 
(Figs. 4.3, 4.4, and 4.5) and parasite burden (Tables 4.2 and 4.3) and markedly lessened 
the severity of cutaneous infections, even when challenge was postponed up to 3 months 
following immunization.  The use of a CLDC adjuvant not only induced protection 
exceeding that elicited by a MAX vaccine formulation employing an Alhydrogel® 
adjuvant (Fig. 4.6; Table 4.4), but avoided the persistent inflammation and tissue damage 
induced by Alhydrogel®+MAX at the site of immunization (Fig. 4.7).  These 
observations suggest that CLDC is not only an effective adjuvant for the induction of 
anti-MAX immune responses protective against L. major infection, but also lacks a 




Important changes in the production of Th1- and Th2-biasing cytokines were 
identified in the lymph nodes draining the footpad lesions of MAX-immunized mice.  
Increases in the percentage of IFN-γ-producing CD4+ cells were identified in MAX-
immunized mice, in comparison to both non-immunized mice and those immunized with 
an irrelevant control antigen (Fig. 4.8A).  Corresponding decreases in the percentage of 
IL-4-producing CD4+ cells were also identified in MAX-immunized mice (Fig. 4.8B), 
indicating that immunization with CLDC+MAX induced an increase in the percentage 
ratio of IFN-γ- vs. IL-4-producing CD4+ cells, suggesting the induction of Th1-biased 
immune responses in some CD4+ cells following challenge with L. major + MAX.  An 
adaptive immune response to MAX characterized by an increased IFN-γ:IL-4 ratio would 
modify the immune environment present during initiation of L. major infection, making 
intracellular occupancy and growth of amastigotes more tenuous due to activation of 
macrophages and a skewing of the immune response toward clearance of intracellular 
parasites.  Additionally, an anti-MAX immune response at the inoculation site would 
reprogram anti-L. major immunity, as priming of the developing anti-L. major immune 
response would take place in a Th1 pro-inflammatory atmosphere, generating the 
requisite protective immune response that interferes with early establishment of L. major 
infection.  These conclusions are similar to those made in other studies investigating the 
effects of anti-saliva cellular immune responses on infection with Leishmania (Oliveira et 
al., 2008; Kamhawi et al., 2000; Gomes et al., 2008; Valenzuela et al., 2001; Belkaid et 
al., 2000), suggesting that the elicitation of cell-mediated immune responses to salivary 




Leishmania infection, providing supportive evidence of the efficacy of anti-salivary 
immunization for the prevention of arthropod-borne disease.                  
A particularly notable observation from this study was the complete lack of 
detectable titers of anti-MAX IgG in the sera of any mice immunized with CLDC+MAX 
(Table 4.5), suggesting that protection induced by immunization with CLDC+MAX 
might instead be due to cell-mediated immune responses.  This is an intriguing 
conclusion, as anti-saliva antibodies induced by immunization with or exposure to sand 
fly salivary components have been suggested as important mediators of protection against 
subsequent challenge with Leishmania parasites + sand fly saliva (Morris et al., 2001; 
Belkaid et al., 1998; Gomes et al., 2002).  The prevailing hypothesis is that anti-saliva 
antibodies neutralize and inhibit binding of immunomodulatory salivary components to 
their respective receptor(s), interfering with modulation of the host immune response.  
Our results suggest that even in the absence of a detectable titer of anti-MAX IgG, the 
cellular immune response(s) induced by immunization with CLDC+MAX are sufficient 
to elicit significant protection against challenge with L. major + MAX.  This conclusion 
is supported by the work of Valenzuela et al. (2001), in which B-cell deficient mice 
(incapable of antibody production) immunized with a plasmid vaccine encoding for a 
salivary protein of the sand fly P. papatasi were protected from challenge with L. major 
+ salivary gland homogenate.    
One of the most intriguing observations stemming from these studies was that 
MAX-immunization elicited such impressive protection against challenge with L. major 
+ MAX in BALB/c mice, a strain genetically biased toward a Th2-type, antibody-




al., 1998).  Previous research has outlined an important series of immunological events 
leading to progressive infection that occur following challenge of BALB/c mice with L. 
major.  Shortly after infection, the L. major antigen LACK (Leishmania homolog of 
receptors for activated C kinase) elicits early production of IL-4 by Vβ4Vα8 CD4+ T 
cells, leading to reduced expression of the β2 subunit of the IL-12 receptor on CD4+ T 
cell precursors that might otherwise develop into protective Th1 cells.  Down-regulation 
of the IL-12 receptor interferes with the ability of BALB/c T cells to respond to IL-12, 
thus inhibiting the production of protective IFN-γ and NO required for the clearance of 
intracellular parasites (Launois et al., 1998).  Furthermore, early production of IL-4 
instead promotes the development of Th2 cells that support the production of anti-L. 
major antibodies demonstrated to be ineffective for control of intracellular infections.  
Considering the inherent programming of BALB/c mice to respond to L. major infection 
with a non-protective antibody-mediated immune response, the cell-mediated protection 
elicited by our CLDC+MAX vaccine in this mouse strain is quite impressive.   
In addition to eliciting protection against infection with L. major, immunization 
against immunomodulatory salivary components of sand flies might have some 
unexpected, yet beneficial consequences worthy of consideration.  The immune responses 
induced by immunization might not only protect against L. major infection, but could 
also interfere with the transmission of any other pathogens vectored by sand flies, even 
those that have yet to be identified (unknown, emerging, or re-emerging) (Travassos da 
Rosa et al., 1984).  Furthermore, repeated exposure of immunized vertebrates to sand fly 




immune response through “natural” boosts, effectively extending the window of 
protection elicited by initial immunization.   
In the experiments described herein, we elected to utilize the experimental 
combination of L. major parasites and a salivary peptide from Lu. longipalpis, although 
this is not a pathogen/vector combination found in nature: rather, L. major is naturally 
transmitted by P. papatasi (which does not encode MAX), and Lu. longipalpis is the 
natural vector of L. chagasi, a causative agent of visceral leishmaniasis.  However, Lu. 
longipalpis saliva modifies the host immune response and exacerbates infection with L. 
major (Titus and Ribeiro, 1988) L. chagasi (Warburg et al., 1994), L. amazonensis 
(Norsworthy et al., 2004) and L. braziliensis (Gillespie et al., 2000; Samuelson et al., 
1991), suggesting that salivary immunomodulation is a natural mechanism exploited by 
many species of Leishmania.  In fact, a recent study by Tavares et al. (2011) 
demonstrated that immunization of hamsters against Lu. longipalpis saliva or salivary 
proteins induces protection against challenge with L. braziliensis + Lu. intermedia saliva, 
suggesting that immunization against Lu. longipalpis saliva might elicit protective 
immune responses against various species of Leishmania, even those naturally-
transmitted by different sand fly species.  As a result, continued investigation of salivary 
immunomodulation is certainly justified, even if unnatural combinations of parasites and 
vectors are utilized.  Additionally, MAX-immunization induced an immune response 
qualitatively appropriate for protection against infection with all Leishmania species, and 
thus it is probable that MAX-immunization would protect against challenge with any 
species of Leishmania, assuming parasites were co-injected with MAX or Lu. longipalpis 




L. major infection have both been extensively characterized in our laboratory and by 
others, and thus the decision was made to perform mechanistic experiments using the 
best-defined systems available.  Lastly, use of the L. major and Lu. longipalpis 
combination enabled us to correlate results with those of previous reports from our 
laboratory, allowing for interpretation of new findings within the context of an entire 
career’s worth of historical work.   
Salivary immunomodulation is not a sand fly-specific phenomenon, as the 
collective efforts of many research groups have identified the presence of 
immunosuppressive or immunomodulatory components in the saliva of most blood-
feeding arthropods (Titus et al., 2006).  Furthermore, vector saliva modulates infection 
with an impressive variety of pathogens, including various parasites (Titus and 
Ribeiro,1988; Mbow et al., 1998; Belkaid et al., 1998; Gillespie et al., 2000; Samuelson 
et al., 1991; Warburg et al., 1994; Norsworthy et al., 2004; Vaughan et al., 1999; Alger et 
al., 1972; Alger and Harant, 1976), viruses (Jones et al., 1989; Edwards et al., 1998; 
Feinsod et al., 1975; Osorio et al., 1996; Limesand et al., 2000; Edwards et al., 1998), and 
bacteria (Wikel and Bergman, 1997; Nazario et al., 1998; Kuthejlova et al., 2001; Zeidner 
et al., 2002).  Thus, the implications of the protection induced by our anti-MAX vaccine 
are far-reaching, suggesting that immunization against salivary components should 
indeed be considered in other models of arthropod-borne disease, especially those of 
world-wide public health concern such as malaria, dengue fever, and yellow fever.  The 
protection described herein stresses the importance of salivary immunomodulation in the 
initiation of vector-borne pathogen infections, and provides supportive evidence of 




control of intracellular pathogens.  The results of this study provide compelling evidence 
in support of the inclusion of vector salivary molecules as antigens in the formulation of 







EXTENDED PROJECT DISCUSSION AND PROSPECTS FOR FUTURE 
RESEARCH 
 The morbidity and mortality affiliated with vector-borne diseases are staggering, 
and the associated economic and social hardships are overwhelming, especially in 
populations without the political or financial means for effective control or treatment.  
Many of these diseases continue to re-emerge in former endemic areas and/or emerge in 
new parts of the world, and conventional means of control are often inadequate due to the 
appearance of pesticide-resistant vectors, drug resistant-pathogens, and the collapse of 
vector control programs, among other factors.  At present, safe and efficacious vaccines 
and therapeutics for prevention and treatment of many of these diseases (including La 
Crosse (LAC) encephalitis and cutaneous/mucocutaneous/visceral leishmaniasis) are 
lacking.  The results of the studies herein suggest that cationic liposome-DNA complexes 
(CLDCs) are novel and effective immunotherapeutics and vaccine adjuvants for 
treatment and/or prevention of infection with arthropod-borne pathogens, whether 
occurring by natural or purposeful means.  We show that (1) La Crosse virus (LACV) is 
transmissible via inhalation, and leads to the development of lethal LAC encephalitis in 
normally-resistant adult mice, (2) CLDC immunotherapy elicits prophylactic and 
therapeutic protection against aerosolized LACV challenge, and (3) immunization against 
the sand fly salivary peptide maxadilan (MAX) using CLDC as adjuvant induces 




significantly enhance our understanding of the transmission and pathogenesis of these 
important pathogens, and provide supportive evidence of the efficacy of CLDCs as both 
immunotherapeutics and vaccine adjuvants for the treatment or prevention of intracellular 
pathogen infection requiring induction of a Th1-biased, cell-mediated immune response 
for control or clearance. 
  Our experiments involving the development of inhalational models of LACV 
infection reveal that aerosol or intranasal delivery of LACV can alter the normal route of 
central nervous system (CNS) invasion associated with parenteral or vector-transmitted 
infection, bypassing the requirement of viremia for navigating through the blood-brain 
barrier via infection of the nasal olfactory epithelium and, presumably, ascent of olfactory 
neurons.  These observations and those of Bennett et al. (2008) are in contrast to previous 
conclusions stemming from models of peripheral LACV infection, in which the 
neuroinvasiveness of LACV has been correlated with development of a high viremia 
(Janssen et al., 1984).  It would be beneficial to separately titrate the olfactory nerves of 
LACV-challenged mice for infectious virus in order to empirically determine whether 
CNS invasion was indeed occurring via ascent of olfactory neurons.  Future experiments 
involving in situ hybridization and/or immunohistochemical staining would allow for 
precise detection and localization of LACV RNA sequences and/or LACV antigens 
within sections of olfactory neurons, enabling definitive determination of whether 
neuroinvasion might be occurring via passage of LACV through the olfactory tract.  In 
addition, comparison of viral titers in rostral vs. caudal brain sections would allow for 




olfactory lobes to the brainstem, which might provide additional evidence of olfactory 
invasion of the CNS following inhalational LACV challenge. 
The unnatural route of inhalational LACV infection may overwhelm the immune 
mechanisms that normally protect adult mice from CNS invasion (see Chapter 2).  It is 
interesting to speculate that this phenomenon might also occur in adult humans exposed 
via aerosol to LACV or related viruses, leading to development of severe neurological 
disease in normally-resistant age cohorts.  These results not only stress the importance of 
the route of challenge in determining resultant pathogenesis, but also demand 
reconsideration of the method used for categorization of viruses as priority pathogens by 
the NIAID.  Furthermore, as many other arthropod-borne viruses can be transmitted via 
aerosol and some are capable of CNS invasion through the olfactory tract (Kuno, 2003, 
Larson et al., 1980; Ryzhikov et. al, 1995a; Ryzhikov et. al, 1995b; Vogel et. al, 1996), 
our studies imply that other arthropod- or rodent-borne viruses delivered via aerosol 
might be infectious to humans, and would therefore be of bioterrorism concern.  The 
inhalational LACV models developed in this study provide useful tools for testing the 
efficacy of vaccines and therapeutics to be used in the event of airborne release of 
members of the Bunyaviridae. 
Prior studies have established the antiviral effects of CLDC administration in 
models of lethal subcutaneous challenge with members of the Bunyaviridae and 
Togaviridae (Gowen et al., 2006; Gowen et al., 2008; Logue et al., 2010); however, this 
study is the first report of CLDC-induced protection against aerosolized virus challenge.  
Prophylactic and therapeutic administration of CLDC increased the survival of LACV-




3.1, 3.2, and 3.4, Chapter 3).  Protection was correlated with the induction of an antiviral 
immunological state characterized by increased expression of type I and II IFNs (Fig. 3.6, 
Chapter 3), and natural killer (NK) cells were identified as integral components for 
complete CLDC-induced protection in the aerosol LACV model (Fig. 3.7, Chapter 3).  
The results from Chapter 3 suggest that CLDC immunotherapy is a novel approach for 
prevention and treatment of aerosol or conventional infection by members of the 
Bunyaviridae and other virus families. 
It is plausible that the protection described in these experiments could be 
improved upon by intranasal/mucosal rather than intraperitoneal administration of CLDC.  
As our observations suggest that CNS invasion following inhalational LACV challenge 
might occur via infection of the nasal epithelium/mucosa, it is not unreasonable to 
speculate that direct elicitation of antiviral immune responses in these tissues might 
drastically improve upon the protection induced by systemic administration.  Mucosal 
CLDC immunotherapy generates nearly-complete protection against lethal inhalational 
murine challenge with Burkholderia mallei, Burkholderia pseudomallei, and Francisella 
tularensis (Goodyear et al., 2009; Troyer et al., 2009).  It would be interesting to 
determine whether mucosal CLDC administration might block LACV infection of nasal 
turbinates and impede neuroinvasion following aerosol challenge.  Additionally, it would 
be beneficial to determine whether CLDC-treated mice surviving LACV challenge were 
immune to subsequent inhalational challenge, as non-sterilizing CLDC-induced immune 
protection that allowed for development of subsequent anti-LACV adaptive immune 
responses would provide the additional benefit of “immunizing” survivors against future 




plasmacytoid dendritic cells (pDCs) prior to CLDC treatment were inconclusive (data not 
shown nor discussed); it would be of interest to identify the potential role(s) of these 
important early producers of type I IFNs in CLDC-induced protection, as we identified a 
correlation between protection and increased peripheral type I IFN gene expression (Fig. 
3.6, Chapter 3).     
LACV is an intracellular pathogen that requires the production of Th1-biasing 
cytokines (e.g., IFNs, IL-12, and TNF-α) and cell-mediated immune responses for 
clearance.  Leishmania major also resides intracellularly within vertebrate hosts, and 
requires nearly-identical pro-inflammatory and cell-mediated immune responses for 
control of infection.  Having identified CLDCs as effective immunotherapeutics for 
elicitation of protective innate immune responses against aerosol challenge with LACV 
(see Chapter 3), we hypothesized that CLDCs might be effective adjuvants for eliciting 
similar Th1-biasing immune responses against a Th2-biasing immunomodulatory salivary 
peptide that impedes development of protective immune responses and exacerbates 
infection with L. major.       
 The protection against challenge with L. major + MAX elicited by immunization 
with CLDC + MAX was discussed in detail in Chapter 4.  A particularly intriguing 
observation in these studies was that protective Th1-biased cellular immune responses 
were elicited in BALB/c mice, which are inherently biased toward development of Th2-
type immune responses ineffective for control of L. major infection.  In addition to their 
inability to down-modulate IL-4 production and respond to potentially-protective IL-12 
signaling (discussed in Chapter 4), BALB/c mice do not respond with an early NK cell 




lack the production of early IFN-γ associated with effective control of initial infection.  
Furthermore, although MAX-immunization induced increased percentage ratios of IFN-
γ- vs. IL-4-producing CD4+ cells in draining lymph nodes (see Chapter 4), continuous 
production of IL-4 and IL-13 by BALB/c mice following infection with L. major 
(Matthews et al., 2000) would abrogate the full protective potential of increased IFN-γ 
production.  Therefore, the same ineffective programmed immune responses of BALB/c 
mice that make our protective results notable may have also exerted profound limitations 
on the extent of the protective efficacy of our vaccine formulation.  Although MAX-
immunization induced notable changes in CD4+  cell cytokine production as well as a 
significant delay in infection following challenge with L. major + MAX, immunized 
BALB/c mice still exhibited progressive disease development that would eventually lead 
to mortality due to disseminated infection.  It would be beneficial to perform these 
immunization experiments using mouse strains resistant to progressive infection with L. 
major (e.g., C3H, C57BL/6, or CBA mice), as it is likely that the protection would be 
more complete, with more pronounced reductions in footpad lesion size and parasite 
burden due to immunization.  The increased percentage ratio of IFN-γ- vs. IL-4-
producing CD4+ cells identified in MAX-immunized BALB/c mice would be far-more 
protective if elicited in resistant mice, as production of IL-4 and IL-13 would be reduced 
(if not absent), and thus protection elicited by production of IFN-γ would not be 
abrogated.  Additionally, the mechanism(s) of immune protection might be more-easily 
investigated using resistant mouse strains not inherently-programmed toward progressive 
disease development.  It would also be beneficial to investigate the correlation between 




TGF-β, as these cytokines are indicators of vaccine-induced resistant vs. susceptible 
immune responses to infection with L. major (Kedzierski et al., 2006).  Finally, as the 
development of a Th1-biased immune response following infection with L. major has 
been partially-attributed to early production of IFN-γ by NK cells (Scharton-Kersten and 
Scott, 1995) and NK cells are the major cell type responsible for the production of IFN-γ 
following CLDC administration (Dow et al., 1999a; Dow et al., 1999b; U’Ren et al., 
2006; Goodyear et al., 2009; Troyer et al., 2009), it would be of interest to systemically-
deplete NK cells prior to immunization (as done in Chapter 3 prior to CLDC treatment) 
in order to investigate their role(s) in protection elicited by CLDC+MAX immunization.  
Further investigation into these matters is certainly warranted.   
Critics of the salivary-immunization approach to prevention of vector-borne 
pathogen transmission have expressed concerns about the substantial variation of salivary 
molecules that are found in nature.  The wide geographic distribution of Lu. longipalpis 
has led to genetic isolation of different sand fly populations, resulting in substantial 
sequence divergence in MAX encoded by sand flies of differing geographical locations.  
Genetic sequencing of MAX molecules from sibling sand fly species has revealed 
nucleotide variation as high as 12.8% and amino acid variation as high as 23% (Lanzaro 
et al., 1999), providing evidence of the evolutionary importance of evasion of  host 
sensitization against sand fly salivary components (Milleron et al., 2004).  Thus, 
successful immunization against a single natural variant of MAX might only elicit 
protection against Leishmania parasites transmitted by sand flies encoding that particular 
MAX variant.  These hypotheses indicate that design of an anti-MAX vaccine intended to 




regions would require the inclusion of multiple immunogenic forms of MAX (Milleron et 
al., 2004; Valenzuela et al., 2001) or conserved peptide regions found in all natural 
variants.  While this is likely true, these suspicions do not detract from the impressive 
protection induced by our vaccine formulation consisting of a single MAX variant, but 
rather highlight the need for continued research involving anti-salivary immunization 
and/or inclusion of salivary immunomodulators as components of subunit vaccines 
intended to protect against transmission of vector-borne pathogens.        
Extensions of the work described in Chapter 4 have recently addressed the 
previously-discussed concerns of BALB/c susceptibility and MAX variation, as we have 
shown impressive protection against challenge with L. major + MAX in resistant C3H 
and C57BL/6 mice following immunization with a 15 amino-acid peptide (p11) spanning 
the C-terminal region of the full-length 63-mer MAX molecule.  It is notable that the C-
terminal domain is highly-conserved among the 4 known natural variants of MAX, and 
construction of deletion mutants has revealed that this domain is required for binding to 
the PACAP receptor (Moro et al., 1999).  Immunization of mice with CLDC + p11 elicits 
the production of antibodies that bind to both p11 and full-length MAX, and we 
hypothesize that the improved protection induced by p11-immunization (in comparison to 
full-length MAX-immunization) is due to anti-p11 antibodies acting as MAX antagonists, 
inhibiting binding of MAX to the PACAP receptor.  By effectively neutralizing the 
immunomodulatory effects of MAX, the p11 vaccine would not only elicit cellular 
immune responses protective against challenge with L. major co-injected with MAX (as 




activity of MAX, abrogating the Th2-bias that allows for the development of an early 
focus of L. major infection.   
Although the induction of protection in the absence of detectable titers of anti-
MAX IgG described in Chapter 4 is impressive, there would be substantial benefits to 
development of an anti-MAX or anti-MAX-peptide vaccine formulation capable of 
eliciting production of anti-MAX antibodies.  Sand flies attempting to feed on immunized 
vertebrate hosts producing anti-MAX antibodies are less successful in obtaining a 
bloodmeal (Milleron et al., 2004).  Bloodmeals are a required step in the maturation and 
development of sand fly eggs (Magnarelli et al., 1984), and there is a direct correlation 
between the size of bloodmeals taken by sand flies and the number of eggs that reach 
maturity (Ready, 1979).  As a result, there is a strong relationship between sand fly 
feeding success and reproductive potential.  Therefore, a MAX-vaccine (such as the p11 
peptide vaccine) that induces anti-MAX antibody production would elicit protection 
against not only vector-transmitted L. major, but would also interfere with the 
reproductive success of sand flies, reducing the overall vector population, thereby 
effectively decreasing pathogen transmission.  These effects could have far-reaching 
implications in the epidemiology of the leishmaniases in endemic areas, especially if 
immunization induced protection in natural vertebrate reservoirs, such as canines that 
serve as amplifying hosts for certain Leishmania species.   
As we utilized the unnatural parasite/vector combination of L. major / Lu. 
longipalpis (as discussed in Chapter 4), it would be valuable to test the protective 
efficacy of our anti-MAX and anti-p11 vaccines against hamster challenge with L. 




were to elicit significant vaccine-induced protection in this natural transmission model, it 
would further legitimize anti-saliva immunization as a realistic approach to control of 
arthropod-borne disease and increase the likelihood of inclusion of salivary molecules as 
antigens in future vaccines intended to protect against transmission of arthropod-borne 
pathogens.   
In these studies, we chose to utilize CLDCs as both immunotherapeutics and 
vaccine adjuvants to induce innate and Th1-type immune responses protective against 
infection with LACV and L. major, both of which are arthropod-borne intracellular 
pathogens that require the induction of pro-inflammatory Th1-biased immune responses 
for control and clearance.  This body of work presents evidence that CLDC 
administration induces protective immune responses against a very formidable LACV 
aerosol challenge and a parenteral challenge with L. major, suggesting that CLDCs are 
versatile and effective vehicles for the elicitation of immune protection against pathogens 
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